text,text_modified,label,group_label,group_label_id,original_text
"Subsequently, << pinosylvin >> suppressed the nuclear translocation of [[ β-catenin ]], one of downstream molecules of PI3K/Akt/GSK-3β signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.","Subsequently, [ENTITY_A] suppressed the nuclear translocation of [ENTITY_B], one of downstream molecules of PI3K/Akt/GSK-3β signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Subsequently, pinosylvin suppressed the nuclear translocation of β-catenin, one of downstream molecules of PI3K/Akt/GSK-3β signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc."
"The improved survival rates for obese mice chronically treated with << vildagliptin >> suggest that chronic [[ DPP4 ]] inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy.","The improved survival rates for obese mice chronically treated with [ENTITY_A] suggest that chronic [ENTITY_B] inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy.",INHIBITOR,CPR:4,1,"The improved survival rates for obese mice chronically treated with vildagliptin suggest that chronic DPP4 inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy."
"CYP2D6 inhibitors, such as paroxetine, are associated with changes in << atomoxetine >> pharmacokinetics similar to those observed among poor [[ CYP2D6 ]] metabolizers.","CYP2D6 inhibitors, such as paroxetine, are associated with changes in [ENTITY_A] pharmacokinetics similar to those observed among poor [ENTITY_B] metabolizers.",SUBSTRATE,CPR:9,4,"CYP2D6 inhibitors, such as paroxetine, are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers."
Reductions in striatal dopamine and << tyrosine hydroxylase >> content were also less pronounced with [[ EHT ]] treatment.,Reductions in striatal dopamine and [ENTITY_A] content were also less pronounced with [ENTITY_B] treatment.,INDIRECT-UPREGULATOR,CPR:3,0,Reductions in striatal dopamine and tyrosine hydroxylase content were also less pronounced with EHT treatment.
<< Kainate-selective ionotropic glutamate receptors >> (GluRs) require external Na+ and Cl- as well as the neurotransmitter [[ L-glutamate ]] for activation.,[ENTITY_A] (GluRs) require external Na+ and Cl- as well as the neurotransmitter [ENTITY_B] for activation.,ACTIVATOR,CPR:3,0,Kainate-selective ionotropic glutamate receptors (GluRs) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation.
<< Rasagiline >> does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit [[ MAO-B ]] but not MAO-A.,[ENTITY_A] does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit [ENTITY_B] but not MAO-A.,INHIBITOR,CPR:4,1,Rasagiline does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit MAO-B but not MAO-A.
"The << alpha(1)-adrenoceptor >> antagonist, [[ tamsulosin ]], is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors.","The [ENTITY_A] antagonist, [ENTITY_B], is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors.",ANTAGONIST,CPR:6,3,"The alpha(1)-adrenoceptor antagonist, tamsulosin, is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors."
"<< Nox4 >> oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific [[ quinone ]] derivatives could modulate this activity.","[ENTITY_A] oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific [ENTITY_B] derivatives could modulate this activity.",ACTIVATOR,CPR:3,0,"Nox4 oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific quinone derivatives could modulate this activity."
"In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and << thymidilate synthase >> (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of [[ TAS-102 ]].","In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and [ENTITY_A] (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of [ENTITY_B].",INHIBITOR,CPR:4,1,"In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102."
"Furthermore, RA significantly inhibited the << CCl(4) >>-induced apoptosis, which was evident from decreased cleavage of [[ caspase-3 ]].","Furthermore, RA significantly inhibited the [ENTITY_A]-induced apoptosis, which was evident from decreased cleavage of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, RA significantly inhibited the CCl(4)-induced apoptosis, which was evident from decreased cleavage of caspase-3."
All compounds showed low activity toward inhibition of << AChE >> caused by [[ dichlorvos ]].,All compounds showed low activity toward inhibition of [ENTITY_A] caused by [ENTITY_B].,INHIBITOR,CPR:4,1,All compounds showed low activity toward inhibition of AChE caused by dichlorvos.
"<< Imatinib mesylate >> is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor ([[ PDGFR ]]), and c-kit kinases.","[ENTITY_A] is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor ([ENTITY_B]), and c-kit kinases.",INHIBITOR,CPR:4,1,"Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases."
"<< Aprepitant >>, the first and only agent clinically available in the [[ NK1 receptor ]] antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV.","[ENTITY_A], the first and only agent clinically available in the [ENTITY_B] antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV.",ANTAGONIST,CPR:6,3,"Aprepitant, the first and only agent clinically available in the NK1 receptor antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV."
The aim of this study was to determine the mechanism of << pranlukast >>-induced [[ interleukin-5 ]] (IL-5) inhibition in allergic inflammation.,The aim of this study was to determine the mechanism of [ENTITY_A]-induced [ENTITY_B] (IL-5) inhibition in allergic inflammation.,INHIBITOR,CPR:4,1,The aim of this study was to determine the mechanism of pranlukast-induced interleukin-5 (IL-5) inhibition in allergic inflammation.
"Nicotinic acid (<< NA >>), a widely used drug to lower elevated plasma lipid levels, induced [[ NNMT ]] enzyme activity in white adipose tissue of mice.","Nicotinic acid ([ENTITY_A]), a widely used drug to lower elevated plasma lipid levels, induced [ENTITY_B] enzyme activity in white adipose tissue of mice.",ACTIVATOR,CPR:3,0,"Nicotinic acid (NA), a widely used drug to lower elevated plasma lipid levels, induced NNMT enzyme activity in white adipose tissue of mice."
"Further characterization of << sorafenib >> revealed that this molecule was a multikinase inhibitor that targeted the [[ vascular endothelial growth factor receptor ]] family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis.","Further characterization of [ENTITY_A] revealed that this molecule was a multikinase inhibitor that targeted the [ENTITY_B] family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis.",INHIBITOR,CPR:4,1,"Further characterization of sorafenib revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis."
"While a number of orally active non-peptide << V(2) >> antagonists (Vaptans); notably, [[ Tolvaptan ]], Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.","While a number of orally active non-peptide [ENTITY_A] antagonists (Vaptans); notably, [ENTITY_B], Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.",ANTAGONIST,CPR:6,3,"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients."
"Quinpirole and 7-OH-DPAT also increased the phosphorylation of << extracellular signal-regulated kinase >> (ERK) within minutes, an effect blocked by pretreatment with [[ SB-277011-A ]].","Quinpirole and 7-OH-DPAT also increased the phosphorylation of [ENTITY_A] (ERK) within minutes, an effect blocked by pretreatment with [ENTITY_B].",INHIBITOR,CPR:4,1,"Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A."
"Tissue-type plasminogen activator (tPA), a << serine >> protease well known for generating plasmin, has been demonstrated to induce [[ matrix metalloproteinase-9 ]] (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts.","Tissue-type plasminogen activator (tPA), a [ENTITY_A] protease well known for generating plasmin, has been demonstrated to induce [ENTITY_B] (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts.",INDIRECT-UPREGULATOR,CPR:3,0,"Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts."
<< P505-15 >> successfully inhibited SYK-mediated [[ B-cell receptor ]] signaling and decreased cell viability in NHL and CLL.,[ENTITY_A] successfully inhibited SYK-mediated [ENTITY_B] signaling and decreased cell viability in NHL and CLL.,INDIRECT-DOWNREGULATOR,CPR:4,1,P505-15 successfully inhibited SYK-mediated B-cell receptor signaling and decreased cell viability in NHL and CLL.
It is proposed that two molecules of << estramustine phosphate >> interact with each of the three tubulin-binding sites of MAP2 and inhibit the [[ MAP2 ]]:tubulin interaction by neutralising two highly conserved basic residues.,It is proposed that two molecules of [ENTITY_A] interact with each of the three tubulin-binding sites of MAP2 and inhibit the [ENTITY_B]:tubulin interaction by neutralising two highly conserved basic residues.,INHIBITOR,CPR:4,1,It is proposed that two molecules of estramustine phosphate interact with each of the three tubulin-binding sites of MAP2 and inhibit the MAP2:tubulin interaction by neutralising two highly conserved basic residues.
UNLABELLED: << Rabeprazole >> is an inhibitor of the [[ gastric proton pump ]].,UNLABELLED: [ENTITY_A] is an inhibitor of the [ENTITY_B].,INHIBITOR,CPR:4,1,UNLABELLED: Rabeprazole is an inhibitor of the gastric proton pump.
"Treatment with << carvedilol >> is associated with a reversal of abnormal regulation of [[ HIF-1alpha ]], VEGF, BNP, and NGF-beta in the hypertrophic myocardium.","Treatment with [ENTITY_A] is associated with a reversal of abnormal regulation of [ENTITY_B], VEGF, BNP, and NGF-beta in the hypertrophic myocardium.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF, BNP, and NGF-beta in the hypertrophic myocardium."
Extracellular << L-arginine >> also dose-dependently increased NO release and [[ arginase ]] activity.,Extracellular [ENTITY_A] also dose-dependently increased NO release and [ENTITY_B] activity.,ACTIVATOR,CPR:3,0,Extracellular L-arginine also dose-dependently increased NO release and arginase activity.
In four (10 %) patients the peak << ACTH >>-stimulated [[ cortisol ]] values were lower than 18 μg/dL.,In four (10 %) patients the peak [ENTITY_A]-stimulated [ENTITY_B] values were lower than 18 μg/dL.,PRODUCT-OF,CPR:9,4,In four (10 %) patients the peak ACTH-stimulated cortisol values were lower than 18 μg/dL.
"In addition, the << factor Xa >> inhibitor [[ apixaban ]] is in late-stage clinical development.","In addition, the [ENTITY_A] inhibitor [ENTITY_B] is in late-stage clinical development.",INHIBITOR,CPR:4,1,"In addition, the factor Xa inhibitor apixaban is in late-stage clinical development."
"<< Gossypol >> and its isomers were non-competitive inhibitors of [[ human and hamster LDH-X ]] with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate.","[ENTITY_A] and its isomers were non-competitive inhibitors of [ENTITY_B] with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate.",INHIBITOR,CPR:4,1,"Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate."
"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (<< F >>, Cl, Br) derivatives are first-generation dual [[ aromatase ]] and sulfatase inhibitors (DASIs).","4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated ([ENTITY_A], Cl, Br) derivatives are first-generation dual [ENTITY_B] and sulfatase inhibitors (DASIs).",INHIBITOR,CPR:4,1,"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)."
Here we report that << alendronate >> is a potent inhibitor of the [[ protein-tyrosine-phosphatase-meg1 ]] (PTPmeg1).,Here we report that [ENTITY_A] is a potent inhibitor of the [ENTITY_B] (PTPmeg1).,INHIBITOR,CPR:4,1,Here we report that alendronate is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (PTPmeg1).
"The suppressive effect of ceruletide on barrel rotation could be partially countered by << MK-329 >>, a selective peripheral [[ CCK ]] (CCK-A) receptor antagonist.","The suppressive effect of ceruletide on barrel rotation could be partially countered by [ENTITY_A], a selective peripheral [ENTITY_B] (CCK-A) receptor antagonist.",ANTAGONIST,CPR:6,3,"The suppressive effect of ceruletide on barrel rotation could be partially countered by MK-329, a selective peripheral CCK (CCK-A) receptor antagonist."
"Exposure to << Cu >> NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of lactate dehydrogenase, intracellular reactive oxygen species and [[ interleukin-8 ]] that mirrored our findings from subacute in vivo inhalation studies in mice.","Exposure to [ENTITY_A] NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of lactate dehydrogenase, intracellular reactive oxygen species and [ENTITY_B] that mirrored our findings from subacute in vivo inhalation studies in mice.",INDIRECT-UPREGULATOR,CPR:3,0,"Exposure to Cu NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of lactate dehydrogenase, intracellular reactive oxygen species and interleukin-8 that mirrored our findings from subacute in vivo inhalation studies in mice."
"The apparent affinity of << benzodiazepine receptors >> for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of [[ alprazolam ]] increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)","The apparent affinity of [ENTITY_A] for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of [ENTITY_B] increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)",ACTIVATOR,CPR:3,0,"The apparent affinity of benzodiazepine receptors for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)"
We conclude that << alprenolol >> and BAAM are competitive slowly reversible [[ beta 1-adrenoceptor ]] antagonists on rat left atria.,We conclude that [ENTITY_A] and BAAM are competitive slowly reversible [ENTITY_B] antagonists on rat left atria.,ANTAGONIST,CPR:6,3,We conclude that alprenolol and BAAM are competitive slowly reversible beta 1-adrenoceptor antagonists on rat left atria.
"Coumarin 7-hydroxylation, catalyzed by << P450 2A13 >>, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, [[ flavanone ]], chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.","Coumarin 7-hydroxylation, catalyzed by [ENTITY_A], was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, [ENTITY_B], chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.",INHIBITOR,CPR:4,1,"Coumarin 7-hydroxylation, catalyzed by P450 2A13, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values."
<< GW660511X >> and omapatrilat increased the production of both [[ BrBK1-8 ]] and Br-Phe5 but not that of BrBK4-8 and BrBK2-8.,[ENTITY_A] and omapatrilat increased the production of both [ENTITY_B] and Br-Phe5 but not that of BrBK4-8 and BrBK2-8.,INDIRECT-UPREGULATOR,CPR:3,0,GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8.
"Clinical experience in heart failure is growing, and recent data suggest an improved survival with << losartan >> versus captopril, a drug from the [[ angiotensin-converting-enzyme ]] inhibitor class with proven benefit in this population.","Clinical experience in heart failure is growing, and recent data suggest an improved survival with [ENTITY_A] versus captopril, a drug from the [ENTITY_B] inhibitor class with proven benefit in this population.",INHIBITOR,CPR:4,1,"Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus captopril, a drug from the angiotensin-converting-enzyme inhibitor class with proven benefit in this population."
Neonatal << quinpirole >> treatment produced a significant decrease in [[ BDNF ]] and ChAT in the frontal cortex that was unaffected by olanzapine treatment.,Neonatal [ENTITY_A] treatment produced a significant decrease in [ENTITY_B] and ChAT in the frontal cortex that was unaffected by olanzapine treatment.,INDIRECT-DOWNREGULATOR,CPR:4,1,Neonatal quinpirole treatment produced a significant decrease in BDNF and ChAT in the frontal cortex that was unaffected by olanzapine treatment.
CONCLUSIONS: Weight reduction with << sibutramine >> is associated with altered gastric functions and increased [[ peptide YY ]] and is significantly associated with SLC6A4 genotype.,CONCLUSIONS: Weight reduction with [ENTITY_A] is associated with altered gastric functions and increased [ENTITY_B] and is significantly associated with SLC6A4 genotype.,INDIRECT-UPREGULATOR,CPR:3,0,CONCLUSIONS: Weight reduction with sibutramine is associated with altered gastric functions and increased peptide YY and is significantly associated with SLC6A4 genotype.
"Our results suggest that easing of Fas-triggered fulminant hepatitis by << minocycline >> may involve a mitochondrial apoptotic pathway, probably through preventing [[ cytochrome c ]] release and thereby blocking downstream caspase activation.","Our results suggest that easing of Fas-triggered fulminant hepatitis by [ENTITY_A] may involve a mitochondrial apoptotic pathway, probably through preventing [ENTITY_B] release and thereby blocking downstream caspase activation.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Our results suggest that easing of Fas-triggered fulminant hepatitis by minocycline may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream caspase activation."
"Since both << TFP >> and W-7 are potent inhibitors of [[ calmodulin ]], we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors.","Since both [ENTITY_A] and W-7 are potent inhibitors of [ENTITY_B], we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors.",INHIBITOR,CPR:4,1,"Since both TFP and W-7 are potent inhibitors of calmodulin, we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors."
"We conclude that expression of << GLUT2 >> is required for efficient killing of neuroendocrine cells by [[ STZ ]], and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1.","We conclude that expression of [ENTITY_A] is required for efficient killing of neuroendocrine cells by [ENTITY_B], and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1.",SUBSTRATE,CPR:9,4,"We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by STZ, and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1."
Mechanism of the irreversible inactivation of << mouse ornithine decarboxylase >> by [[ alpha-difluoromethylornithine ]].,Mechanism of the irreversible inactivation of [ENTITY_A] by [ENTITY_B].,INHIBITOR,CPR:4,1,Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha-difluoromethylornithine.
The starting point for the calculations is the recent X-ray crystal structure of << GNMT >> complexed with [[ SAM ]] and acetate.,The starting point for the calculations is the recent X-ray crystal structure of [ENTITY_A] complexed with [ENTITY_B] and acetate.,SUBSTRATE,CPR:9,4,The starting point for the calculations is the recent X-ray crystal structure of GNMT complexed with SAM and acetate.
"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit << NO >> production and [[ inducible NO synthase ]] (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit [ENTITY_A] production and [ENTITY_B] (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).",PRODUCT-OF,CPR:9,4,"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible NO synthase (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)."
"When menadione was omitted from the diet, however, << 4HPR >>-dosed animals had elevated [[ prothrombin ]] times.","When menadione was omitted from the diet, however, [ENTITY_A]-dosed animals had elevated [ENTITY_B] times.",INDIRECT-UPREGULATOR,CPR:3,0,"When menadione was omitted from the diet, however, 4HPR-dosed animals had elevated prothrombin times."
"Furthermore, silymarin, << silybin A >>, and silybin B (100 µM) significantly inhibited [[ OATP ]]-mediated estradiol-17β-glucuronide and rosuvastatin uptake into human hepatocytes.","Furthermore, silymarin, [ENTITY_A], and silybin B (100 µM) significantly inhibited [ENTITY_B]-mediated estradiol-17β-glucuronide and rosuvastatin uptake into human hepatocytes.",INHIBITOR,CPR:4,1,"Furthermore, silymarin, silybin A, and silybin B (100 µM) significantly inhibited OATP-mediated estradiol-17β-glucuronide and rosuvastatin uptake into human hepatocytes."
"Pharmacogenetic analysis of two genes, the << warfarin >> metabolic enzyme [[ CYP2C9 ]] and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose.","Pharmacogenetic analysis of two genes, the [ENTITY_A] metabolic enzyme [ENTITY_B] and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose.",SUBSTRATE,CPR:9,4,"Pharmacogenetic analysis of two genes, the warfarin metabolic enzyme CYP2C9 and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose."
The effects of the << adenosine A3 receptor >> agonist [[ IB-MECA ]] on sodium taurocholate-induced experimental acute pancreatitis.,The effects of the [ENTITY_A] agonist [ENTITY_B] on sodium taurocholate-induced experimental acute pancreatitis.,AGONIST,CPR:5,2,The effects of the adenosine A3 receptor agonist IB-MECA on sodium taurocholate-induced experimental acute pancreatitis.
"alpha-Tocopherol transfer protein (<< alpha-TTP >>), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma [[ alpha-tocopherol ]] level by mediating the secretion of alpha-tocopherol by the liver.","alpha-Tocopherol transfer protein ([ENTITY_A]), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma [ENTITY_B] level by mediating the secretion of alpha-tocopherol by the liver.",SUBSTRATE,CPR:9,4,"alpha-Tocopherol transfer protein (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of alpha-tocopherol by the liver."
A molecular mechanism for << ibuprofen >>-mediated [[ RhoA ]] inhibition in neurons.,A molecular mechanism for [ENTITY_A]-mediated [ENTITY_B] inhibition in neurons.,INHIBITOR,CPR:4,1,A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons.
"The juvenile visceral steatosis (jvs) mouse, having a mutation in the << carnitine >> transporter gene [[ Octn2 ]], is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140).","The juvenile visceral steatosis (jvs) mouse, having a mutation in the [ENTITY_A] transporter gene [ENTITY_B], is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140).",SUBSTRATE,CPR:9,4,"The juvenile visceral steatosis (jvs) mouse, having a mutation in the carnitine transporter gene Octn2, is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140)."
We examined if subcutaneous << decitabine >> could increase [[ HbF ]] levels and improve SSD pathophysiology without cytotoxicity.,We examined if subcutaneous [ENTITY_A] could increase [ENTITY_B] levels and improve SSD pathophysiology without cytotoxicity.,INDIRECT-UPREGULATOR,CPR:3,0,We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity.
"We found that << helenalin >> markedly induced endoplasmic reticulum (ER) stress-related genes, such as [[ regulated in development and DNA damage responses (REDD) 1 ]], activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).","We found that [ENTITY_A] markedly induced endoplasmic reticulum (ER) stress-related genes, such as [ENTITY_B], activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).",INDIRECT-UPREGULATOR,CPR:3,0,"We found that helenalin markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP)."
Discovery of << aryl ureas >> and aryl amides as potent and selective [[ histamine H3 receptor ]] antagonists for the treatment of obesity (Part I).,Discovery of [ENTITY_A] and aryl amides as potent and selective [ENTITY_B] antagonists for the treatment of obesity (Part I).,ANTAGONIST,CPR:6,3,Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (Part I).
Administration of a concentration (100 microM) of << dipyridamole >> that blocks [[ PDE8 ]] inhibited ecto-phosphodiesterase activity (by 44%).,Administration of a concentration (100 microM) of [ENTITY_A] that blocks [ENTITY_B] inhibited ecto-phosphodiesterase activity (by 44%).,INHIBITOR,CPR:4,1,Administration of a concentration (100 microM) of dipyridamole that blocks PDE8 inhibited ecto-phosphodiesterase activity (by 44%).
"Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the << VMAT >> inhibitor [[ reserpine ]] and a proton ionophore, but not by tetrabenazine, which has a high affinity for VMAT-2.","Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the [ENTITY_A] inhibitor [ENTITY_B] and a proton ionophore, but not by tetrabenazine, which has a high affinity for VMAT-2.",INHIBITOR,CPR:4,1,"Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the VMAT inhibitor reserpine and a proton ionophore, but not by tetrabenazine, which has a high affinity for VMAT-2."
<< Amprenavir >> efficiently activated [[ PXR ]] and induced PXR target gene expression in vitro and in vivo.,[ENTITY_A] efficiently activated [ENTITY_B] and induced PXR target gene expression in vitro and in vivo.,ACTIVATOR,CPR:3,0,Amprenavir efficiently activated PXR and induced PXR target gene expression in vitro and in vivo.
"Ex vivo, << lumiracoxib >> inhibited [[ COX-1 ]]-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).","Ex vivo, [ENTITY_A] inhibited [ENTITY_B]-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",INHIBITOR,CPR:4,1,"Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)."
OBJECTIVE: Celecoxib and << rofecoxib >> are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the [[ cyclo-oxygenase-2 ]] (COX-2) isoenzyme at therapeutic concentrations.,OBJECTIVE: Celecoxib and [ENTITY_A] are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the [ENTITY_B] (COX-2) isoenzyme at therapeutic concentrations.,INHIBITOR,CPR:4,1,OBJECTIVE: Celecoxib and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 (COX-2) isoenzyme at therapeutic concentrations.
<< PF-04859989 >> as a template for structure-based drug design: identification of new pyrazole series of irreversible [[ KAT II ]] inhibitors with improved lipophilic efficiency.,[ENTITY_A] as a template for structure-based drug design: identification of new pyrazole series of irreversible [ENTITY_B] inhibitors with improved lipophilic efficiency.,INHIBITOR,CPR:4,1,PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency.
Discovery of a synthetic << Aminopeptidase N >> inhibitor [[ LB-4b ]] as a potential anticancer agent.,Discovery of a synthetic [ENTITY_A] inhibitor [ENTITY_B] as a potential anticancer agent.,INHIBITOR,CPR:4,1,Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.
"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the << BDZ receptor >>, including [[ Ro 15-1788 ]] and the beta CCs.","The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the [ENTITY_A], including [ENTITY_B] and the beta CCs.",AGONIST,CPR:5,2,"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the BDZ receptor, including Ro 15-1788 and the beta CCs."
"Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of << DNMT1 >>, which was rescued by re-isoprenylation by both [[ geranylgeranyl-pyrophosphate ]] and farnesylpyrophosphate.","Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of [ENTITY_A], which was rescued by re-isoprenylation by both [ENTITY_B] and farnesylpyrophosphate.",UPREGULATOR,CPR:3,0,"Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and farnesylpyrophosphate."
"In the present study, using in vitro Th17 differentiation model, we examined effects of << AhR >> activation by [[ indoxyl 3-sulfate ]] (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.","In the present study, using in vitro Th17 differentiation model, we examined effects of [ENTITY_A] activation by [ENTITY_B] (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.",ACTIVATOR,CPR:3,0,"In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms."
"These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective << 5-HT2A >>/5-HT2C antagonist [[ ritanserin ]].","These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective [ENTITY_A]/5-HT2C antagonist [ENTITY_B].",ANTAGONIST,CPR:6,3,"These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin."
"Among these differentially expressed lncRNAs, the greatest change was noted for << uc002mbe.2 >>, which had more than 300 folds induction upon [[ TSA ]] treatment.","Among these differentially expressed lncRNAs, the greatest change was noted for [ENTITY_A], which had more than 300 folds induction upon [ENTITY_B] treatment.",INDIRECT-UPREGULATOR,CPR:3,0,"Among these differentially expressed lncRNAs, the greatest change was noted for uc002mbe.2, which had more than 300 folds induction upon TSA treatment."
"In the hot-plate test in mice, the antinociceptive action of the << alpha 2-adrenoceptor >> agonist, [[ UK 14,304 ]], was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.","In the hot-plate test in mice, the antinociceptive action of the [ENTITY_A] agonist, [ENTITY_B], was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.",AGONIST,CPR:5,2,"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408."
"It undergoes extensive biotransformation, which is affected by poor metabolism by << cytochrome P450 (CYP) 2D6 >> in a small percentage of the population; these patients have greater exposure to and slower elimination of [[ atomoxetine ]] than extensive metabolizers.","It undergoes extensive biotransformation, which is affected by poor metabolism by [ENTITY_A] in a small percentage of the population; these patients have greater exposure to and slower elimination of [ENTITY_B] than extensive metabolizers.",SUBSTRATE,CPR:9,4,"It undergoes extensive biotransformation, which is affected by poor metabolism by cytochrome P450 (CYP) 2D6 in a small percentage of the population; these patients have greater exposure to and slower elimination of atomoxetine than extensive metabolizers."
"<< MK-801 >> ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive [[ NMDA receptor ]] antagonist, partially prevented the decrease in cell viability and the energy impairment.","[ENTITY_A] ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive [ENTITY_B] antagonist, partially prevented the decrease in cell viability and the energy impairment.",ANTAGONIST,CPR:6,3,"MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment."
"In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and << EETs >> markedly suppressed Ang II-induced inflammatory [[ cytokine ]] expression.","In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and [ENTITY_A] markedly suppressed Ang II-induced inflammatory [ENTITY_B] expression.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and EETs markedly suppressed Ang II-induced inflammatory cytokine expression."
"To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a << 5-HT(1A) >> antagonist, [[ N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt ]] (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).","To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a [ENTITY_A] antagonist, [ENTITY_B] (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).",ANTAGONIST,CPR:6,3,"To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a 5-HT(1A) antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally)."
"Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and << pelargonidin >> and delphinidin inhibit the [[ CYP1A1 ]] catalytic activity.","Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and [ENTITY_A] and delphinidin inhibit the [ENTITY_B] catalytic activity.",INHIBITOR,CPR:4,1,"Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity."
"Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking << oxysterol >>-related [[ NOX1 ]] induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.","Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking [ENTITY_A]-related [ENTITY_B] induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.",ACTIVATOR,CPR:3,0,"Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related NOX1 induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols."
The << Hsp90 >>-specific inhibitor [[ geldanamycin ]] selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.,The [ENTITY_A]-specific inhibitor [ENTITY_B] selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.,INHIBITOR,CPR:4,1,The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.
"BACKGROUND AND PURPOSE: << AMP-activated protein kinase >> (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside ([[ AICAR ]]).","BACKGROUND AND PURPOSE: [ENTITY_A] (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside ([ENTITY_B]).",ACTIVATOR,CPR:3,0,"BACKGROUND AND PURPOSE: AMP-activated protein kinase (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)."
"In this study, we demonstrate that << geldanamycin >> treatment blocks [[ interleukin (IL)-2 ]] secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes.","In this study, we demonstrate that [ENTITY_A] treatment blocks [ENTITY_B] secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In this study, we demonstrate that geldanamycin treatment blocks interleukin (IL)-2 secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes."
"For determination of << plasmin >> activity, 10 microL thereof was incubated with 150 microL 1.5 M [[ arginine ]], pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C).","For determination of [ENTITY_A] activity, 10 microL thereof was incubated with 150 microL 1.5 M [ENTITY_B], pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C).",SUBSTRATE,CPR:9,4,"For determination of plasmin activity, 10 microL thereof was incubated with 150 microL 1.5 M arginine, pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C)."
<< Trichostatin A >> inhibits [[ transforming growth factor-β ]]-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling.,[ENTITY_A] inhibits [ENTITY_B]-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling.,INHIBITOR,CPR:4,1,Trichostatin A inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling.
"The << PARP >> inhibitor [[ PJ34 ]] modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.","The [ENTITY_A] inhibitor [ENTITY_B] modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.",INHIBITOR,CPR:4,1,"The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines."
Pentosan polysulfate << sodium >> (PPS) has been shown to exert antitumor activity by antagonizing the binding of [[ bFGF ]] to cell surface receptors.,Pentosan polysulfate [ENTITY_A] (PPS) has been shown to exert antitumor activity by antagonizing the binding of [ENTITY_B] to cell surface receptors.,ANTAGONIST,CPR:6,3,Pentosan polysulfate sodium (PPS) has been shown to exert antitumor activity by antagonizing the binding of bFGF to cell surface receptors.
"<< Ca(v)1.3 >> channels were less sensitive to [[ pentobarbital ]] inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists.","[ENTITY_A] channels were less sensitive to [ENTITY_B] inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists.",INHIBITOR,CPR:4,1,"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists."
"Among the various enzymes, dicoumarol inhibitable cytosolic << NAD(P)H:quinone oxidoreductase1 >> (NQO1) was shown to catalyse bioreductive activation of [[ MMC ]] leading to cross-linking of the DNA and cytotoxicity.","Among the various enzymes, dicoumarol inhibitable cytosolic [ENTITY_A] (NQO1) was shown to catalyse bioreductive activation of [ENTITY_B] leading to cross-linking of the DNA and cytotoxicity.",SUBSTRATE,CPR:9,4,"Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity."
Effects of the << histamine H1 >> antagonist [[ chlorcyclizine ]] on rat fetal palate development.,Effects of the [ENTITY_A] antagonist [ENTITY_B] on rat fetal palate development.,ANTAGONIST,CPR:6,3,Effects of the histamine H1 antagonist chlorcyclizine on rat fetal palate development.
"6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (<< TAK-441 >>) is a potent, selective [[ hedgehog ]] signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer.","6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide ([ENTITY_A]) is a potent, selective [ENTITY_B] signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer.",INHIBITOR,CPR:4,1,"6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (TAK-441) is a potent, selective hedgehog signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer."
The anticonvulsant << felbamate >> blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other [[ NMDA receptor ]] antagonists.,The anticonvulsant [ENTITY_A] blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other [ENTITY_B] antagonists.,ANTAGONIST,CPR:6,3,The anticonvulsant felbamate blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists.
"In another experiment, topical application of CFB, CFE or << CLS >> prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of [[ COX-2 ]], iNOS, and TNF-α.","In another experiment, topical application of CFB, CFE or [ENTITY_A] prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of [ENTITY_B], iNOS, and TNF-α.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In another experiment, topical application of CFB, CFE or CLS prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of COX-2, iNOS, and TNF-α."
"Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of << phenylpropanolamine >>, to stimulate directly [[ alpha 1-adrenoceptors ]].","Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of [ENTITY_A], to stimulate directly [ENTITY_B].",ACTIVATOR,CPR:3,0,"Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly alpha 1-adrenoceptors."
"Here, we have determined the molecular mechanism of this male-specific activation of the Kcnk1 gene and characterized << KCNK1 >> as a [[ phenobarbital ]]-inducible antihyperplasia factor.","Here, we have determined the molecular mechanism of this male-specific activation of the Kcnk1 gene and characterized [ENTITY_A] as a [ENTITY_B]-inducible antihyperplasia factor.",ACTIVATOR,CPR:3,0,"Here, we have determined the molecular mechanism of this male-specific activation of the Kcnk1 gene and characterized KCNK1 as a phenobarbital-inducible antihyperplasia factor."
"Ornithine decarboxylase (<< ODC >>) catalyses the first step in the synthesis of the polyamines putrescine, [[ spermidine ]] and spermine.","Ornithine decarboxylase ([ENTITY_A]) catalyses the first step in the synthesis of the polyamines putrescine, [ENTITY_B] and spermine.",PRODUCT-OF,CPR:9,4,"Ornithine decarboxylase (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and spermine."
CONCLUSIONS: These results collectively indicate that << thalidomide >> prevents alcoholic liver injury through suppression of [[ TNF-alpha ]] production and abolishment of KC sensitization.,CONCLUSIONS: These results collectively indicate that [ENTITY_A] prevents alcoholic liver injury through suppression of [ENTITY_B] production and abolishment of KC sensitization.,INDIRECT-DOWNREGULATOR,CPR:4,1,CONCLUSIONS: These results collectively indicate that thalidomide prevents alcoholic liver injury through suppression of TNF-alpha production and abolishment of KC sensitization.
"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by << alanine >>, serine, and cysteine, which is consistent with amino acid transport through [[ ASCT2 ]].","In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by [ENTITY_A], serine, and cysteine, which is consistent with amino acid transport through [ENTITY_B].",INHIBITOR,CPR:4,1,"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through ASCT2."
"In Alexander cells, only when they were transfected with FXR+RXR, << GW4064 >> caused up-regulation of [[ SHP ]] and OSTβ, and a down-regulation of CYP27A1.","In Alexander cells, only when they were transfected with FXR+RXR, [ENTITY_A] caused up-regulation of [ENTITY_B] and OSTβ, and a down-regulation of CYP27A1.",INDIRECT-UPREGULATOR,CPR:3,0,"In Alexander cells, only when they were transfected with FXR+RXR, GW4064 caused up-regulation of SHP and OSTβ, and a down-regulation of CYP27A1."
"Structure-based design of << aliskiren >>, a novel orally effective [[ renin ]] inhibitor.","Structure-based design of [ENTITY_A], a novel orally effective [ENTITY_B] inhibitor.",INHIBITOR,CPR:4,1,"Structure-based design of aliskiren, a novel orally effective renin inhibitor."
"Once formed, the molecule can be converted to << glycine >> by [[ alanine-glyoxylate aminotransferase ]] (AGAT).","Once formed, the molecule can be converted to [ENTITY_A] by [ENTITY_B] (AGAT).",PRODUCT-OF,CPR:9,4,"Once formed, the molecule can be converted to glycine by alanine-glyoxylate aminotransferase (AGAT)."
"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the << ALD >>-induced increase of [[ calpain ]] and AIF levels.","Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the [ENTITY_A]-induced increase of [ENTITY_B] and AIF levels.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of calpain and AIF levels."
"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3β phosphorylation, cleaved PARP and deceased << AEG-1 >> induced by [[ ursolic acid ]] in HepG2 cells.","Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3β phosphorylation, cleaved PARP and deceased [ENTITY_A] induced by [ENTITY_B] in HepG2 cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3β phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells."
"Although the data collected on << IGFBP-rP3 >> in prostate are modest, its role as a growth stimulator and/or protooncogene is supported by its preferential expression in cancerous cells and its down-regulation by [[ atRA ]].","Although the data collected on [ENTITY_A] in prostate are modest, its role as a growth stimulator and/or protooncogene is supported by its preferential expression in cancerous cells and its down-regulation by [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Although the data collected on IGFBP-rP3 in prostate are modest, its role as a growth stimulator and/or protooncogene is supported by its preferential expression in cancerous cells and its down-regulation by atRA."
"However, several promising nonpeptide, << vasopressin receptor >> antagonists have been described; these agents are [[ VPA-985 ]] (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.","However, several promising nonpeptide, [ENTITY_A] antagonists have been described; these agents are [ENTITY_B] (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.",ANTAGONIST,CPR:6,3,"However, several promising nonpeptide, vasopressin receptor antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463."
"However, << GSK1292263 >> inhibited [[ BCRP ]] and OATP1B1, which are transporters involved in statin disposition.","However, [ENTITY_A] inhibited [ENTITY_B] and OATP1B1, which are transporters involved in statin disposition.",INHIBITOR,CPR:4,1,"However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition."
"These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the Kir6.2/SUR1 complex, i.e., the pancreatic beta-cell << K(ATP) channel >>, and suggest that [[ mitiglinide ]] may be a clinically useful anti-diabetic drug.","These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the Kir6.2/SUR1 complex, i.e., the pancreatic beta-cell [ENTITY_A], and suggest that [ENTITY_B] may be a clinically useful anti-diabetic drug.",AGONIST,CPR:5,2,"These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the Kir6.2/SUR1 complex, i.e., the pancreatic beta-cell K(ATP) channel, and suggest that mitiglinide may be a clinically useful anti-diabetic drug."
"In addition, << glucosamine >> attenuated [[ p21 ]] protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation.","In addition, [ENTITY_A] attenuated [ENTITY_B] protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, glucosamine attenuated p21 protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation."
"Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram/ml) for 24 h at 37 degrees C, and << prostaglandin E2 >> was measured in plasma as an index of monocyte [[ COX-2 ]] activity.","Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram/ml) for 24 h at 37 degrees C, and [ENTITY_A] was measured in plasma as an index of monocyte [ENTITY_B] activity.",PRODUCT-OF,CPR:9,4,"Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram/ml) for 24 h at 37 degrees C, and prostaglandin E2 was measured in plasma as an index of monocyte COX-2 activity."
<< Bupropion >> has an antidepressant effect through blocking the [[ dopamine transporter ]].,[ENTITY_A] has an antidepressant effect through blocking the [ENTITY_B].,INHIBITOR,CPR:4,1,Bupropion has an antidepressant effect through blocking the dopamine transporter.
"We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to << [3H]L-Cit >>, indicating [[ eNOS ]] activation.","We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [ENTITY_A], indicating [ENTITY_B] activation.",PRODUCT-OF,CPR:9,4,"We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating eNOS activation."
"In addition, << tolvaptan >> is metabolized by the [[ CYP3A4 ]] system; thus physicians should be aware of the potential for increased interactions with other medications.","In addition, [ENTITY_A] is metabolized by the [ENTITY_B] system; thus physicians should be aware of the potential for increased interactions with other medications.",SUBSTRATE,CPR:9,4,"In addition, tolvaptan is metabolized by the CYP3A4 system; thus physicians should be aware of the potential for increased interactions with other medications."
"With either substrate, << alendronate >> was a slow binding inhibitor of [[ PTPmeg1 ]].","With either substrate, [ENTITY_A] was a slow binding inhibitor of [ENTITY_B].",INHIBITOR,CPR:4,1,"With either substrate, alendronate was a slow binding inhibitor of PTPmeg1."
"CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired << pyridoxal kinase >> for the conversion of pyridoxine and pyridoxal to [[ PLP ]].","CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired [ENTITY_A] for the conversion of pyridoxine and pyridoxal to [ENTITY_B].",PRODUCT-OF,CPR:9,4,"CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired pyridoxal kinase for the conversion of pyridoxine and pyridoxal to PLP."
"However, while << Akt >> phosphorylation was prevented by CHX, Erk1/2 phosphorylation was further enhanced by [[ CHX ]].","However, while [ENTITY_A] phosphorylation was prevented by CHX, Erk1/2 phosphorylation was further enhanced by [ENTITY_B].",INHIBITOR,CPR:4,1,"However, while Akt phosphorylation was prevented by CHX, Erk1/2 phosphorylation was further enhanced by CHX."
"Among the various enzymes, << dicoumarol >> inhibitable cytosolic [[ NAD(P)H:quinone oxidoreductase1 ]] (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.","Among the various enzymes, [ENTITY_A] inhibitable cytosolic [ENTITY_B] (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.",INHIBITOR,CPR:4,1,"Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity."
Receptor binding was significantly reduced by specific << AhR >> antagonist [[ salicyl amide ]].,Receptor binding was significantly reduced by specific [ENTITY_A] antagonist [ENTITY_B].,ANTAGONIST,CPR:6,3,Receptor binding was significantly reduced by specific AhR antagonist salicyl amide.
"In the in vitro model we observed high permeability of << imperatorin >> and isoimperatorin with the [[ P-gp ]]-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82.","In the in vitro model we observed high permeability of [ENTITY_A] and isoimperatorin with the [ENTITY_B]-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82.",SUBSTRATE,CPR:9,4,"In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the P-gp-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82."
"We used mutagenesis of these residues, combined with an investigation of << hERG >> block by close analogs of [[ clofilium ]] and ibutilide, to assess how specific alterations in drug structure affected potency and binding interactions.","We used mutagenesis of these residues, combined with an investigation of [ENTITY_A] block by close analogs of [ENTITY_B] and ibutilide, to assess how specific alterations in drug structure affected potency and binding interactions.",INHIBITOR,CPR:4,1,"We used mutagenesis of these residues, combined with an investigation of hERG block by close analogs of clofilium and ibutilide, to assess how specific alterations in drug structure affected potency and binding interactions."
"Firstly, transgenic plants overexpressing << formate dehydrogenase >> (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in [[ formate ]] metabolism.","Firstly, transgenic plants overexpressing [ENTITY_A] (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in [ENTITY_B] metabolism.",SUBSTRATE,CPR:9,4,"Firstly, transgenic plants overexpressing formate dehydrogenase (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in formate metabolism."
"To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. << adenosine >> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, [[ theophylline ]] and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.","To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. [ENTITY_A] agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, [ENTITY_B] and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",ANTAGONIST,CPR:6,3,"To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod."
"<< Hydralazine >> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF ([[ endothelin-1 ]], adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.","[ENTITY_A] induced rapid and transient expression of HIF-1alpha and downstream targets of HIF ([ENTITY_B], adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.",INDIRECT-UPREGULATOR,CPR:3,0,"Hydralazine induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation."
"Despite the importance of << AKRs >> in [[ PAHs ]] metabolism, there are no studies that evaluate, in general human populations, the effect of PAHs on AKRs expression in peripheral blood lymphocytes (PBLs).","Despite the importance of [ENTITY_A] in [ENTITY_B] metabolism, there are no studies that evaluate, in general human populations, the effect of PAHs on AKRs expression in peripheral blood lymphocytes (PBLs).",SUBSTRATE,CPR:9,4,"Despite the importance of AKRs in PAHs metabolism, there are no studies that evaluate, in general human populations, the effect of PAHs on AKRs expression in peripheral blood lymphocytes (PBLs)."
A << TXA2 receptor >> antagonist ([[ S-1452 ]]) attenuated the contraction in a concentration-dependent manner.,A [ENTITY_A] antagonist ([ENTITY_B]) attenuated the contraction in a concentration-dependent manner.,ANTAGONIST,CPR:6,3,A TXA2 receptor antagonist (S-1452) attenuated the contraction in a concentration-dependent manner.
The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed << bufotenine >> formation was confirmed by in vitro study using purified [[ CYP2D6 ]].,The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed [ENTITY_A] formation was confirmed by in vitro study using purified [ENTITY_B].,PRODUCT-OF,CPR:9,4,The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6.
Effects of a << serotonin 5-HT(4) receptor >> antagonist [[ SB-207266 ]] on gastrointestinal motor and sensory function in humans.,Effects of a [ENTITY_A] antagonist [ENTITY_B] on gastrointestinal motor and sensory function in humans.,ANTAGONIST,CPR:6,3,Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans.
<< Bevantolol >>: a [[ beta-1 adrenoceptor ]] antagonist with unique additional actions.,[ENTITY_A]: a [ENTITY_B] antagonist with unique additional actions.,ANTAGONIST,CPR:6,3,Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions.
"To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective << 5-HT1F >> receptor agonist ([[ LY 344864 ]]) on c-fos protein expression in the trigeminal nucleus caudalis.","To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective [ENTITY_A] receptor agonist ([ENTITY_B]) on c-fos protein expression in the trigeminal nucleus caudalis.",AGONIST,CPR:5,2,"To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective 5-HT1F receptor agonist (LY 344864) on c-fos protein expression in the trigeminal nucleus caudalis."
"In a double-blind, placebo-controlled, randomized design, nine healthy male volunteers received disodium cromoglycate (4 x 200 mg/day, p.o.) or placebo for 3 weeks with terbutaline (3 x 5 mg/day, p.o.) administered concomitantly during the last 2 weeks. beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective << beta-adrenoceptor >> agonist [[ isoprenaline ]]; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia.","In a double-blind, placebo-controlled, randomized design, nine healthy male volunteers received disodium cromoglycate (4 x 200 mg/day, p.o.) or placebo for 3 weeks with terbutaline (3 x 5 mg/day, p.o.) administered concomitantly during the last 2 weeks. beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective [ENTITY_A] agonist [ENTITY_B]; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia.",AGONIST,CPR:5,2,"In a double-blind, placebo-controlled, randomized design, nine healthy male volunteers received disodium cromoglycate (4 x 200 mg/day, p.o.) or placebo for 3 weeks with terbutaline (3 x 5 mg/day, p.o.) administered concomitantly during the last 2 weeks. beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective beta-adrenoceptor agonist isoprenaline; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia."
"<< (+/-)-Tamsulosin >>, over the range of concentrations at which it antagonized the positive inotropic effect mediated by [[ alpha 1-adrenoceptors ]], did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine.","[ENTITY_A], over the range of concentrations at which it antagonized the positive inotropic effect mediated by [ENTITY_B], did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine.",ANTAGONIST,CPR:6,3,"(+/-)-Tamsulosin, over the range of concentrations at which it antagonized the positive inotropic effect mediated by alpha 1-adrenoceptors, did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine."
"After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received << aurintrycarboxilic acid >> (ATA), an inhibitor of platelet [[ glycoprotein Ib ]]/von Willebrand factor interaction (10 mg/kg i.v. bolus).","After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received [ENTITY_A] (ATA), an inhibitor of platelet [ENTITY_B]/von Willebrand factor interaction (10 mg/kg i.v. bolus).",INHIBITOR,CPR:4,1,"After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (ATA), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus)."
"METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of COX-2 in the wound healing process by comparing the effects of a nonselective << COX >> inhibitor, [[ diclofenac ]], with a selective COX-2 inhibitor, SC-791.","METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of COX-2 in the wound healing process by comparing the effects of a nonselective [ENTITY_A] inhibitor, [ENTITY_B], with a selective COX-2 inhibitor, SC-791.",INHIBITOR,CPR:4,1,"METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of COX-2 in the wound healing process by comparing the effects of a nonselective COX inhibitor, diclofenac, with a selective COX-2 inhibitor, SC-791."
<< Verrucarin A >> sensitizes TRAIL-induced apoptosis via the upregulation of [[ DR5 ]] in an eIF2α/CHOP-dependent manner.,[ENTITY_A] sensitizes TRAIL-induced apoptosis via the upregulation of [ENTITY_B] in an eIF2α/CHOP-dependent manner.,INDIRECT-UPREGULATOR,CPR:3,0,Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2α/CHOP-dependent manner.
<< CYP3A5 >> carrier status had no influence on [[ midazolam ]] oral clearance or its inhibition by ketoconazole.,[ENTITY_A] carrier status had no influence on [ENTITY_B] oral clearance or its inhibition by ketoconazole.,SUBSTRATE,CPR:9,4,CYP3A5 carrier status had no influence on midazolam oral clearance or its inhibition by ketoconazole.
"<< Esmolol >>, a unique cardioselective [[ beta 1-adrenergic receptor ]] blocker with a half-life of 9 minutes, can enable some patients with relative contraindications to beta blockers to nevertheless benefit from early beta-blocking therapy.","[ENTITY_A], a unique cardioselective [ENTITY_B] blocker with a half-life of 9 minutes, can enable some patients with relative contraindications to beta blockers to nevertheless benefit from early beta-blocking therapy.",INHIBITOR,CPR:4,1,"Esmolol, a unique cardioselective beta 1-adrenergic receptor blocker with a half-life of 9 minutes, can enable some patients with relative contraindications to beta blockers to nevertheless benefit from early beta-blocking therapy."
An investigation of the absolute configuration of the potent << histamine H3 receptor >> antagonist [[ GT-2331 ]] using vibrational circular dichroism.,An investigation of the absolute configuration of the potent [ENTITY_A] antagonist [ENTITY_B] using vibrational circular dichroism.,ANTAGONIST,CPR:6,3,An investigation of the absolute configuration of the potent histamine H3 receptor antagonist GT-2331 using vibrational circular dichroism.
A double mutant of the two << fumarate reductase >> isozyme genes (OSM1 and FRDS) showed a [[ succinate ]] productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.,A double mutant of the two [ENTITY_A] isozyme genes (OSM1 and FRDS) showed a [ENTITY_B] productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.,PRODUCT-OF,CPR:9,4,A double mutant of the two fumarate reductase isozyme genes (OSM1 and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.
"Moreover, since reduced levels of << p21CIP1 >> and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after [[ BSC ]] 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.","Moreover, since reduced levels of [ENTITY_A] and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after [ENTITY_B] 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis."
"<< (+/-)-tamsulosin >>, an [[ alpha 1A-adrenoceptor ]] antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart.","[ENTITY_A], an [ENTITY_B] antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart.",ANTAGONIST,CPR:6,3,"(+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart."
"In Experiment 1, << Antag I >>, Antag II and TT-235 inhibited the integrated uterine response to [[ oxytocin ]] at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).","In Experiment 1, [ENTITY_A], Antag II and TT-235 inhibited the integrated uterine response to [ENTITY_B] at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).",INHIBITOR,CPR:4,1,"In Experiment 1, Antag I, Antag II and TT-235 inhibited the integrated uterine response to oxytocin at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)."
"This investigation tested the hypothesis that << CYP2B6 >> is a prominent CYP isoform responsible for clinical [[ methadone ]] N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.","This investigation tested the hypothesis that [ENTITY_A] is a prominent CYP isoform responsible for clinical [ENTITY_B] N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.",SUBSTRATE,CPR:9,4,"This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days."
"<< Cobalt chloride >>, a typical [[ HIF ]] activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.","[ENTITY_A], a typical [ENTITY_B] activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.",ACTIVATOR,CPR:3,0,"Cobalt chloride, a typical HIF activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver."
"<< Pinosylvin >> was also found to attenuate the activation of proteins involved in f[[ ocal adhesion kinase ]] (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway.","[ENTITY_A] was also found to attenuate the activation of proteins involved in f[ENTITY_B] (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway."
<< AZD6140 >> is a reversible oral [[ P2Y(12) ]] receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study).,[ENTITY_A] is a reversible oral [ENTITY_B] receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study).,ANTAGONIST,CPR:6,3,AZD6140 is a reversible oral P2Y(12) receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study).
"METHODS: We conducted a case-control study to measure the association between selective << cox-2 >> inhibitors, particularly [[ celecoxib ]], rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk.","METHODS: We conducted a case-control study to measure the association between selective [ENTITY_A] inhibitors, particularly [ENTITY_B], rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk.",INHIBITOR,CPR:4,1,"METHODS: We conducted a case-control study to measure the association between selective cox-2 inhibitors, particularly celecoxib, rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk."
"The potency of MrIA was greater for inhibition of uptake by << hNET >> of [[ [3H]norepinephrine ]] (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).","The potency of MrIA was greater for inhibition of uptake by [ENTITY_A] of [ENTITY_B] (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).",SUBSTRATE,CPR:9,4,"The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM)."
"Treatment of lactating mice with a single injection of << bezafibrate >>, an activator of the [[ peroxisome proliferator-activated receptor ]] (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.","Treatment of lactating mice with a single injection of [ENTITY_A], an activator of the [ENTITY_B] (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.",ACTIVATOR,CPR:3,0,"Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice."
"The cholesterol-lowering drug << simvastatin >> inhibits [[ LFA-1 ]] signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation.","The cholesterol-lowering drug [ENTITY_A] inhibits [ENTITY_B] signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The cholesterol-lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation."
The present study determined the influence of a << retinoid X receptor >> agonist [[ bexarotene ]] on angiogenesis and metastasis in solid tumours.,The present study determined the influence of a [ENTITY_A] agonist [ENTITY_B] on angiogenesis and metastasis in solid tumours.,AGONIST,CPR:5,2,The present study determined the influence of a retinoid X receptor agonist bexarotene on angiogenesis and metastasis in solid tumours.
A series of << indazole arylsulfonamides >> were synthesized and examined as [[ human CCR4 ]] antagonists.,A series of [ENTITY_A] were synthesized and examined as [ENTITY_B] antagonists.,ANTAGONIST,CPR:6,3,A series of indazole arylsulfonamides were synthesized and examined as human CCR4 antagonists.
"The antipsychotic drugs << sertindole >> and pimozide block [[ erg3 ]], a human brain K(+) channel.","The antipsychotic drugs [ENTITY_A] and pimozide block [ENTITY_B], a human brain K(+) channel.",INHIBITOR,CPR:4,1,"The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel."
"<< Denufosol tetrasodium >> (INS37217) is a selective [[ P2Y(2) ]] agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.","[ENTITY_A] (INS37217) is a selective [ENTITY_B] agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.",AGONIST,CPR:5,2,"Denufosol tetrasodium (INS37217) is a selective P2Y(2) agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF."
The beta-adrenergic/<< 5-HT1A >> receptor antagonist [[ (+/-)pindolol ]] and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA.,The beta-adrenergic/[ENTITY_A] receptor antagonist [ENTITY_B] and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA.,ANTAGONIST,CPR:6,3,The beta-adrenergic/5-HT1A receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA.
"Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-β-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by << troglitazone >>, a [[ PPARγ ]] agonist.","Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-β-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by [ENTITY_A], a [ENTITY_B] agonist.",AGONIST,CPR:5,2,"Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-β-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist."
"This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based << CYP2B6 >> inhibitor [[ ticlopidine ]], given orally for 4 days.","This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based [ENTITY_A] inhibitor [ENTITY_B], given orally for 4 days.",INHIBITOR,CPR:4,1,"This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days."
<< Butein >> also increased [[ heme oxygenase-1 ]] (HO-1) protein expression and HO activity.,[ENTITY_A] also increased [ENTITY_B] (HO-1) protein expression and HO activity.,INDIRECT-UPREGULATOR,CPR:3,0,Butein also increased heme oxygenase-1 (HO-1) protein expression and HO activity.
"We recently reported that << AMPK >> is activated by [[ metformin ]] in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production.","We recently reported that [ENTITY_A] is activated by [ENTITY_B] in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production.",ACTIVATOR,CPR:3,0,"We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production."
"In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel << CB(1) >> full agonist [[ AM4054 ]].","In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel [ENTITY_A] full agonist [ENTITY_B].",AGONIST-ACTIVATOR,CPR:5,2,"In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054."
"Consistent with two << glucose >> uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or [[ glucose transporter ]] (GLUT4), and blocked by dual blockade.","Consistent with two [ENTITY_A] uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or [ENTITY_B] (GLUT4), and blocked by dual blockade.",SUBSTRATE,CPR:9,4,"Consistent with two glucose uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (GLUT4), and blocked by dual blockade."
The << sordarins >> group are protein synthesis inhibitors that work by blocking the function of [[ fungal translation elongation factor 2 ]].,The [ENTITY_A] group are protein synthesis inhibitors that work by blocking the function of [ENTITY_B].,INHIBITOR,CPR:4,1,The sordarins group are protein synthesis inhibitors that work by blocking the function of fungal translation elongation factor 2.
The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that << troglitazone >> was a competitive inhibitor of [[ ENT1 ]].,The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that [ENTITY_A] was a competitive inhibitor of [ENTITY_B].,INHIBITOR,CPR:4,1,The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that troglitazone was a competitive inhibitor of ENT1.
<< Metformin >>-induced increases in [[ AMPK ]] activity were associated with higher rates of glucose disposal and muscle glycogen concentrations.,[ENTITY_A]-induced increases in [ENTITY_B] activity were associated with higher rates of glucose disposal and muscle glycogen concentrations.,ACTIVATOR,CPR:3,0,Metformin-induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle glycogen concentrations.
"A series of << benzenesulfonamides >> incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the β-carbonic anhydrase (CA, [[ EC 4.2.1.1 ]]) from Saccharomyces cerevisiae, ScCA.","A series of [ENTITY_A] incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the β-carbonic anhydrase (CA, [ENTITY_B]) from Saccharomyces cerevisiae, ScCA.",INHIBITOR,CPR:4,1,"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the β-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA."
"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and << ergot alkaloid >> inhibition of [[ vasoactive intestinal peptide ]] (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.","Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and [ENTITY_A] inhibition of [ENTITY_B] (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.",INHIBITOR,CPR:4,1,"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated."
"The lysosomal inhibitor << chloroquine >> significantly increased [[ RCAN1 ]] accumulation in +/+ cells, consistent with the hypothesis that higher lysosomal pH impairs RCAN1 degradation, leading to a higher RCAN1/NFATc1 ratio and consequently NFATc1 inhibition.","The lysosomal inhibitor [ENTITY_A] significantly increased [ENTITY_B] accumulation in +/+ cells, consistent with the hypothesis that higher lysosomal pH impairs RCAN1 degradation, leading to a higher RCAN1/NFATc1 ratio and consequently NFATc1 inhibition.",INDIRECT-UPREGULATOR,CPR:3,0,"The lysosomal inhibitor chloroquine significantly increased RCAN1 accumulation in +/+ cells, consistent with the hypothesis that higher lysosomal pH impairs RCAN1 degradation, leading to a higher RCAN1/NFATc1 ratio and consequently NFATc1 inhibition."
"We show that << sorafenib >> (BAY 43-9006, Nexavar) potently inhibits [[ FLT3 ]] enzymatic and signaling activities.","We show that [ENTITY_A] (BAY 43-9006, Nexavar) potently inhibits [ENTITY_B] enzymatic and signaling activities.",INHIBITOR,CPR:4,1,"We show that sorafenib (BAY 43-9006, Nexavar) potently inhibits FLT3 enzymatic and signaling activities."
"Consistent with these results, << prunetin >> significantly reduced serum levels of inflammatory [[ cytokines ]] and mortality in mice challenged with lipopolysaccharide.","Consistent with these results, [ENTITY_A] significantly reduced serum levels of inflammatory [ENTITY_B] and mortality in mice challenged with lipopolysaccharide.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Consistent with these results, prunetin significantly reduced serum levels of inflammatory cytokines and mortality in mice challenged with lipopolysaccharide."
"In << NE >>-desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of [[ alpha-AR ]] mRNA.","In [ENTITY_A]-desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of [ENTITY_B] mRNA.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In NE-desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of alpha-AR mRNA."
"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked << ABCA1 >>-mediated [[ cholesterol ]] efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).","Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked [ENTITY_A]-mediated [ENTITY_B] efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).",SUBSTRATE,CPR:9,4,"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)."
"At 4 hours, losartan blocked 43% of the << Ang II >>-induced systolic blood pressure increase; [[ valsartan ]], 51%; and irbesartan, 88% (P<0.01 between drugs).","At 4 hours, losartan blocked 43% of the [ENTITY_A]-induced systolic blood pressure increase; [ENTITY_B], 51%; and irbesartan, 88% (P<0.01 between drugs).",INDIRECT-DOWNREGULATOR,CPR:4,1,"At 4 hours, losartan blocked 43% of the Ang II-induced systolic blood pressure increase; valsartan, 51%; and irbesartan, 88% (P<0.01 between drugs)."
"All HIV PIs except nelfinavir are coadministered with a low dose of << ritonavir >>, a potent [[ CYP3A ]] inhibitor to improve their pharmacokinetic properties.","All HIV PIs except nelfinavir are coadministered with a low dose of [ENTITY_A], a potent [ENTITY_B] inhibitor to improve their pharmacokinetic properties.",INHIBITOR,CPR:4,1,"All HIV PIs except nelfinavir are coadministered with a low dose of ritonavir, a potent CYP3A inhibitor to improve their pharmacokinetic properties."
The pharmacological inhibitors << SB203580 >> ([[ p38 ]] inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.,The pharmacological inhibitors [ENTITY_A] ([ENTITY_B] inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.,INHIBITOR,CPR:4,1,The pharmacological inhibitors SB203580 (p38 inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.
Culture of HepG2 cells with << griseofulvin >> has now been shown to induce both the formation of intracellular aggregates containing [[ K18 ]] as well as an increase in the abundance of K18 mRNA.,Culture of HepG2 cells with [ENTITY_A] has now been shown to induce both the formation of intracellular aggregates containing [ENTITY_B] as well as an increase in the abundance of K18 mRNA.,INDIRECT-UPREGULATOR,CPR:3,0,Culture of HepG2 cells with griseofulvin has now been shown to induce both the formation of intracellular aggregates containing K18 as well as an increase in the abundance of K18 mRNA.
"Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface << glucose transporter isoform 4 >> (GLUT4) and [[ glucose ]] uptake.","Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface [ENTITY_A] (GLUT4) and [ENTITY_B] uptake.",SUBSTRATE,CPR:9,4,"Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and glucose uptake."
"Meanwhile, the serum level of KC (a functional homolog of << IL-8 >> and the main proinflammatory alpha chemokine in mice) in apoE(-/-) mice was up to 357pg/ml in [[ SFO ]]-HD treated group.","Meanwhile, the serum level of KC (a functional homolog of [ENTITY_A] and the main proinflammatory alpha chemokine in mice) in apoE(-/-) mice was up to 357pg/ml in [ENTITY_B]-HD treated group.",INDIRECT-UPREGULATOR,CPR:3,0,"Meanwhile, the serum level of KC (a functional homolog of IL-8 and the main proinflammatory alpha chemokine in mice) in apoE(-/-) mice was up to 357pg/ml in SFO-HD treated group."
"Pre-clinical pharmacology of << zolmitriptan >> (Zomig; formerly 311C90), a centrally and peripherally acting [[ 5HT1B/1D ]] agonist for migraine.","Pre-clinical pharmacology of [ENTITY_A] (Zomig; formerly 311C90), a centrally and peripherally acting [ENTITY_B] agonist for migraine.",AGONIST,CPR:5,2,"Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine."
"Moreover, a normal level of expression of << PSS1 >> and/or PSS2 is not required for generating the pool of [[ PtdSer ]] externalized during apoptosis.","Moreover, a normal level of expression of [ENTITY_A] and/or PSS2 is not required for generating the pool of [ENTITY_B] externalized during apoptosis.",PRODUCT-OF,CPR:9,4,"Moreover, a normal level of expression of PSS1 and/or PSS2 is not required for generating the pool of PtdSer externalized during apoptosis."
"Structural optimization of << 2,5-thiophene amides >> as highly potent and selective [[ 17β-hydroxysteroid dehydrogenase type 2 ]] inhibitors for the treatment of osteoporosis.",Structural optimization of [ENTITY_A] as highly potent and selective [ENTITY_B] inhibitors for the treatment of osteoporosis.,INHIBITOR,CPR:4,1,"Structural optimization of 2,5-thiophene amides as highly potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis."
"However, << amantadine >> induction of [[ Fos ]] in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride.","However, [ENTITY_A] induction of [ENTITY_B] in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride.",INDIRECT-UPREGULATOR,CPR:3,0,"However, amantadine induction of Fos in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride."
"Collectively, these initial findings suggest that design and systematic modification of << aminoalkylindoles >> such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/[[ CB2R ]] agonist activity with potential for use as treatments of alcohol abuse.","Collectively, these initial findings suggest that design and systematic modification of [ENTITY_A] such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/[ENTITY_B] agonist activity with potential for use as treatments of alcohol abuse.",AGONIST,CPR:5,2,"Collectively, these initial findings suggest that design and systematic modification of aminoalkylindoles such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse."
"<< GW572016 >>, a reversible small molecule inhibitor of [[ EGFR ]] and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts.","[ENTITY_A], a reversible small molecule inhibitor of [ENTITY_B] and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts.",INHIBITOR,CPR:4,1,"GW572016, a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts."
"<< Cannabinoid receptor 1 >> (CB(1)) inverse agonists (e.g., [[ rimonabant ]]) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.","[ENTITY_A] (CB(1)) inverse agonists (e.g., [ENTITY_B]) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.",AGONIST-INHIBITOR,CPR:5,2,"Cannabinoid receptor 1 (CB(1)) inverse agonists (e.g., rimonabant) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications."
"The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with << GF-120918 >>, a dual [[ BCRP ]] and P-gp inhibitor).","The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with [ENTITY_A], a dual [ENTITY_B] and P-gp inhibitor).",INHIBITOR,CPR:4,1,"The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with GF-120918, a dual BCRP and P-gp inhibitor)."
"MeHg significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10µM), revealing that << MeHg >> increases [[ tyrosine hydroxylase ]] activity.","MeHg significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10µM), revealing that [ENTITY_A] increases [ENTITY_B] activity.",ACTIVATOR,CPR:3,0,"MeHg significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10µM), revealing that MeHg increases tyrosine hydroxylase activity."
"The most successful example of << kinase >> blockers is [[ Imatinib ]] (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.","The most successful example of [ENTITY_A] blockers is [ENTITY_B] (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.",INHIBITOR,CPR:4,1,"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia."
"GABA-evoked currents were completely and reversibly blocked by the competitive << GABAA receptor >> antagonist [[ bicuculline ]] (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors.","GABA-evoked currents were completely and reversibly blocked by the competitive [ENTITY_A] antagonist [ENTITY_B] (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors.",ANTAGONIST,CPR:6,3,"GABA-evoked currents were completely and reversibly blocked by the competitive GABAA receptor antagonist bicuculline (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors."
"Accordingly, self-administration of a group of local anesthetics that are << DAT >> ligands was compared to their effects as [[ DA ]] uptake blockers in vitro in brain tissue.","Accordingly, self-administration of a group of local anesthetics that are [ENTITY_A] ligands was compared to their effects as [ENTITY_B] uptake blockers in vitro in brain tissue.",SUBSTRATE,CPR:9,4,"Accordingly, self-administration of a group of local anesthetics that are DAT ligands was compared to their effects as DA uptake blockers in vitro in brain tissue."
"In this work, the metabolism of four frequently prescribed inhaled GCs, << triamcinolone acetonide >>, flunisolide, budesonide, and fluticasone propionate, by the [[ CYP3A ]] family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.","In this work, the metabolism of four frequently prescribed inhaled GCs, [ENTITY_A], flunisolide, budesonide, and fluticasone propionate, by the [ENTITY_B] family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.",SUBSTRATE,CPR:9,4,"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide, and fluticasone propionate, by the CYP3A family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites."
"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-<< MMC >> rats showed higher quinone reductase and depleted [[ xanthine oxidase ]] activities.","Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-[ENTITY_A] rats showed higher quinone reductase and depleted [ENTITY_B] activities.",INHIBITOR,CPR:4,1,"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities."
"Interestingly, part of << MCT2 >> immunoreactivity is located at postsynaptic sites, suggesting a particular role of [[ monocarboxylates ]] and their transporters in synaptic transmission.","Interestingly, part of [ENTITY_A] immunoreactivity is located at postsynaptic sites, suggesting a particular role of [ENTITY_B] and their transporters in synaptic transmission.",SUBSTRATE,CPR:9,4,"Interestingly, part of MCT2 immunoreactivity is located at postsynaptic sites, suggesting a particular role of monocarboxylates and their transporters in synaptic transmission."
"CONCLUSION: << CysLT1 receptor >> expression in neurons is upregulated after [[ NMDA ]] injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.","CONCLUSION: [ENTITY_A] expression in neurons is upregulated after [ENTITY_B] injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.",INDIRECT-UPREGULATOR,CPR:3,0,"CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity."
The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when << GABA >> is introduced into the secretory cell and competes for uptake by [[ VIAAT ]].,The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when [ENTITY_A] is introduced into the secretory cell and competes for uptake by [ENTITY_B].,SUBSTRATE,CPR:9,4,The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when GABA is introduced into the secretory cell and competes for uptake by VIAAT.
"No effects were observed when << fenclozic acid >> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major [[ human cytochrome P450 ]] enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.","No effects were observed when [ENTITY_A] was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major [ENTITY_B] enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.",INHIBITOR,CPR:4,1,"No effects were observed when fenclozic acid was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells."
"<< Ambenonium >> is known to be an inhibitor of [[ acetylcholinesterase ]], and recent data have shown this drug to antagonize muscarinic receptors as well.","[ENTITY_A] is known to be an inhibitor of [ENTITY_B], and recent data have shown this drug to antagonize muscarinic receptors as well.",INHIBITOR,CPR:4,1,"Ambenonium is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize muscarinic receptors as well."
"These results show that << haloperidol >> promotes mTORC1- and S6K1-dependent phosphorylation of [[ rpS6 ]] at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs.","These results show that [ENTITY_A] promotes mTORC1- and S6K1-dependent phosphorylation of [ENTITY_B] at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs.",ACTIVATOR,CPR:3,0,"These results show that haloperidol promotes mTORC1- and S6K1-dependent phosphorylation of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs."
"However, upon addition of NO to << CDO >> in the presence of substrate [[ l-cysteine ]], a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops.","However, upon addition of NO to [ENTITY_A] in the presence of substrate [ENTITY_B], a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops.",SUBSTRATE,CPR:9,4,"However, upon addition of NO to CDO in the presence of substrate l-cysteine, a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops."
"From these data, it is inferred that both the << SERT >> and NET contribute to the active clearance of exogenously applied [[ 5-HT ]] in the dentate gyrus.","From these data, it is inferred that both the [ENTITY_A] and NET contribute to the active clearance of exogenously applied [ENTITY_B] in the dentate gyrus.",SUBSTRATE,CPR:9,4,"From these data, it is inferred that both the SERT and NET contribute to the active clearance of exogenously applied 5-HT in the dentate gyrus."
"<< Sorafenib >> (BAY43-9006, Nexavar) is a small molecule [[ B-RAF ]] inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.","[ENTITY_A] (BAY43-9006, Nexavar) is a small molecule [ENTITY_B] inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.",INHIBITOR,CPR:4,1,"Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families."
Oral << l-glutamine >> increases active [[ GLP-1 ]] (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.,Oral [ENTITY_A] increases active [ENTITY_B] (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.,INDIRECT-UPREGULATOR,CPR:3,0,Oral l-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.
"In lymphocytes, the NTPDase and << ADA >> activities were increased in all groups treated with [[ caffeic acid ]] when compared to control (P<0.05).","In lymphocytes, the NTPDase and [ENTITY_A] activities were increased in all groups treated with [ENTITY_B] when compared to control (P<0.05).",ACTIVATOR,CPR:3,0,"In lymphocytes, the NTPDase and ADA activities were increased in all groups treated with caffeic acid when compared to control (P<0.05)."
We have identified << 3-hydroxypyridin-2-thione >> (3-HPT) as a novel ZBG that is compatible with [[ HDAC ]] inhibition.,We have identified [ENTITY_A] (3-HPT) as a novel ZBG that is compatible with [ENTITY_B] inhibition.,INHIBITOR,CPR:4,1,We have identified 3-hydroxypyridin-2-thione (3-HPT) as a novel ZBG that is compatible with HDAC inhibition.
"An increase in the << ADP >>/ATP ratio opens [[ K(ATP) channels ]], leading to membrane hyperpolarization.","An increase in the [ENTITY_A]/ATP ratio opens [ENTITY_B], leading to membrane hyperpolarization.",ACTIVATOR,CPR:3,0,"An increase in the ADP/ATP ratio opens K(ATP) channels, leading to membrane hyperpolarization."
"Both << fatty acids >>, but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of [[ cytokine ]]-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.","Both [ENTITY_A], but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of [ENTITY_B]-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Both fatty acids, but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells."
"In summary, the therapeutic effect of << clozapine >> in reversing PPI impairment was mimicked by the [[ H(1) ]] antagonist pyrilamine, while pyrilamine had a mixed effect on cognition.","In summary, the therapeutic effect of [ENTITY_A] in reversing PPI impairment was mimicked by the [ENTITY_B] antagonist pyrilamine, while pyrilamine had a mixed effect on cognition.",DOWNREGULATOR,CPR:4,1,"In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the H(1) antagonist pyrilamine, while pyrilamine had a mixed effect on cognition."
"Furthermore, MDZ caused mechanism-based inactivation of << cytochrome P450 3A >>-dependent [[ TRZ ]] 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.","Furthermore, MDZ caused mechanism-based inactivation of [ENTITY_A]-dependent [ENTITY_B] 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.",SUBSTRATE,CPR:9,4,"Furthermore, MDZ caused mechanism-based inactivation of cytochrome P450 3A-dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies."
"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas << troglitazone >>, a specific activator of [[ PPAR-gamma ]], also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.","4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas [ENTITY_A], a specific activator of [ENTITY_B], also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.",ACTIVATOR,CPR:3,0,"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice."
Combined application of << dexamethasone >> and amrinone caused additive inhibition of [[ TNF ]] biosynthesis in vitro.,Combined application of [ENTITY_A] and amrinone caused additive inhibition of [ENTITY_B] biosynthesis in vitro.,INHIBITOR,CPR:4,1,Combined application of dexamethasone and amrinone caused additive inhibition of TNF biosynthesis in vitro.
Optimization of << 5-hydroxytryptamines >> as dual function inhibitors targeting [[ phospholipase A2 ]] and leukotriene A4 hydrolase.,Optimization of [ENTITY_A] as dual function inhibitors targeting [ENTITY_B] and leukotriene A4 hydrolase.,INHIBITOR,CPR:4,1,Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase.
<< DHODH >> inhibition occurs at lower concentrations of [[ A77 1726 ]] than that of tyrosine kinases and is currently considered the major mode of action.,[ENTITY_A] inhibition occurs at lower concentrations of [ENTITY_B] than that of tyrosine kinases and is currently considered the major mode of action.,INHIBITOR,CPR:4,1,DHODH inhibition occurs at lower concentrations of A77 1726 than that of tyrosine kinases and is currently considered the major mode of action.
<< Irbesartan >> may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of [[ angiotensin II ]].,[ENTITY_A] may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of [ENTITY_B].,DOWNREGULATOR,CPR:4,1,Irbesartan may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II.
"A dominant negative PKA (DNPKA) reduced << GnRH >>-stimulated [[ pCREB ]] and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.","A dominant negative PKA (DNPKA) reduced [ENTITY_A]-stimulated [ENTITY_B] and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.",ACTIVATOR,CPR:3,0,"A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway."
This inhibition was mediated by a << TCDD >>-induced secreted factor which was identified as [[ insulin-like growth factor binding protein 4 ]] (IGFBP-4).,This inhibition was mediated by a [ENTITY_A]-induced secreted factor which was identified as [ENTITY_B] (IGFBP-4).,UPREGULATOR,CPR:3,0,This inhibition was mediated by a TCDD-induced secreted factor which was identified as insulin-like growth factor binding protein 4 (IGFBP-4).
"This aminophospholipid ""<< flippase >>"" selectively transports [[ PS ]] to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents.","This aminophospholipid ""[ENTITY_A]"" selectively transports [ENTITY_B] to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents.",SUBSTRATE,CPR:9,4,"This aminophospholipid ""flippase"" selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents."
The related piperidines ohmefentanyl and << sufentanil >> and the nonselective opioid receptor agonist etorphine were less potent [[ nociceptin receptor ]] agonists.,The related piperidines ohmefentanyl and [ENTITY_A] and the nonselective opioid receptor agonist etorphine were less potent [ENTITY_B] agonists.,AGONIST,CPR:5,2,The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent nociceptin receptor agonists.
These findings suggest that << RhBG >> and RhCG may play important and cell-specific roles in [[ ammonium ]] transport and signaling in these regions of the kidney.,These findings suggest that [ENTITY_A] and RhCG may play important and cell-specific roles in [ENTITY_B] transport and signaling in these regions of the kidney.,SUBSTRATE,CPR:9,4,These findings suggest that RhBG and RhCG may play important and cell-specific roles in ammonium transport and signaling in these regions of the kidney.
"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of << Na,K-ATPase beta >> subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of [[ SC-51089 ]].","In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of [ENTITY_A] subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089."
"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFα levels) was seen in LPS-stimulated human PBMCs, except with << JWH-210 >> and JWH-122 which caused a decrease of [[ TNFα ]] and IL-12/23p40.","Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFα levels) was seen in LPS-stimulated human PBMCs, except with [ENTITY_A] and JWH-122 which caused a decrease of [ENTITY_B] and IL-12/23p40.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFα levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and JWH-122 which caused a decrease of TNFα and IL-12/23p40."
"We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by << adenosine triphosphate-binding cassette A1 >>- (ABCA1), dependent [[ cholesterol ]] efflux from macrophages.","We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by [ENTITY_A]- (ABCA1), dependent [ENTITY_B] efflux from macrophages.",SUBSTRATE,CPR:9,4,"We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1- (ABCA1), dependent cholesterol efflux from macrophages."
"Also, prophylactic, as well as therapeutic, treatment with the << CSE >> inhibitor, [[ DL-propargylglycine ]] (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.","Also, prophylactic, as well as therapeutic, treatment with the [ENTITY_A] inhibitor, [ENTITY_B] (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.",INHIBITOR,CPR:4,1,"Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury."
"This agent acts synergistically with many << penicillins >>, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the [[ peptidoglycan ]] of the bacterial cell wall.","This agent acts synergistically with many [ENTITY_A], such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the [ENTITY_B] of the bacterial cell wall.",INDIRECT-UPREGULATOR,CPR:3,0,"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the peptidoglycan of the bacterial cell wall."
"Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (<< ACh >>); [[ choline acetyltransferase ]] (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).","Lymphocytes possess the essential components of a cholinergic system, including acetylcholine ([ENTITY_A]); [ENTITY_B] (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).",PRODUCT-OF,CPR:9,4,"Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)."
"Interestingly, << gemfibrozil >> strongly inhibited the activation of [[ NF-kappaB ]], AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells.","Interestingly, [ENTITY_A] strongly inhibited the activation of [ENTITY_B], AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells.",INHIBITOR,CPR:4,1,"Interestingly, gemfibrozil strongly inhibited the activation of NF-kappaB, AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells."
"Also, << SB365 >> showed anti-angiogenic activity by decreasing the expression of [[ HIF-1α ]] and VEGF.","Also, [ENTITY_A] showed anti-angiogenic activity by decreasing the expression of [ENTITY_B] and VEGF.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Also, SB365 showed anti-angiogenic activity by decreasing the expression of HIF-1α and VEGF."
"A broad-spectrum << phosphodiesterase >> (PDE) inhibitor ([[ 1,3-isobutyl-1-methylxanthine ]], 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively.","A broad-spectrum [ENTITY_A] (PDE) inhibitor ([ENTITY_B], 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively.",INHIBITOR,CPR:4,1,"A broad-spectrum phosphodiesterase (PDE) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively."
"<< Dabigatran >> has an advantage over the indirect [[ thrombin ]] inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin.","[ENTITY_A] has an advantage over the indirect [ENTITY_B] inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin.",INHIBITOR,CPR:4,1,"Dabigatran has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin."
"Moreover, << curcumin >> alleviated [[ Sim2 ]] expression, and reversely raised Drebrin expression in neurons treated with hyperglycaemia.","Moreover, [ENTITY_A] alleviated [ENTITY_B] expression, and reversely raised Drebrin expression in neurons treated with hyperglycaemia.",INDIRECT-UPREGULATOR,CPR:3,0,"Moreover, curcumin alleviated Sim2 expression, and reversely raised Drebrin expression in neurons treated with hyperglycaemia."
The significantly decreased levels of << p-PI3K >> and p-AKT expression were observed in SGC-7901 cells after [[ β-ionone ]] treatments in a time- and dose-dependent manner (P < 0.01).,The significantly decreased levels of [ENTITY_A] and p-AKT expression were observed in SGC-7901 cells after [ENTITY_B] treatments in a time- and dose-dependent manner (P < 0.01).,INDIRECT-DOWNREGULATOR,CPR:4,1,The significantly decreased levels of p-PI3K and p-AKT expression were observed in SGC-7901 cells after β-ionone treatments in a time- and dose-dependent manner (P < 0.01).
"Furthermore, RT-PCR analyses revealed that << minocycline >> treatment increased expression of [[ interleukin-10 ]] mRNA but decreased tumor necrosis factor-alpha expression.","Furthermore, RT-PCR analyses revealed that [ENTITY_A] treatment increased expression of [ENTITY_B] mRNA but decreased tumor necrosis factor-alpha expression.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, RT-PCR analyses revealed that minocycline treatment increased expression of interleukin-10 mRNA but decreased tumor necrosis factor-alpha expression."
Two mechanisms of action have been identified for << A77 1726 >>: inhibition of [[ dihydroorotate dehydrogenase ]] (DHODH) and inhibition of tyrosine kinases.,Two mechanisms of action have been identified for [ENTITY_A]: inhibition of [ENTITY_B] (DHODH) and inhibition of tyrosine kinases.,INHIBITOR,CPR:4,1,Two mechanisms of action have been identified for A77 1726: inhibition of dihydroorotate dehydrogenase (DHODH) and inhibition of tyrosine kinases.
"Furthermore, MG132 prevented << glutamate >>-stimulated reduction in surface amount of [[ GluR2 ]], and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons.","Furthermore, MG132 prevented [ENTITY_A]-stimulated reduction in surface amount of [ENTITY_B], and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, MG132 prevented glutamate-stimulated reduction in surface amount of GluR2, and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons."
Mobility shift assays on whole cell extracts showed that << clenbuterol >> increased AP1 binding in 3T3 cells prior to increasing [[ NGF ]] synthesis.,Mobility shift assays on whole cell extracts showed that [ENTITY_A] increased AP1 binding in 3T3 cells prior to increasing [ENTITY_B] synthesis.,INDIRECT-UPREGULATOR,CPR:3,0,Mobility shift assays on whole cell extracts showed that clenbuterol increased AP1 binding in 3T3 cells prior to increasing NGF synthesis.
<< Am80 >> inhibited VEGF-induced phosphorylation of [[ VEGF receptor ]].,[ENTITY_A] inhibited VEGF-induced phosphorylation of [ENTITY_B].,INHIBITOR,CPR:4,1,Am80 inhibited VEGF-induced phosphorylation of VEGF receptor.
8-pCPT-2'-O-Me-cAMP-AM potentiation of << insulin >> secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor [[ bisindolylmaleimide I ]] (1 μM).,8-pCPT-2'-O-Me-cAMP-AM potentiation of [ENTITY_A] secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor [ENTITY_B] (1 μM).,INDIRECT-UPREGULATOR,CPR:3,0,8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM).
"Small interfering RNA directed BDNF, orexin-A, and << SB334867 >> [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific [[ orexin-1 receptor ]] antagonist] were administered directly into the hypothalamus.","Small interfering RNA directed BDNF, orexin-A, and [ENTITY_A] [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific [ENTITY_B] antagonist] were administered directly into the hypothalamus.",ANTAGONIST,CPR:6,3,"Small interfering RNA directed BDNF, orexin-A, and SB334867 [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus."
"Moreover, the production of << TXB2 >> during whole blood clotting was assessed as an index of the [[ cyclooxygenase ]] activity of platelet PGHS-1 ex vivo.","Moreover, the production of [ENTITY_A] during whole blood clotting was assessed as an index of the [ENTITY_B] activity of platelet PGHS-1 ex vivo.",PRODUCT-OF,CPR:9,4,"Moreover, the production of TXB2 during whole blood clotting was assessed as an index of the cyclooxygenase activity of platelet PGHS-1 ex vivo."
"<< Rasagiline >> is a novel, potent, and irreversible [[ monoamine oxidase type B ]] (MAO-B) inhibitor which has been approved for treatment of PD.","[ENTITY_A] is a novel, potent, and irreversible [ENTITY_B] (MAO-B) inhibitor which has been approved for treatment of PD.",INHIBITOR,CPR:4,1,"Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD."
<< Caerulein >> increased the levels of H(2)S and CSE mRNA expression while [[ CBS ]] mRNA expression was decreased.,[ENTITY_A] increased the levels of H(2)S and CSE mRNA expression while [ENTITY_B] mRNA expression was decreased.,INDIRECT-DOWNREGULATOR,CPR:4,1,Caerulein increased the levels of H(2)S and CSE mRNA expression while CBS mRNA expression was decreased.
"Taken together with a recent crystal structure of a lumiracoxib-COX-2 complex, the kinetic analyses presented herein of the inhibition of mutant << COX-2s >> by [[ lumiracoxib ]] allows the definition of the molecular basis of COX-2 inhibition.","Taken together with a recent crystal structure of a lumiracoxib-COX-2 complex, the kinetic analyses presented herein of the inhibition of mutant [ENTITY_A] by [ENTITY_B] allows the definition of the molecular basis of COX-2 inhibition.",INHIBITOR,CPR:4,1,"Taken together with a recent crystal structure of a lumiracoxib-COX-2 complex, the kinetic analyses presented herein of the inhibition of mutant COX-2s by lumiracoxib allows the definition of the molecular basis of COX-2 inhibition."
"4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with << GSK1292263 >>, which is consistent with an inhibitory effect on intestinal BCRP and [[ CYP3A4 ]].","4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with [ENTITY_A], which is consistent with an inhibitory effect on intestinal BCRP and [ENTITY_B].",INHIBITOR,CPR:4,1,"4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and CYP3A4."
"Next, we examined the role of Rho family GTPases in the << ceramide >>-induced signalling to [[ SRE ]] activation.","Next, we examined the role of Rho family GTPases in the [ENTITY_A]-induced signalling to [ENTITY_B] activation.",ACTIVATOR,CPR:3,0,"Next, we examined the role of Rho family GTPases in the ceramide-induced signalling to SRE activation."
"Furthermore, << DPEP >> inhibited the LPS-induced phosphorylation of inhibitor κB (IκB)-α and NF-κB [[ p50 ]].","Furthermore, [ENTITY_A] inhibited the LPS-induced phosphorylation of inhibitor κB (IκB)-α and NF-κB [ENTITY_B].",INHIBITOR,CPR:4,1,"Furthermore, DPEP inhibited the LPS-induced phosphorylation of inhibitor κB (IκB)-α and NF-κB p50."
<< Proline dehydrogenase >> (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to [[ glutamate ]].,[ENTITY_A] (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to [ENTITY_B].,PRODUCT-OF,CPR:9,4,Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate.
"In this study, we have synthesized novel << alpha-hydroxyphenylamide >> analogues of diphenylhydantoin and examined their ability to inhibit [[ human Na(V)1.5 ]] sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells.","In this study, we have synthesized novel [ENTITY_A] analogues of diphenylhydantoin and examined their ability to inhibit [ENTITY_B] sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells.",INHIBITOR,CPR:4,1,"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells."
<< Voltage-gated sodium (Na) channels >>[[ Na ]]) channels are a critical component of electrically excitable cells.,[ENTITY_A][ENTITY_B]) channels are a critical component of electrically excitable cells.,SUBSTRATE,CPR:9,4,Voltage-gated sodium (Na) channelsNa) channels are a critical component of electrically excitable cells.
"In addition to << CYP2B6 >>, [[ anisomycin ]] co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs.","In addition to [ENTITY_A], [ENTITY_B] co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs.",INDIRECT-UPREGULATOR,CPR:3,0,"In addition to CYP2B6, anisomycin co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs."
"Our study revealed that high << glucose >>/Fe concentrations in MIN6 cells induced an increase of the [[ Bcl2 ]]/Bax ratio, an indicator of increased cell apoptosis.","Our study revealed that high [ENTITY_A]/Fe concentrations in MIN6 cells induced an increase of the [ENTITY_B]/Bax ratio, an indicator of increased cell apoptosis.",INDIRECT-UPREGULATOR,CPR:3,0,"Our study revealed that high glucose/Fe concentrations in MIN6 cells induced an increase of the Bcl2/Bax ratio, an indicator of increased cell apoptosis."
"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, << WAY100635 >>, a selective [[ 5-HT(1A) ]] antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.","Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, [ENTITY_A], a selective [ENTITY_B] antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.",ANTAGONIST,CPR:6,3,"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade."
"<< Mibefradil >> blocked [[ Nav1.5 ]] in a use/frequency-dependent manner, indicating preferential binding to states visited during depolarization.","[ENTITY_A] blocked [ENTITY_B] in a use/frequency-dependent manner, indicating preferential binding to states visited during depolarization.",INHIBITOR,CPR:4,1,"Mibefradil blocked Nav1.5 in a use/frequency-dependent manner, indicating preferential binding to states visited during depolarization."
"<< DPEP >> inhibited LPS-induced phosphorylation of [[ ERK ]], JNK, and p38.","[ENTITY_A] inhibited LPS-induced phosphorylation of [ENTITY_B], JNK, and p38.",INHIBITOR,CPR:4,1,"DPEP inhibited LPS-induced phosphorylation of ERK, JNK, and p38."
<< All-trans retinoic acid >> protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating [[ collagen 8A2 ]].,[ENTITY_A] protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating [ENTITY_B].,UPREGULATOR,CPR:3,0,All-trans retinoic acid protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating collagen 8A2.
"This study shows that the potency of << GW660511X >> in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of [[ ACE ]]/NEP inhibition in relation to effects in humans.","This study shows that the potency of [ENTITY_A] in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of [ENTITY_B]/NEP inhibition in relation to effects in humans.",INHIBITOR,CPR:4,1,"This study shows that the potency of GW660511X in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE/NEP inhibition in relation to effects in humans."
Combination chemotherapy with a << substance P receptor >> antagonist ([[ aprepitant ]]) and melarsoprol in a mouse model of human African trypanosomiasis.,Combination chemotherapy with a [ENTITY_A] antagonist ([ENTITY_B]) and melarsoprol in a mouse model of human African trypanosomiasis.,ANTAGONIST,CPR:6,3,Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis.
"Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with << carbon monoxide >> (CO), an end product of [[ HO-1 ]].","Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with [ENTITY_A] (CO), an end product of [ENTITY_B].",PRODUCT-OF,CPR:9,4,"Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1."
These results suggest that << ACS1 >> and ACS4 may be linked to [[ triacylglycerol ]] synthesis.,These results suggest that [ENTITY_A] and ACS4 may be linked to [ENTITY_B] synthesis.,PRODUCT-OF,CPR:9,4,These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis.
The << mianserin >> analogue mirtazapine also displayed [[ kappa-opioid ]] agonist activity.,The [ENTITY_A] analogue mirtazapine also displayed [ENTITY_B] agonist activity.,AGONIST,CPR:5,2,The mianserin analogue mirtazapine also displayed kappa-opioid agonist activity.
"<< mTOR >> was still inhibited by [[ aspirin ]] in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR.","[ENTITY_A] was still inhibited by [ENTITY_B] in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR.",INHIBITOR,CPR:4,1,"mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR."
4. Administration of a single dose of << DEX-P >> showed a temporal increase in [[ CYP3A ]] activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration.,4. Administration of a single dose of [ENTITY_A] showed a temporal increase in [ENTITY_B] activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration.,ACTIVATOR,CPR:3,0,4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12 h after DEX-P administration.
"Plasmacytoid dendritic cells produce cytokines and mature in response to the << TLR7 >> agonists, imiquimod and [[ resiquimod ]].","Plasmacytoid dendritic cells produce cytokines and mature in response to the [ENTITY_A] agonists, imiquimod and [ENTITY_B].",AGONIST,CPR:5,2,"Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod."
<< Genistein >> also reduced the formation of stress fibers by [[ thrombin ]] and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs).,[ENTITY_A] also reduced the formation of stress fibers by [ENTITY_B] and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs).,INHIBITOR,CPR:4,1,Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs).
<< Trichostatin A >> inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced [[ NF-E2-related factor 2 ]]-antioxidant response element signaling.,[ENTITY_A] inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced [ENTITY_B]-antioxidant response element signaling.,INDIRECT-UPREGULATOR,CPR:3,0,Trichostatin A inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling.
"One exception is << tranexamic acid >> (TXA), which, as a lysine mimetic, inhibits binding of [[ plasminogen ]] to fibrin.","One exception is [ENTITY_A] (TXA), which, as a lysine mimetic, inhibits binding of [ENTITY_B] to fibrin.",INHIBITOR,CPR:4,1,"One exception is tranexamic acid (TXA), which, as a lysine mimetic, inhibits binding of plasminogen to fibrin."
The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the << GluR5 >> kainate receptor antagonist [[ LY293558 ]].,The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the [ENTITY_A] kainate receptor antagonist [ENTITY_B].,ANTAGONIST,CPR:6,3,The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 kainate receptor antagonist LY293558.
"The results of clinical trials with << enalkiren >> are encouraging, and suggest that [[ renin ]] inhibitors may be safe, useful therapeutic agents in the management of hypertension.","The results of clinical trials with [ENTITY_A] are encouraging, and suggest that [ENTITY_B] inhibitors may be safe, useful therapeutic agents in the management of hypertension.",INHIBITOR,CPR:4,1,"The results of clinical trials with enalkiren are encouraging, and suggest that renin inhibitors may be safe, useful therapeutic agents in the management of hypertension."
"<< Pseudoephedrine >> inhibits T-cell activation by targeting [[ NF-kappaB ]], NFAT and AP-1 signaling pathways.","[ENTITY_A] inhibits T-cell activation by targeting [ENTITY_B], NFAT and AP-1 signaling pathways.",INHIBITOR,CPR:4,1,"Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways."
"<< Celecoxib >> selectively suppressed PGE2 but not TxB2 at time points consistent with [[ COX-2 ]] activity, while producing analgesia.","[ENTITY_A] selectively suppressed PGE2 but not TxB2 at time points consistent with [ENTITY_B] activity, while producing analgesia.",INHIBITOR,CPR:4,1,"Celecoxib selectively suppressed PGE2 but not TxB2 at time points consistent with COX-2 activity, while producing analgesia."
<< GDC-0152 >> is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing [[ IAPs ]].,[ENTITY_A] is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing [ENTITY_B].,ANTAGONIST,CPR:6,3,GDC-0152 is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing IAPs.
"Neuroprotective effect of << nimesulide >>, a preferential [[ COX-2 ]] inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice.","Neuroprotective effect of [ENTITY_A], a preferential [ENTITY_B] inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice.",INHIBITOR,CPR:4,1,"Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice."
"Aspirin and << metformin >> (an activator of AMPK) increased inhibition of [[ mTOR ]] and Akt, as well as autophagy in CRC cells.","Aspirin and [ENTITY_A] (an activator of AMPK) increased inhibition of [ENTITY_B] and Akt, as well as autophagy in CRC cells.",INHIBITOR,CPR:4,1,"Aspirin and metformin (an activator of AMPK) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells."
"Although << thioredoxin reductase >> (TRR) inhibitors ([[ aurothioglucose ]] and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.","Although [ENTITY_A] (TRR) inhibitors ([ENTITY_B] and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.",INHIBITOR,CPR:4,1,"Although thioredoxin reductase (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction."
FMLP/CB-stimulated translocation of << cPLA2 >> to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by [[ FP ]].,FMLP/CB-stimulated translocation of [ENTITY_A] to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by [ENTITY_B].,INDIRECT-DOWNREGULATOR,CPR:4,1,FMLP/CB-stimulated translocation of cPLA2 to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by FP.
"Furthermore, << TSA >> also decreased cellular ROS and H(2)O(2) accumulation induced by [[ TGF-β ]], whereas it elevated intracellular GSH level and cellular total antioxidant capacity.","Furthermore, [ENTITY_A] also decreased cellular ROS and H(2)O(2) accumulation induced by [ENTITY_B], whereas it elevated intracellular GSH level and cellular total antioxidant capacity.",INHIBITOR,CPR:4,1,"Furthermore, TSA also decreased cellular ROS and H(2)O(2) accumulation induced by TGF-β, whereas it elevated intracellular GSH level and cellular total antioxidant capacity."
"<< Tamsulosin >>, the first prostate-selective [[ alpha 1A-adrenoceptor ]] antagonist.","[ENTITY_A], the first prostate-selective [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist."
"In unstimulated cells, << Nor-NOHA >> dose-dependently reduced the [[ arginase ]] activity with maximal inhibition at 20 microM.","In unstimulated cells, [ENTITY_A] dose-dependently reduced the [ENTITY_B] activity with maximal inhibition at 20 microM.",INHIBITOR,CPR:4,1,"In unstimulated cells, Nor-NOHA dose-dependently reduced the arginase activity with maximal inhibition at 20 microM."
The expressions of << HSP70 >> and HO-1 were significantly (P<0.05) increased in the [[ NaAsO2 ]] group and reduced in the combined treatment group.,The expressions of [ENTITY_A] and HO-1 were significantly (P<0.05) increased in the [ENTITY_B] group and reduced in the combined treatment group.,INDIRECT-UPREGULATOR,CPR:3,0,The expressions of HSP70 and HO-1 were significantly (P<0.05) increased in the NaAsO2 group and reduced in the combined treatment group.
"<< Lenalidomide >> and pomalidomide inhibited autoubiquitination of [[ CRBN ]] in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA).","[ENTITY_A] and pomalidomide inhibited autoubiquitination of [ENTITY_B] in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA).",INHIBITOR,CPR:4,1,"Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA)."
"We now show that mutation of the 769R/ G desensitization site (Lomeli, H.M.J., Melcher, T., Hoger, T., Geiger, J.R., Kuner, T., Monyer, H., Higuchi, M.B.A. and Seeburg, P.H, Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science, 9(266) (1994) 1709-1713) greatly attenuates the << lithium >>-induced potentiation of [[ GluR3 ]].","We now show that mutation of the 769R/ G desensitization site (Lomeli, H.M.J., Melcher, T., Hoger, T., Geiger, J.R., Kuner, T., Monyer, H., Higuchi, M.B.A. and Seeburg, P.H, Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science, 9(266) (1994) 1709-1713) greatly attenuates the [ENTITY_A]-induced potentiation of [ENTITY_B].",ACTIVATOR,CPR:3,0,"We now show that mutation of the 769R/ G desensitization site (Lomeli, H.M.J., Melcher, T., Hoger, T., Geiger, J.R., Kuner, T., Monyer, H., Higuchi, M.B.A. and Seeburg, P.H, Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science, 9(266) (1994) 1709-1713) greatly attenuates the lithium-induced potentiation of GluR3."
"Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the << isoprenaline >> responses of the atria and the pA2 values were 8.60 and 8.98 at the [[ beta 1-adrenoceptors ]] of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.","Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the [ENTITY_A] responses of the atria and the pA2 values were 8.60 and 8.98 at the [ENTITY_B] of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.",AGONIST,CPR:5,2,"Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the beta 1-adrenoceptors of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors."
<< Licofelone >> almost abolished [[ 5-LOX ]] activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.,[ENTITY_A] almost abolished [ENTITY_B] activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.,INHIBITOR,CPR:4,1,Licofelone almost abolished 5-LOX activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.
"Taken together, these findings indicate that the inhibition of melanogenesis by << artemisinic acid >> occurs through reduced expression of the [[ HMG CoA reductase ]] gene, which is mediated by C/EBP α inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor.","Taken together, these findings indicate that the inhibition of melanogenesis by [ENTITY_A] occurs through reduced expression of the [ENTITY_B] gene, which is mediated by C/EBP α inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Taken together, these findings indicate that the inhibition of melanogenesis by artemisinic acid occurs through reduced expression of the HMG CoA reductase gene, which is mediated by C/EBP α inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor."
<< VGLUT1 >> is localized in transcytotic vesicles and accumulates [[ L-glutamate ]].,[ENTITY_A] is localized in transcytotic vesicles and accumulates [ENTITY_B].,SUBSTRATE,CPR:9,4,VGLUT1 is localized in transcytotic vesicles and accumulates L-glutamate.
<< Nicotinamide N-methyltransferase >> (NNMT) catalyses the conversion of nicotinamide to [[ 1-methylnicotinamide ]] and plays an important role in hepatic detoxification reactions.,[ENTITY_A] (NNMT) catalyses the conversion of nicotinamide to [ENTITY_B] and plays an important role in hepatic detoxification reactions.,PRODUCT-OF,CPR:9,4,Nicotinamide N-methyltransferase (NNMT) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.
"<< Indomethacin >> completely antagonizes [[ CA ]] activity, i.e. abolishes the inhibitory effect of acetazolamide on CA.","[ENTITY_A] completely antagonizes [ENTITY_B] activity, i.e. abolishes the inhibitory effect of acetazolamide on CA.",ACTIVATOR,CPR:3,0,"Indomethacin completely antagonizes CA activity, i.e. abolishes the inhibitory effect of acetazolamide on CA."
"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the << mAChR >> antagonist [[ atropine ]].","Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the [ENTITY_A] antagonist [ENTITY_B].",ANTAGONIST,CPR:6,3,"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine."
"Furthermore, << insulin >>-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by [[ rapamycin ]].","Furthermore, [ENTITY_A]-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by rapamycin."
"However, when naloxone was administered concurrently with << ethanol >> treatment, it antagonized the down-regulation of [[ p-CREB ]] protein in the nucleus accumbens (142 %) of rats exposed to ethanol.","However, when naloxone was administered concurrently with [ENTITY_A] treatment, it antagonized the down-regulation of [ENTITY_B] protein in the nucleus accumbens (142 %) of rats exposed to ethanol.",INDIRECT-DOWNREGULATOR,CPR:4,1,"However, when naloxone was administered concurrently with ethanol treatment, it antagonized the down-regulation of p-CREB protein in the nucleus accumbens (142 %) of rats exposed to ethanol."
<< CYP1A1 >> and CYP1A2 mRNAs were also increased by [[ pelargonidin ]] in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.,[ENTITY_A] and CYP1A2 mRNAs were also increased by [ENTITY_B] in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.,INDIRECT-UPREGULATOR,CPR:3,0,CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.
"Fisetin treatment inhibited adipocyte differentiation, consistent with the negative effect of << fisetin >> on [[ mTOR ]].","Fisetin treatment inhibited adipocyte differentiation, consistent with the negative effect of [ENTITY_A] on [ENTITY_B].",DOWNREGULATOR,CPR:4,1,"Fisetin treatment inhibited adipocyte differentiation, consistent with the negative effect of fisetin on mTOR."
<< N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase >> (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the [[ mannose 6-phosphate ]] determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.,[ENTITY_A] (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the [ENTITY_B] determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.,PRODUCT-OF,CPR:9,4,N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.
"<< 13cisRA >> and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma [[ osteocalcin ]], an effect that correlated with retinoid-induced bone effects.","[ENTITY_A] and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma [ENTITY_B], an effect that correlated with retinoid-induced bone effects.",INDIRECT-DOWNREGULATOR,CPR:4,1,"13cisRA and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma osteocalcin, an effect that correlated with retinoid-induced bone effects."
"With respect to the << quinone >> co-substrate of the [[ dihydroorotate dehydrogenase ]], atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase.","With respect to the [ENTITY_A] co-substrate of the [ENTITY_B], atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase.",SUBSTRATE,CPR:9,4,"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase."
"Activation of PPARgamma with traditional agonists mimics the << RhoA >>-inhibiting properties of [[ ibuprofen ]] in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors.","Activation of PPARgamma with traditional agonists mimics the [ENTITY_A]-inhibiting properties of [ENTITY_B] in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors.",INHIBITOR,CPR:4,1,"Activation of PPARgamma with traditional agonists mimics the RhoA-inhibiting properties of ibuprofen in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors."
"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with << alpha(2A)-autoreceptors >>, at which, however, both rilmenidine and [[ oxymetazoline ]] exhibit different properties (antagonism and agonism, respectively).","The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with [ENTITY_A], at which, however, both rilmenidine and [ENTITY_B] exhibit different properties (antagonism and agonism, respectively).",AGONIST,CPR:5,2,"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with alpha(2A)-autoreceptors, at which, however, both rilmenidine and oxymetazoline exhibit different properties (antagonism and agonism, respectively)."
"In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete << Cl- >> into the luminal fluid through [[ NKCC1 ]]-mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane.","In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete [ENTITY_A] into the luminal fluid through [ENTITY_B]-mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane.",SUBSTRATE,CPR:9,4,"In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through NKCC1-mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane."
"In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective << alpha 1A-adrenoceptor >> antagonist [[ WB 4101 ]] (100 nM).","In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective [ENTITY_A] antagonist [ENTITY_B] (100 nM).",ANTAGONIST,CPR:6,3,"In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective alpha 1A-adrenoceptor antagonist WB 4101 (100 nM)."
"Agents which have recently been shown to block << cyclin D1 >> translation by regulating calcium levels are the [[ unsaturated essential fatty acid ]], eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole.","Agents which have recently been shown to block [ENTITY_A] translation by regulating calcium levels are the [ENTITY_B], eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Agents which have recently been shown to block cyclin D1 translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole."
"<< KCNK1 >>, a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after [[ phenobarbital ]] treatment.","[ENTITY_A], a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after [ENTITY_B] treatment.",ACTIVATOR,CPR:3,0,"KCNK1, a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after phenobarbital treatment."
The mechanism of << PAK1 >> inhibition and induction of membranous translocation of adhesion proteins by [[ 5-ASA ]] might be independent of its known anti-inflammatory action.,The mechanism of [ENTITY_A] inhibition and induction of membranous translocation of adhesion proteins by [ENTITY_B] might be independent of its known anti-inflammatory action.,INHIBITOR,CPR:4,1,The mechanism of PAK1 inhibition and induction of membranous translocation of adhesion proteins by 5-ASA might be independent of its known anti-inflammatory action.
"CONCLUSION: Our findings demonstrate that << (R)-omeprazole >> HI correlated better with [[ CYP2C19 ]] genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.","CONCLUSION: Our findings demonstrate that [ENTITY_A] HI correlated better with [ENTITY_B] genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.",SUBSTRATE,CPR:9,4,"CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with CYP2C19 genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment."
<< Mammalian cysteine dioxygenase >> (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative [[ cysteine ]] catabolism.,[ENTITY_A] (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative [ENTITY_B] catabolism.,SUBSTRATE,CPR:9,4,Mammalian cysteine dioxygenase (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism.
"Thus, our findings indicate that the expression of Brms1L depends on β-catenin activity and contributes to << FSHβ >> induction by [[ GnRH ]].","Thus, our findings indicate that the expression of Brms1L depends on β-catenin activity and contributes to [ENTITY_A] induction by [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"Thus, our findings indicate that the expression of Brms1L depends on β-catenin activity and contributes to FSHβ induction by GnRH."
<< Rasagiline >> is a propargylamine and irreversible [[ monoamine oxidase (MAO) B ]] inhibitor used for the treatment of Parkinson's disease (PD).,[ENTITY_A] is a propargylamine and irreversible [ENTITY_B] inhibitor used for the treatment of Parkinson's disease (PD).,INHIBITOR,CPR:4,1,Rasagiline is a propargylamine and irreversible monoamine oxidase (MAO) B inhibitor used for the treatment of Parkinson's disease (PD).
"A N,N-dimethylaminopropyl derivative showed promising inhibition of << Trypanosoma cruzi OSC >> in combination with low cytotoxicity, and showed significant reduction of [[ cholesterol ]] biosynthesis in a human cell line.","A N,N-dimethylaminopropyl derivative showed promising inhibition of [ENTITY_A] in combination with low cytotoxicity, and showed significant reduction of [ENTITY_B] biosynthesis in a human cell line.",PRODUCT-OF,CPR:9,4,"A N,N-dimethylaminopropyl derivative showed promising inhibition of Trypanosoma cruzi OSC in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line."
"During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to << retinal dehydrogenase 2 >> (raldh2), the key enzyme for [[ retinoic acid ]] synthesis.","During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to [ENTITY_A] (raldh2), the key enzyme for [ENTITY_B] synthesis.",PRODUCT-OF,CPR:9,4,"During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (raldh2), the key enzyme for retinoic acid synthesis."
<< MMP-2 >> and MMP-9 expressions and activities in right ventricles increased significantly in [[ monocrotaline ]]-injected rats and captopril inhibited them.,[ENTITY_A] and MMP-9 expressions and activities in right ventricles increased significantly in [ENTITY_B]-injected rats and captopril inhibited them.,ACTIVATOR,CPR:3,0,MMP-2 and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and captopril inhibited them.
"The identity of the lung << beta-ADHs >> was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by [[ 4-methylpyrazole ]] or 1,10-phenanthroline.","The identity of the lung [ENTITY_A] was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by [ENTITY_B] or 1,10-phenanthroline.",INHIBITOR,CPR:4,1,"The identity of the lung beta-ADHs was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline."
"<< [-]-Huperzine A >> ([-]-Hup A), is a naturally occurring potent reversible [[ AChE ]] inhibitor that penetrates the blood-brain barrier.","[ENTITY_A] ([-]-Hup A), is a naturally occurring potent reversible [ENTITY_B] inhibitor that penetrates the blood-brain barrier.",INHIBITOR,CPR:4,1,"[-]-Huperzine A ([-]-Hup A), is a naturally occurring potent reversible AChE inhibitor that penetrates the blood-brain barrier."
"In addition, << PFD >> reduces the protein levels of the [[ matrix metalloproteinase (MMP)-11 ]], a TGF-beta target gene and furin substrate involved in carcinogenesis.","In addition, [ENTITY_A] reduces the protein levels of the [ENTITY_B], a TGF-beta target gene and furin substrate involved in carcinogenesis.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, PFD reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and furin substrate involved in carcinogenesis."
"Results showed that << DMF >> increased nuclear levels of [[ Nrf2 ]], and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).","Results showed that [ENTITY_A] increased nuclear levels of [ENTITY_B], and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).",INDIRECT-UPREGULATOR,CPR:3,0,"Results showed that DMF increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)."
<< Multidrug resistance-associated proteins >> are involved in the transport of the [[ glutathione ]] conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells.,[ENTITY_A] are involved in the transport of the [ENTITY_B] conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells.,SUBSTRATE,CPR:9,4,Multidrug resistance-associated proteins are involved in the transport of the glutathione conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells.
"SIRT1 co-precipitated with PPARα and nicotinamide increased the acetylation of the PPARα coactivator << PGC-1α >>, which was suppressed by [[ resveratrol ]].","SIRT1 co-precipitated with PPARα and nicotinamide increased the acetylation of the PPARα coactivator [ENTITY_A], which was suppressed by [ENTITY_B].",INHIBITOR,CPR:4,1,"SIRT1 co-precipitated with PPARα and nicotinamide increased the acetylation of the PPARα coactivator PGC-1α, which was suppressed by resveratrol."
"We observed similar effects of << Ag >> NPs on inflammatory mediator expression in vitro and in vivo with increase of [[ interleukin-8 ]] (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro.","We observed similar effects of [ENTITY_A] NPs on inflammatory mediator expression in vitro and in vivo with increase of [ENTITY_B] (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro.",INDIRECT-UPREGULATOR,CPR:3,0,"We observed similar effects of Ag NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro."
"<< P505-15 >> (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule [[ SYK ]] inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.","[ENTITY_A] (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule [ENTITY_B] inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.",INHIBITOR,CPR:4,1,"P505-15 (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases."
"The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) << PhIP >> (10 and/or 15mg/kg) significantly decreased [[ superoxide dismutase ]] (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control.","The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) [ENTITY_A] (10 and/or 15mg/kg) significantly decreased [ENTITY_B] (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control.",DOWNREGULATOR,CPR:4,1,"The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control."
<< Troglitazone >> reduces [[ plasminogen activator inhibitor-1 ]] expression and secretion in cultured human adipocytes.,[ENTITY_A] reduces [ENTITY_B] expression and secretion in cultured human adipocytes.,INDIRECT-DOWNREGULATOR,CPR:4,1,Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes.
"These compounds were evaluated for their acetylcholinesterase (AChE) inhibitory activity and << 5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile >> was found to be the most potent against [[ AChE ]] with IC50 4.16 μmol/L.",These compounds were evaluated for their acetylcholinesterase (AChE) inhibitory activity and [ENTITY_A] was found to be the most potent against [ENTITY_B] with IC50 4.16 μmol/L.,INHIBITOR,CPR:4,1,"These compounds were evaluated for their acetylcholinesterase (AChE) inhibitory activity and 5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile was found to be the most potent against AChE with IC50 4.16 μmol/L."
<< Simvastatin >> induces [[ interleukin-18 ]] production in human peripheral blood mononuclear cells.,[ENTITY_A] induces [ENTITY_B] production in human peripheral blood mononuclear cells.,INDIRECT-UPREGULATOR,CPR:3,0,Simvastatin induces interleukin-18 production in human peripheral blood mononuclear cells.
"This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of << Bcl-2 >>, as has been demonstrated for some nonselective NSAIDs, for instance, [[ flurbiprofen ]].","This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of [ENTITY_A], as has been demonstrated for some nonselective NSAIDs, for instance, [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of Bcl-2, as has been demonstrated for some nonselective NSAIDs, for instance, flurbiprofen."
"Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas << PRA >> was down-regulated in the uterus and oviduct after [[ ethanol ]] consumption.","Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas [ENTITY_A] was down-regulated in the uterus and oviduct after [ENTITY_B] consumption.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption."
"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for << 4-iodopropofol >>, 4-bromopropofol and 4-chloropropofol in [[ Na(V)1.4 ]], and 450 nM for 4-chloropropofol in Na(V)1.2.","Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for [ENTITY_A], 4-bromopropofol and 4-chloropropofol in [ENTITY_B], and 450 nM for 4-chloropropofol in Na(V)1.2.",INHIBITOR,CPR:4,1,"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in Na(V)1.4, and 450 nM for 4-chloropropofol in Na(V)1.2."
"Upon co-exposure to V(5+) and << TCDD >>, V(5+) significantly potentiated the TCDD-mediated induction of the [[ Cyp1a1 ]], Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24 h.","Upon co-exposure to V(5+) and [ENTITY_A], V(5+) significantly potentiated the TCDD-mediated induction of the [ENTITY_B], Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24 h.",ACTIVATOR,CPR:3,0,"Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24 h."
"It was, therefore, proposed that H. pylori may in fact, antagonize, << aspirin >>-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from [[ COX-2 ]] expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.","It was, therefore, proposed that H. pylori may in fact, antagonize, [ENTITY_A]-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from [ENTITY_B] expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.",ACTIVATOR,CPR:3,0,"It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF."
"Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the << GABA >> metabolizing enzyme, [[ GABA transaminase ]] (GABA-T).","Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the [ENTITY_A] metabolizing enzyme, [ENTITY_B] (GABA-T).",SUBSTRATE,CPR:9,4,"Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (GABA-T)."
"In addition, we found that << neoechinulin A >> significantly suppressed the production of neurotoxic inflammatory mediator [[ tumour necrosis factor-α ]] (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.","In addition, we found that [ENTITY_A] significantly suppressed the production of neurotoxic inflammatory mediator [ENTITY_B] (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells."
<< Celastrol >> highlights the therapeutic potential of agents targeting [[ TAK1 ]] as a key node in this pro-oncogenic TGF-β-NF-κB signal pathway.,[ENTITY_A] highlights the therapeutic potential of agents targeting [ENTITY_B] as a key node in this pro-oncogenic TGF-β-NF-κB signal pathway.,INHIBITOR,CPR:4,1,Celastrol highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic TGF-β-NF-κB signal pathway.
"<< VPA >> caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its [[ HDAC ]] inhibitory effect.","[ENTITY_A] caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its [ENTITY_B] inhibitory effect.",INHIBITOR,CPR:4,1,"VPA caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its HDAC inhibitory effect."
"The << benzothiophene hydroxyurea >>, zileuton, is the first selective [[ 5-LO ]] inhibitor evaluated for the treatment of patients with IBD.","The [ENTITY_A], zileuton, is the first selective [ENTITY_B] inhibitor evaluated for the treatment of patients with IBD.",INHIBITOR,CPR:4,1,"The benzothiophene hydroxyurea, zileuton, is the first selective 5-LO inhibitor evaluated for the treatment of patients with IBD."
Thus prolonged activation of NMDA receptors in hippocampal neurons reduced << GABAR δ subunit >> expression through [[ Ca2+ ]] entry and at least in part by ERK1/2 activation.,Thus prolonged activation of NMDA receptors in hippocampal neurons reduced [ENTITY_A] expression through [ENTITY_B] entry and at least in part by ERK1/2 activation.,DOWNREGULATOR,CPR:4,1,Thus prolonged activation of NMDA receptors in hippocampal neurons reduced GABAR δ subunit expression through Ca2+ entry and at least in part by ERK1/2 activation.
The ability of << sorafenib >> to inhibit oncogenic [[ PDGFRbeta ]] and FLT3 mutants and overcome resistance to other small molecule inhibitors.,The ability of [ENTITY_A] to inhibit oncogenic [ENTITY_B] and FLT3 mutants and overcome resistance to other small molecule inhibitors.,INHIBITOR,CPR:4,1,The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
"Furthermore, << gallium >> also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on [[ vacuolar-type H(+)-ATPases ]].","Furthermore, [ENTITY_A] also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on [ENTITY_B].",INHIBITOR,CPR:4,1,"Furthermore, gallium also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on vacuolar-type H(+)-ATPases."
"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between << diethylcarbamazine >> and piriprost, a [[ 5-lipoxygenase ]] inhibitor.","Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between [ENTITY_A] and piriprost, a [ENTITY_B] inhibitor.",INHIBITOR,CPR:4,1,"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor."
"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the << tert-butylcarbamate >> group at the CAP moiety as [[ histone deacetylase ]] (HDAC) inhibitors.","Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the [ENTITY_A] group at the CAP moiety as [ENTITY_B] (HDAC) inhibitors.",INHIBITOR,CPR:4,1,"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors."
"Finally, chronic administration of << metformin >> in diabetic mice restored cardiac autophagy by activating [[ JNK1 ]]-Bcl-2 pathways and dissociating Beclin1 and Bcl-2.","Finally, chronic administration of [ENTITY_A] in diabetic mice restored cardiac autophagy by activating [ENTITY_B]-Bcl-2 pathways and dissociating Beclin1 and Bcl-2.",ACTIVATOR,CPR:3,0,"Finally, chronic administration of metformin in diabetic mice restored cardiac autophagy by activating JNK1-Bcl-2 pathways and dissociating Beclin1 and Bcl-2."
"Here, we characterized the target profile of the dual << SRC >>/ABL inhibitor [[ bosutinib ]] employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.","Here, we characterized the target profile of the dual [ENTITY_A]/ABL inhibitor [ENTITY_B] employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.",INHIBITOR,CPR:4,1,"Here, we characterized the target profile of the dual SRC/ABL inhibitor bosutinib employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel."
Coupling this computational technique with a high-quality low-throughput screen identified << 5-(4-piperidyl)-3-isoxazolol >> (4-PIOL) as a potent [[ plasminogen ]] binding inhibitor with the potential for the treatment of various bleeding disorders.,Coupling this computational technique with a high-quality low-throughput screen identified [ENTITY_A] (4-PIOL) as a potent [ENTITY_B] binding inhibitor with the potential for the treatment of various bleeding disorders.,INHIBITOR,CPR:4,1,Coupling this computational technique with a high-quality low-throughput screen identified 5-(4-piperidyl)-3-isoxazolol (4-PIOL) as a potent plasminogen binding inhibitor with the potential for the treatment of various bleeding disorders.
"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against << alpha 1a-adrenoceptor >>-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for [[ WB4101 ]] and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.","The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against [ENTITY_A]-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for [ENTITY_B] and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",ANTAGONIST,CPR:6,3,"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against alpha 1a-adrenoceptor-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil."
<< Haloperidol >> promotes mTORC1-dependent phosphorylation of [[ ribosomal protein S6 ]] via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.,[ENTITY_A] promotes mTORC1-dependent phosphorylation of [ENTITY_B] via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.,ACTIVATOR,CPR:3,0,Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.
"When cultured in YPD medium containing 15% glucose under aerobic conditions, the << KGD1 >> (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of [[ succinate ]] than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.","When cultured in YPD medium containing 15% glucose under aerobic conditions, the [ENTITY_A] (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of [ENTITY_B] than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.",PRODUCT-OF,CPR:9,4,"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate."
"CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to H3 antagonists, indicates that << ABT-288 >> is unlikely to possess a high potential for abuse in the human population and suggests that [[ H3 ]] antagonists, as a class, are similar in this regard.","CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to H3 antagonists, indicates that [ENTITY_A] is unlikely to possess a high potential for abuse in the human population and suggests that [ENTITY_B] antagonists, as a class, are similar in this regard.",ANTAGONIST,CPR:6,3,"CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to H3 antagonists, indicates that ABT-288 is unlikely to possess a high potential for abuse in the human population and suggests that H3 antagonists, as a class, are similar in this regard."
"The results showed that IR tyrosine phosphorylation (<< pIR >>) was reduced by 42 % in MSG-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.); control, 11.5 ± 0.4 a.u.); on the other hand, exercise training increased pIR by 76 % in MSG mice without affecting control mice ([[ MSG ]], 11.8 ± 0.3; control, 12.8 ± 0.2 a.u.).","The results showed that IR tyrosine phosphorylation ([ENTITY_A]) was reduced by 42 % in MSG-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.); control, 11.5 ± 0.4 a.u.); on the other hand, exercise training increased pIR by 76 % in MSG mice without affecting control mice ([ENTITY_B], 11.8 ± 0.3; control, 12.8 ± 0.2 a.u.).",DOWNREGULATOR,CPR:4,1,"The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42 % in MSG-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.); control, 11.5 ± 0.4 a.u.); on the other hand, exercise training increased pIR by 76 % in MSG mice without affecting control mice (MSG, 11.8 ± 0.3; control, 12.8 ± 0.2 a.u.)."
"<< Mimosine >>, a well-known competitive inhibitor of [[ tyrosinase ]], competitively inhibited the new reaction also.","[ENTITY_A], a well-known competitive inhibitor of [ENTITY_B], competitively inhibited the new reaction also.",INHIBITOR,CPR:4,1,"Mimosine, a well-known competitive inhibitor of tyrosinase, competitively inhibited the new reaction also."
"<< Gemfibrozil >>, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of [[ inducible nitric-oxide synthase ]] (iNOS) in human U373MG astroglial cells and primary astrocytes.","[ENTITY_A], a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of [ENTITY_B] (iNOS) in human U373MG astroglial cells and primary astrocytes.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes."
"Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against << menadione >>-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma [[ alanine aminotransferase ]] activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.","Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against [ENTITY_A]-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma [ENTITY_B] activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.",INHIBITOR,CPR:4,1,"Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control."
"<< Estrogen >>-regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although [[ Cyp3a25 ]] was suppressed.","[ENTITY_A]-regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although [ENTITY_B] was suppressed.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Estrogen-regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed."
"In monocytes, both << EPA >> and DHA increased [[ interleukin (IL)-10 ]] without affecting tumor necrosis factor (TNF)-α and IL-6.","In monocytes, both [ENTITY_A] and DHA increased [ENTITY_B] without affecting tumor necrosis factor (TNF)-α and IL-6.",UPREGULATOR,CPR:3,0,"In monocytes, both EPA and DHA increased interleukin (IL)-10 without affecting tumor necrosis factor (TNF)-α and IL-6."
"<< Plerixafor >> (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine [[ stromal cell-derived factor-1 ]] (SDF-1) to its cognate receptor CXCR4.","[ENTITY_A] (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine [ENTITY_B] (SDF-1) to its cognate receptor CXCR4.",INHIBITOR,CPR:4,1,"Plerixafor (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4."
"In addition to effects on cell proliferation, << DHT >> increased the percentage of [[ alkaline phosphatase ]] (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens.","In addition to effects on cell proliferation, [ENTITY_A] increased the percentage of [ENTITY_B] (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens.",INDIRECT-UPREGULATOR,CPR:3,0,"In addition to effects on cell proliferation, DHT increased the percentage of alkaline phosphatase (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens."
"Dexamethasone (<< DEX >>) inhibited the anti-CD3-induced production of [[ IL-4 ]], IL-5 and IFN-gamma in all 20 clones tested.","Dexamethasone ([ENTITY_A]) inhibited the anti-CD3-induced production of [ENTITY_B], IL-5 and IFN-gamma in all 20 clones tested.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Dexamethasone (DEX) inhibited the anti-CD3-induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested."
"Thus, << U50,488H >>-induced internalization and down-regulation of the [[ hkor ]] share initial common mechanisms.","Thus, [ENTITY_A]-induced internalization and down-regulation of the [ENTITY_B] share initial common mechanisms.",DOWNREGULATOR,CPR:4,1,"Thus, U50,488H-induced internalization and down-regulation of the hkor share initial common mechanisms."
The objective of the present investigation was to evaluate << l-glutamine >> increases [[ glucagon like peptide-1 ]] (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.,The objective of the present investigation was to evaluate [ENTITY_A] increases [ENTITY_B] (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.,INDIRECT-UPREGULATOR,CPR:3,0,The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.
"Several active analogues were also evaluated for their ability to block uptake of DA, << 5-HT >>, and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-[[ hSERT ]], and HEK-hNET cells.","Several active analogues were also evaluated for their ability to block uptake of DA, [ENTITY_A], and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-[ENTITY_B], and HEK-hNET cells.",SUBSTRATE,CPR:9,4,"Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-hSERT, and HEK-hNET cells."
<< Ibuprofen >> activates [[ PPARgamma ]] in neuron-like PC12 and B104 cells.,[ENTITY_A] activates [ENTITY_B] in neuron-like PC12 and B104 cells.,ACTIVATOR,CPR:3,0,Ibuprofen activates PPARgamma in neuron-like PC12 and B104 cells.
"Although << fisetin >> greatly increases the stability of both [[ Nrf2 ]] and ATF4, only the effect on ATF4 is dependent on protein kinase activity.","Although [ENTITY_A] greatly increases the stability of both [ENTITY_B] and ATF4, only the effect on ATF4 is dependent on protein kinase activity.",INDIRECT-UPREGULATOR,CPR:3,0,"Although fisetin greatly increases the stability of both Nrf2 and ATF4, only the effect on ATF4 is dependent on protein kinase activity."
<< Epi >> increased the activity of the [[ human WNT6 promoter ]] through Cav1-dependent binding of β-catenin to the proximal WNT6 promoter.,[ENTITY_A] increased the activity of the [ENTITY_B] through Cav1-dependent binding of β-catenin to the proximal WNT6 promoter.,ACTIVATOR,CPR:3,0,Epi increased the activity of the human WNT6 promoter through Cav1-dependent binding of β-catenin to the proximal WNT6 promoter.
The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective << alpha 1A-adrenoceptor >> agonist [[ A-61603 ]] (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.,The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective [ENTITY_A] agonist [ENTITY_B] (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.,AGONIST,CPR:5,2,The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.
"Two << imidazoquinoline >> molecules, imiquimod and gardiquimod, markedly activated both [[ porcine TLR7 ]] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.","Two [ENTITY_A] molecules, imiquimod and gardiquimod, markedly activated both [ENTITY_B] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.",ACTIVATOR,CPR:3,0,"Two imidazoquinoline molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands."
"Considerable attention has focused on the antitumor effect of << histone deacetylase >> inhibitor ([[ Trichostatin A ]], TSA) as well as the coding gene expression-induced apoptosis of cancer cells.","Considerable attention has focused on the antitumor effect of [ENTITY_A] inhibitor ([ENTITY_B], TSA) as well as the coding gene expression-induced apoptosis of cancer cells.",INHIBITOR,CPR:4,1,"Considerable attention has focused on the antitumor effect of histone deacetylase inhibitor (Trichostatin A, TSA) as well as the coding gene expression-induced apoptosis of cancer cells."
"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the << lipoxygenase >> (LOX)-pathway (one having as precursors the [[ polyunsaturated fatty acids ]] containing a cis-cis-1,4-pentadiene system).","Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the [ENTITY_A] (LOX)-pathway (one having as precursors the [ENTITY_B] containing a cis-cis-1,4-pentadiene system).",SUBSTRATE,CPR:9,4,"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (LOX)-pathway (one having as precursors the polyunsaturated fatty acids containing a cis-cis-1,4-pentadiene system)."
These results suggest that << pitavastatin >> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of [[ HMG-CoA reductase ]] and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.,These results suggest that [ENTITY_A] efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of [ENTITY_B] and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.,INHIBITOR,CPR:4,1,These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.
"Herein, we report the identification and characterization of << 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile >> (ESI-09), a novel noncyclic nucleotide [[ EPAC ]] antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Herein, we report the identification and characterization of [ENTITY_A] (ESI-09), a novel noncyclic nucleotide [ENTITY_B] antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.",ANTAGONIST,CPR:6,3,"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells."
The modification of the inhibitor scaffold of 1 and 2 from a << dihydroquinolinone >> core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent [[ KAT II ]] inhibitors with excellent physicochemical properties.,The modification of the inhibitor scaffold of 1 and 2 from a [ENTITY_A] core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent [ENTITY_B] inhibitors with excellent physicochemical properties.,INHIBITOR,CPR:4,1,The modification of the inhibitor scaffold of 1 and 2 from a dihydroquinolinone core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent KAT II inhibitors with excellent physicochemical properties.
"Using a unique biosensor-based assay, << trifluoperazine >> (TFP) was identified as an inhibitor that disrupts the [[ S100A4 ]]/myosin-IIA interaction.","Using a unique biosensor-based assay, [ENTITY_A] (TFP) was identified as an inhibitor that disrupts the [ENTITY_B]/myosin-IIA interaction.",INHIBITOR,CPR:4,1,"Using a unique biosensor-based assay, trifluoperazine (TFP) was identified as an inhibitor that disrupts the S100A4/myosin-IIA interaction."
The antinociceptive activity of the << alpha 2-adrenoceptor >> agonist [[ clonidine ]] was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31).,The antinociceptive activity of the [ENTITY_A] agonist [ENTITY_B] was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31).,AGONIST,CPR:5,2,The antinociceptive activity of the alpha 2-adrenoceptor agonist clonidine was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31).
BACKGROUND: << Histamine >> synthesized by [[ histidine decarboxylase ]] (HDC) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.,BACKGROUND: [ENTITY_A] synthesized by [ENTITY_B] (HDC) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.,PRODUCT-OF,CPR:9,4,BACKGROUND: Histamine synthesized by histidine decarboxylase (HDC) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.
Synthesis and in vitro evaluation of << N-Aryl pyrido-quinazolines >> derivatives as potent [[ EGFR ]] inhibitors.,Synthesis and in vitro evaluation of [ENTITY_A] derivatives as potent [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Synthesis and in vitro evaluation of N-Aryl pyrido-quinazolines derivatives as potent EGFR inhibitors.
"Furthermore, the up-regulation of << IL-12 >> and TNF-α was found in the [[ procyanidin ]] trimers-treated cells in the presence of OVA.","Furthermore, the up-regulation of [ENTITY_A] and TNF-α was found in the [ENTITY_B] trimers-treated cells in the presence of OVA.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, the up-regulation of IL-12 and TNF-α was found in the procyanidin trimers-treated cells in the presence of OVA."
"To this end, 158N murine oligodendrocytes were treated with << 7KC >> or 7βOHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving [[ Mcl-1 ]], and caspase-3 activation.","To this end, 158N murine oligodendrocytes were treated with [ENTITY_A] or 7βOHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving [ENTITY_B], and caspase-3 activation.",ACTIVATOR,CPR:3,0,"To this end, 158N murine oligodendrocytes were treated with 7KC or 7βOHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1, and caspase-3 activation."
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual << ACE >>/NEP inhibitors ([[ GW660511X ]] and omapatrilat) currently under clinical trial.,In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual [ENTITY_A]/NEP inhibitors ([ENTITY_B] and omapatrilat) currently under clinical trial.,INHIBITOR,CPR:4,1,In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial.
"Among the current << AT1 >> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of [[ losartan ]]) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.","Among the current [ENTITY_A] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of [ENTITY_B]) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.",ANTAGONIST,CPR:6,3,"Among the current AT1 receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280."
"We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as << mycophenolic acid >> and 6-mercaptopurine, up-regulated [[ F7 ]] expression.","We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as [ENTITY_A] and 6-mercaptopurine, up-regulated [ENTITY_B] expression.",INDIRECT-UPREGULATOR,CPR:3,0,"We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression."
"<< SB225002 >> (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit [[ IL-8 ]]-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.","[ENTITY_A] (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit [ENTITY_B]-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.",INHIBITOR,CPR:4,1,"SB225002 (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects."
Density functional theory calculations using the hybrid functional B3LYP have been performed to study the << methyl >> transfer step in [[ glycine N-methyltransferase ]] (GNMT).,Density functional theory calculations using the hybrid functional B3LYP have been performed to study the [ENTITY_A] transfer step in [ENTITY_B] (GNMT).,SUBSTRATE,CPR:9,4,Density functional theory calculations using the hybrid functional B3LYP have been performed to study the methyl transfer step in glycine N-methyltransferase (GNMT).
RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml << troglitazone >> for 72 h caused a reduction of both [[ PAI-1 ]] secretion (by 29 +/- 5%; p < 0.01) and PAI-1 mRNA expression (by 26 +/- 3%; p < 0.05).,RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml [ENTITY_A] for 72 h caused a reduction of both [ENTITY_B] secretion (by 29 +/- 5%; p < 0.01) and PAI-1 mRNA expression (by 26 +/- 3%; p < 0.05).,INDIRECT-DOWNREGULATOR,CPR:4,1,RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml troglitazone for 72 h caused a reduction of both PAI-1 secretion (by 29 +/- 5%; p < 0.01) and PAI-1 mRNA expression (by 26 +/- 3%; p < 0.05).
RESULTS: Fractionated bulb extracts and the two isolated << steroidal glycoalkaloids >> (1) and (2) induced NO production and [[ TGF-β receptor I ]] mRNA expression in fibroblast cell culture.,RESULTS: Fractionated bulb extracts and the two isolated [ENTITY_A] (1) and (2) induced NO production and [ENTITY_B] mRNA expression in fibroblast cell culture.,INDIRECT-UPREGULATOR,CPR:3,0,RESULTS: Fractionated bulb extracts and the two isolated steroidal glycoalkaloids (1) and (2) induced NO production and TGF-β receptor I mRNA expression in fibroblast cell culture.
"OBJECTIVE: This randomized, double-blind study tested the hypothesis that << rofecoxib >>, a drug that specifically inhibits [[ cyclooxygenase 2 ]], would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design).","OBJECTIVE: This randomized, double-blind study tested the hypothesis that [ENTITY_A], a drug that specifically inhibits [ENTITY_B], would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design).",INHIBITOR,CPR:4,1,"OBJECTIVE: This randomized, double-blind study tested the hypothesis that rofecoxib, a drug that specifically inhibits cyclooxygenase 2, would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design)."
"However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of << MPP+ >>, indicating the [[ NAT ]] and not an OCT as their primary site of action.","However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of [ENTITY_A], indicating the [ENTITY_B] and not an OCT as their primary site of action.",SUBSTRATE,CPR:9,4,"However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action."
"<< Ozone >> plus PM(2.5) exposure, however, induced [[ CRP ]], IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way.","[ENTITY_A] plus PM(2.5) exposure, however, induced [ENTITY_B], IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way.",INDIRECT-UPREGULATOR,CPR:3,0,"Ozone plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way."
Induction of << HO-1 >> through p38 MAPK/Nrf2 signaling pathway by [[ ethanol ]] extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.,Induction of [ENTITY_A] through p38 MAPK/Nrf2 signaling pathway by [ENTITY_B] extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.,ACTIVATOR,CPR:3,0,Induction of HO-1 through p38 MAPK/Nrf2 signaling pathway by ethanol extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.
"<< Aspirin >> (ASA) and other non-steroidal anti-inflammatory drugs, which are [[ cyclooxygenase ]] (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.","[ENTITY_A] (ASA) and other non-steroidal anti-inflammatory drugs, which are [ENTITY_B] (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.",INHIBITOR,CPR:4,1,"Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients."
A 5'-flanking region capable of supporting << RA >>-induced [[ blr1 ]] activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA.,A 5'-flanking region capable of supporting [ENTITY_A]-induced [ENTITY_B] activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA.,ACTIVATOR,CPR:3,0,A 5'-flanking region capable of supporting RA-induced blr1 activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA.
"In contrast, activation of both << ERK >> and CREB in the PFC was found following memory retrieval but not other processes in [[ METH ]]-treated mouse groups.","In contrast, activation of both [ENTITY_A] and CREB in the PFC was found following memory retrieval but not other processes in [ENTITY_B]-treated mouse groups.",ACTIVATOR,CPR:3,0,"In contrast, activation of both ERK and CREB in the PFC was found following memory retrieval but not other processes in METH-treated mouse groups."
Promoter assay revealed that << prunetin >> inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of [[ iNOS ]] and COX-2 at the transcriptional level.,Promoter assay revealed that [ENTITY_A] inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of [ENTITY_B] and COX-2 at the transcriptional level.,INDIRECT-DOWNREGULATOR,CPR:4,1,Promoter assay revealed that prunetin inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of iNOS and COX-2 at the transcriptional level.
"<< Mammalian ALDH1B1 >>, another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing [[ acetaldehyde ]] but has a tissue distribution and pattern of activity distinct from that of ALDH2.","[ENTITY_A], another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing [ENTITY_B] but has a tissue distribution and pattern of activity distinct from that of ALDH2.",SUBSTRATE,CPR:9,4,"Mammalian ALDH1B1, another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing acetaldehyde but has a tissue distribution and pattern of activity distinct from that of ALDH2."
Electrical stimulation transiently elevated extracellular ATP and caused << Akt >> phosphorylation that was additive to insulin and inhibited by [[ suramin ]].,Electrical stimulation transiently elevated extracellular ATP and caused [ENTITY_A] phosphorylation that was additive to insulin and inhibited by [ENTITY_B].,INHIBITOR,CPR:4,1,Electrical stimulation transiently elevated extracellular ATP and caused Akt phosphorylation that was additive to insulin and inhibited by suramin.
"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (<< OSC >>)-mediated cyclization of 2,3-oxidosqualen to [[ lanosterol ]] was prepared from Grundmann's ketone.","A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) ([ENTITY_A])-mediated cyclization of 2,3-oxidosqualen to [ENTITY_B] was prepared from Grundmann's ketone.",PRODUCT-OF,CPR:9,4,"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone."
"However, Ca(2+) blockers also obviously attenuated << NF-κB >> activation and transnuclear transport induced by [[ TCDD ]].","However, Ca(2+) blockers also obviously attenuated [ENTITY_A] activation and transnuclear transport induced by [ENTITY_B].",ACTIVATOR,CPR:3,0,"However, Ca(2+) blockers also obviously attenuated NF-κB activation and transnuclear transport induced by TCDD."
"The obtained results indicate that << rat brain CYP2D >> isoforms catalyze the formation of [[ serotonin ]] from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain.","The obtained results indicate that [ENTITY_A] isoforms catalyze the formation of [ENTITY_B] from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain.",PRODUCT-OF,CPR:9,4,"The obtained results indicate that rat brain CYP2D isoforms catalyze the formation of serotonin from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain."
<< Ribavirin >> unregulated [[ ELL ]] (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation.,[ENTITY_A] unregulated [ENTITY_B] (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation.,INDIRECT-UPREGULATOR,CPR:3,0,Ribavirin unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation.
L-arg is converted to << urea >> by [[ arginase I ]] in the liver and arginase II in the kidney.,L-arg is converted to [ENTITY_A] by [ENTITY_B] in the liver and arginase II in the kidney.,PRODUCT-OF,CPR:9,4,L-arg is converted to urea by arginase I in the liver and arginase II in the kidney.
"Treatment with << CAPE >> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3β, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-κB, phospho-NF-κB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor [[ p27Kip ]].","Treatment with [ENTITY_A] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3β, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-κB, phospho-NF-κB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3β, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-κB, phospho-NF-κB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip."
<< Mercury >> induces the expression of [[ cyclooxygenase-2 ]] and inducible nitric oxide synthase.,[ENTITY_A] induces the expression of [ENTITY_B] and inducible nitric oxide synthase.,INDIRECT-UPREGULATOR,CPR:3,0,Mercury induces the expression of cyclooxygenase-2 and inducible nitric oxide synthase.
"There is, however, much information on the direct (acute and chronic) effects of << alcohol >> on the binding properties of opioid receptors, as well as modulation of opioid peptide synthesis and secretion (e.g. a suggested increase in [[ beta-endorphin ]] release).","There is, however, much information on the direct (acute and chronic) effects of [ENTITY_A] on the binding properties of opioid receptors, as well as modulation of opioid peptide synthesis and secretion (e.g. a suggested increase in [ENTITY_B] release).",INDIRECT-UPREGULATOR,CPR:3,0,"There is, however, much information on the direct (acute and chronic) effects of alcohol on the binding properties of opioid receptors, as well as modulation of opioid peptide synthesis and secretion (e.g. a suggested increase in beta-endorphin release)."
"We demonstrate that only treatment of HaCaT with << GLA >> and EPA or a PPARgamma ligand (roziglitazone), induced [[ COX-2 ]] expression (protein and mRNA).","We demonstrate that only treatment of HaCaT with [ENTITY_A] and EPA or a PPARgamma ligand (roziglitazone), induced [ENTITY_B] expression (protein and mRNA).",INDIRECT-UPREGULATOR,CPR:3,0,"We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand (roziglitazone), induced COX-2 expression (protein and mRNA)."
<< Captopril >> directly inhibits [[ matrix metalloproteinase-2 ]] activity in continuous ambulatory peritoneal dialysis therapy.,[ENTITY_A] directly inhibits [ENTITY_B] activity in continuous ambulatory peritoneal dialysis therapy.,INHIBITOR,CPR:4,1,Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy.
SAR and lead optimization studies for << Rock >> inhibitors based on [[ amino acid ]]-derived quinazolines are described.,SAR and lead optimization studies for [ENTITY_A] inhibitors based on [ENTITY_B]-derived quinazolines are described.,INHIBITOR,CPR:4,1,SAR and lead optimization studies for Rock inhibitors based on amino acid-derived quinazolines are described.
"It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in << PGE(2) >> possibly derived from [[ COX-2 ]] expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.","It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in [ENTITY_A] possibly derived from [ENTITY_B] expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.",PRODUCT-OF,CPR:9,4,"It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF."
"OBJECTIVE: << Telmisartan >>, an [[ angiotensin II type 1 receptor ]] (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).","OBJECTIVE: [ENTITY_A], an [ENTITY_B] (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).",ANTAGONIST,CPR:6,3,"OBJECTIVE: Telmisartan, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma)."
The direct inhibition of << stathmin >> by [[ CCNU ]] is likely a contributing factor.,The direct inhibition of [ENTITY_A] by [ENTITY_B] is likely a contributing factor.,INHIBITOR,CPR:4,1,The direct inhibition of stathmin by CCNU is likely a contributing factor.
"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the << G protein-coupled receptor >> agonist [[ acetylcholine ]] (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump.","Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the [ENTITY_A] agonist [ENTITY_B] (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump.",AGONIST,CPR:5,2,"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump."
"The compounds << 5'-azacytidine >> (AZC) and procainamide (PCA) belong to inhibitors of [[ DNMT1 ]], whose low activity correlates with increase in transcription of various genes.","The compounds [ENTITY_A] (AZC) and procainamide (PCA) belong to inhibitors of [ENTITY_B], whose low activity correlates with increase in transcription of various genes.",INHIBITOR,CPR:4,1,"The compounds 5'-azacytidine (AZC) and procainamide (PCA) belong to inhibitors of DNMT1, whose low activity correlates with increase in transcription of various genes."
"Results: The administration of << prallethrin >> 1.6% w/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, [[ hemoglobin ]], packed cell volume, platelets, mean corpuscular volume, and mean corpuscular hemoglobin in rats after 24, 48, and 72 h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h.","Results: The administration of [ENTITY_A] 1.6% w/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, [ENTITY_B], packed cell volume, platelets, mean corpuscular volume, and mean corpuscular hemoglobin in rats after 24, 48, and 72 h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h.",INDIRECT-UPREGULATOR,CPR:3,0,"Results: The administration of prallethrin 1.6% w/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, hemoglobin, packed cell volume, platelets, mean corpuscular volume, and mean corpuscular hemoglobin in rats after 24, 48, and 72 h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h."
"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by << milrinone >> and cilostazol, specific inhibitors of [[ PDE3 ]].","We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by [ENTITY_A] and cilostazol, specific inhibitors of [ENTITY_B].",INHIBITOR,CPR:4,1,"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and cilostazol, specific inhibitors of PDE3."
The in vivo inhibitory effect of << harmaline >> on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified [[ CYP2D6 ]].,The in vivo inhibitory effect of [ENTITY_A] on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified [ENTITY_B].,DOWNREGULATOR,CPR:4,1,The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6.
Manipulation of kinetic profiles in << 2-aryl propionic acid >> [[ cyclooxygenase ]] inhibitors.,Manipulation of kinetic profiles in [ENTITY_A] [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors.
"The earliest known << AChE >> inhibitors, namely, [[ physostigmine ]] and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).","The earliest known [ENTITY_A] inhibitors, namely, [ENTITY_B] and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).",INHIBITOR,CPR:4,1,"The earliest known AChE inhibitors, namely, physostigmine and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability)."
This study was conducted in order to understand the association between acute renal failure and the two << COX-2 >> inhibitors [[ celecoxib ]] and rofecoxib.,This study was conducted in order to understand the association between acute renal failure and the two [ENTITY_A] inhibitors [ENTITY_B] and rofecoxib.,INHIBITOR,CPR:4,1,This study was conducted in order to understand the association between acute renal failure and the two COX-2 inhibitors celecoxib and rofecoxib.
"The present studies were undertaken to compare two compounds, a << vitamin D(3) >> analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce [[ NGF ]] synthesis in vivo.","The present studies were undertaken to compare two compounds, a [ENTITY_A] analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce [ENTITY_B] synthesis in vivo.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce NGF synthesis in vivo."
"<< ADP >> initiates platelet aggregation by 'simultaneous activation of two [[ G protein-coupled receptors ]], P2Y1 and P2Y12.","[ENTITY_A] initiates platelet aggregation by 'simultaneous activation of two [ENTITY_B], P2Y1 and P2Y12.",ACTIVATOR,CPR:3,0,"ADP initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, P2Y1 and P2Y12."
"Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum << Ca >> regulates [[ PTH ]] secretion mediated by the Ca-sensing receptor (CaSR).","Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum [ENTITY_A] regulates [ENTITY_B] secretion mediated by the Ca-sensing receptor (CaSR).",INDIRECT-UPREGULATOR,CPR:3,0,"Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (CaSR)."
"Whole-cell voltage-clamp of << hNET >>-293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and [[ cocaine ]] that are absent in parental cells.","Whole-cell voltage-clamp of [ENTITY_A]-293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and [ENTITY_B] that are absent in parental cells.",INHIBITOR,CPR:4,1,"Whole-cell voltage-clamp of hNET-293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells."
"A streamlined and high-yielding synthesis of << aprepitant >> (1), a potent [[ substance P (SP) receptor ]] antagonist, is described.","A streamlined and high-yielding synthesis of [ENTITY_A] (1), a potent [ENTITY_B] antagonist, is described.",ANTAGONIST,CPR:6,3,"A streamlined and high-yielding synthesis of aprepitant (1), a potent substance P (SP) receptor antagonist, is described."
In addition the production of << BrBK1-8 >> was enhanced in the presence of these inhibitors with a greater accumulation being observed with [[ omapatrilat ]].,In addition the production of [ENTITY_A] was enhanced in the presence of these inhibitors with a greater accumulation being observed with [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,In addition the production of BrBK1-8 was enhanced in the presence of these inhibitors with a greater accumulation being observed with omapatrilat.
"These findings lend evidence of a 5-HT1B receptor/eNOS pathway, accounting in part for the activation of << eNOS >> by [[ 5-HT ]].","These findings lend evidence of a 5-HT1B receptor/eNOS pathway, accounting in part for the activation of [ENTITY_A] by [ENTITY_B].",ACTIVATOR,CPR:3,0,"These findings lend evidence of a 5-HT1B receptor/eNOS pathway, accounting in part for the activation of eNOS by 5-HT."
Treatment with << cabozantinib >> inhibited [[ MET ]] and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.,Treatment with [ENTITY_A] inhibited [ENTITY_B] and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.,INHIBITOR,CPR:4,1,Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.
"In the in vitro assay, << kinsenoside >> (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), [[ lactic dehydrogenase ]] (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","In the in vitro assay, [ENTITY_A] (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), [ENTITY_B] (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system."
"The identification of the << succinate receptor >> SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of [[ succinate ]] were shown to potentiate the effect of low doses of a variety of platelet agonists.","The identification of the [ENTITY_A] SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of [ENTITY_B] were shown to potentiate the effect of low doses of a variety of platelet agonists.",AGONIST,CPR:5,2,"The identification of the succinate receptor SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of succinate were shown to potentiate the effect of low doses of a variety of platelet agonists."
Central << 5-HT3 >> receptor stimulation by [[ m-CPBG ]] increases blood glucose in rats.,Central [ENTITY_A] receptor stimulation by [ENTITY_B] increases blood glucose in rats.,ACTIVATOR,CPR:3,0,Central 5-HT3 receptor stimulation by m-CPBG increases blood glucose in rats.
"To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual << EGFR >>/HER2 inhibitor, [[ GW572016 ]], on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines.","To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual [ENTITY_A]/HER2 inhibitor, [ENTITY_B], on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines.",INHIBITOR,CPR:4,1,"To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR/HER2 inhibitor, GW572016, on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines."
"We report here that << lovastatin >>, a drug clinically used for lowering cholesterol levels, inhibits the interaction of [[ human LFA-1 ]] with its counter-receptor intercellular adhesion molecule-1.","We report here that [ENTITY_A], a drug clinically used for lowering cholesterol levels, inhibits the interaction of [ENTITY_B] with its counter-receptor intercellular adhesion molecule-1.",INHIBITOR,CPR:4,1,"We report here that lovastatin, a drug clinically used for lowering cholesterol levels, inhibits the interaction of human LFA-1 with its counter-receptor intercellular adhesion molecule-1."
"In contrast to << diethylcarbamazine >>, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the [[ 5-lipoxygenase ]] step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.","In contrast to [ENTITY_A], piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the [ENTITY_B] step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.",INHIBITOR,CPR:4,1,"In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells."
"Finally, we demonstrate that << T. thermophilus PRODH >> reacts with O(2) producing [[ superoxide ]].","Finally, we demonstrate that [ENTITY_A] reacts with O(2) producing [ENTITY_B].",PRODUCT-OF,CPR:9,4,"Finally, we demonstrate that T. thermophilus PRODH reacts with O(2) producing superoxide."
"Computational docking analysis was conducted to model the interaction of these antagonists with the human ERα and showed that they could tightly bind to the ERα in a manner similar to that of << ICI-182,780 >>, a pure [[ ER ]] antagonist.","Computational docking analysis was conducted to model the interaction of these antagonists with the human ERα and showed that they could tightly bind to the ERα in a manner similar to that of [ENTITY_A], a pure [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"Computational docking analysis was conducted to model the interaction of these antagonists with the human ERα and showed that they could tightly bind to the ERα in a manner similar to that of ICI-182,780, a pure ER antagonist."
"Taken together, our findings indicate that << 5HHMF >> suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of [[ Nrf2 ]]-dependent HO-1 activity.","Taken together, our findings indicate that [ENTITY_A] suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of [ENTITY_B]-dependent HO-1 activity.",ACTIVATOR,CPR:3,0,"Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity."
"Colonic << cyclooxygenase-2 >> and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by [[ ATB-429 ]], but not by mesalamine.","Colonic [ENTITY_A] and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by [ENTITY_B], but not by mesalamine.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Colonic cyclooxygenase-2 and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by ATB-429, but not by mesalamine."
"<< Auranofin >>, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and [[ glutathione peroxidase ]].","[ENTITY_A], an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and [ENTITY_B].",INHIBITOR,CPR:4,1,"Auranofin, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and glutathione peroxidase."
"2. In vitro experiments assessed the inhibition of << transporters >> and CYP enzymes by [[ GSK1292263 ]], and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose).","2. In vitro experiments assessed the inhibition of [ENTITY_A] and CYP enzymes by [ENTITY_B], and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose).",INHIBITOR,CPR:4,1,"2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose)."
"Overall, our results suggest that inhibition of the << p38 >> MAPK signaling by [[ metformin ]] coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.","Overall, our results suggest that inhibition of the [ENTITY_A] MAPK signaling by [ENTITY_B] coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.",INHIBITOR,CPR:4,1,"Overall, our results suggest that inhibition of the p38 MAPK signaling by metformin coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation."
"Here, we have now found that activation of << p38 >> MAPK by [[ anisomycin ]] potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.","Here, we have now found that activation of [ENTITY_A] MAPK by [ENTITY_B] potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.",INDIRECT-UPREGULATOR,CPR:3,0,"Here, we have now found that activation of p38 MAPK by anisomycin potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes."
"The << hemoglobin A1c >> (HbA1c) of all patients improved significantly from 8.1±1.2% to 7.6±1.1% after 12 weeks of add-on therapy with [[ sitagliptin ]] (p<0.01), and the insulin dosage was reduced from 27.3±15.8 U/day to 24.5±16.5 U/day (p<0.001).","The [ENTITY_A] (HbA1c) of all patients improved significantly from 8.1±1.2% to 7.6±1.1% after 12 weeks of add-on therapy with [ENTITY_B] (p<0.01), and the insulin dosage was reduced from 27.3±15.8 U/day to 24.5±16.5 U/day (p<0.001).",INDIRECT-UPREGULATOR,CPR:3,0,"The hemoglobin A1c (HbA1c) of all patients improved significantly from 8.1±1.2% to 7.6±1.1% after 12 weeks of add-on therapy with sitagliptin (p<0.01), and the insulin dosage was reduced from 27.3±15.8 U/day to 24.5±16.5 U/day (p<0.001)."
"<< Peroxisome proliferator-activated receptor alpha >> (PPARalpha) activators, [[ bezafibrate ]] and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.","[ENTITY_A] (PPARalpha) activators, [ENTITY_B] and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.",ACTIVATOR,CPR:3,0,"Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes."
"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of << navitoclax >>, a selective inhibitor of both [[ BCL-2 ]] and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers.","The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of [ENTITY_A], a selective inhibitor of both [ENTITY_B] and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers.",INHIBITOR,CPR:4,1,"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers."
"VT recurred with the addition of << aminophylline >>, a competitive [[ adenosine A1-receptor ]] antagonist.","VT recurred with the addition of [ENTITY_A], a competitive [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"VT recurred with the addition of aminophylline, a competitive adenosine A1-receptor antagonist."
"RESULT(S): The expression of endometrial << ERalpha >>, PRAB, PRB, and SRC-1 was increased significantly after 1 week of [[ mifepristone ]], but the increase was no longer seen after 10 weeks.","RESULT(S): The expression of endometrial [ENTITY_A], PRAB, PRB, and SRC-1 was increased significantly after 1 week of [ENTITY_B], but the increase was no longer seen after 10 weeks.",INDIRECT-UPREGULATOR,CPR:3,0,"RESULT(S): The expression of endometrial ERalpha, PRAB, PRB, and SRC-1 was increased significantly after 1 week of mifepristone, but the increase was no longer seen after 10 weeks."
"AIM: To assess the efficacy and safety of a 24-week treatment with << sitagliptin >>, a highly selective once-daily oral [[ dipeptidyl peptidase-4 ]] (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin.","AIM: To assess the efficacy and safety of a 24-week treatment with [ENTITY_A], a highly selective once-daily oral [ENTITY_B] (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin.",INHIBITOR,CPR:4,1,"AIM: To assess the efficacy and safety of a 24-week treatment with sitagliptin, a highly selective once-daily oral dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin."
Comparison of << captopril >> and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with [[ ACE ]] inhibitors in high dieted methionine mice.,Comparison of [ENTITY_A] and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with [ENTITY_B] inhibitors in high dieted methionine mice.,INHIBITOR,CPR:4,1,Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in high dieted methionine mice.
"Moreover, compared with the model group, << sophocarpine >> could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and [[ ACC ]] (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.","Moreover, compared with the model group, [ENTITY_A] could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and [ENTITY_B] (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.",INDIRECT-UPREGULATOR,CPR:3,0,"Moreover, compared with the model group, sophocarpine could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression."
"A head-to-head comparison between insulin detemir and NPH insulin in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma << glucose >> improved with [[ insulin ]] detemir without an increased incidence of hypoglycaemia.","A head-to-head comparison between insulin detemir and NPH insulin in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma [ENTITY_A] improved with [ENTITY_B] detemir without an increased incidence of hypoglycaemia.",INDIRECT-UPREGULATOR,CPR:3,0,"A head-to-head comparison between insulin detemir and NPH insulin in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma glucose improved with insulin detemir without an increased incidence of hypoglycaemia."
"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and << kappa-opioid receptor >> ([[ BRL 52974 ]]) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.","Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and [ENTITY_A] ([ENTITY_B]) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.",AGONIST,CPR:5,2,"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively."
"Given that << M-CSF >> signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with [[ imatinib ]] may modulate osteoclast activity.","Given that [ENTITY_A] signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with [ENTITY_B] may modulate osteoclast activity.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Given that M-CSF signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with imatinib may modulate osteoclast activity."
"Comparison of the << monoamine oxidase >> inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors [[ moclobemide ]] and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.","Comparison of the [ENTITY_A] inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors [ENTITY_B] and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.",INHIBITOR,CPR:4,1,"Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects."
"As a prodrug << leflunomide >> is completely converted to its active metabolite A 77 1726 (M1) which blocks the [[ dihydroorotate dehydrogenase ]], a key enzyme of the pyrimidine de novo synthesis.","As a prodrug [ENTITY_A] is completely converted to its active metabolite A 77 1726 (M1) which blocks the [ENTITY_B], a key enzyme of the pyrimidine de novo synthesis.",INHIBITOR,CPR:4,1,"As a prodrug leflunomide is completely converted to its active metabolite A 77 1726 (M1) which blocks the dihydroorotate dehydrogenase, a key enzyme of the pyrimidine de novo synthesis."
"At the enzymatic activity level, << doxycycline >> started to suppress [[ MMP-9 ]] activity at 5 mg/kg/day (P<0.001), while minocycline had an effect at a lower dose, 1 mg/kg/day (P<0.02).","At the enzymatic activity level, [ENTITY_A] started to suppress [ENTITY_B] activity at 5 mg/kg/day (P<0.001), while minocycline had an effect at a lower dose, 1 mg/kg/day (P<0.02).",INHIBITOR,CPR:4,1,"At the enzymatic activity level, doxycycline started to suppress MMP-9 activity at 5 mg/kg/day (P<0.001), while minocycline had an effect at a lower dose, 1 mg/kg/day (P<0.02)."
"The identity of the lung << beta-ADHs >> was further demonstrated by their characteristic pH-activity profiles for [[ ethanol ]] oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline.","The identity of the lung [ENTITY_A] was further demonstrated by their characteristic pH-activity profiles for [ENTITY_B] oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline.",SUBSTRATE,CPR:9,4,"The identity of the lung beta-ADHs was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline."
"The effects of << meloxicam >> were compared with those of diclofenac, a nonselective [[ COX ]] inhibitor.","The effects of [ENTITY_A] were compared with those of diclofenac, a nonselective [ENTITY_B] inhibitor.",INHIBITOR,CPR:4,1,"The effects of meloxicam were compared with those of diclofenac, a nonselective COX inhibitor."
"Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by << yohimbine >>, an [[ alpha 2-adrenoceptor ]] antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.","Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by [ENTITY_A], an [ENTITY_B] antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.",ANTAGONIST,CPR:6,3,"Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by yohimbine, an alpha 2-adrenoceptor antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice."
"Noradrenaline and << phenylephrine >> ([[ alpha(1)-adrenoceptor ]] agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively.","Noradrenaline and [ENTITY_A] ([ENTITY_B] agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively.",AGONIST,CPR:5,2,"Noradrenaline and phenylephrine (alpha(1)-adrenoceptor agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively."
<< NFD >> abrogated [[ EGF ]]-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt.,[ENTITY_A] abrogated [ENTITY_B]-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt.,DOWNREGULATOR,CPR:4,1,NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt.
"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of << rasagiline >> does not depend on inhibition of [[ MAO-B ]], but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins.","However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of [ENTITY_A] does not depend on inhibition of [ENTITY_B], but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins.",INHIBITOR,CPR:4,1,"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins."
These findings indicate that << captopril >> attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of [[ MMP-2 ]] and MMP-9 in rats.,These findings indicate that [ENTITY_A] attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of [ENTITY_B] and MMP-9 in rats.,INHIBITOR,CPR:4,1,These findings indicate that captopril attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of MMP-2 and MMP-9 in rats.
"The intrinsic clearance for both << ketamine >> enantiomers by the high affinity enzyme in HLMs with [[ CYP2B6*1 ]]/*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1/*6 genotype and CYP2B6*6/*6 genotype.","The intrinsic clearance for both [ENTITY_A] enantiomers by the high affinity enzyme in HLMs with [ENTITY_B]/*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1/*6 genotype and CYP2B6*6/*6 genotype.",SUBSTRATE,CPR:9,4,"The intrinsic clearance for both ketamine enantiomers by the high affinity enzyme in HLMs with CYP2B6*1/*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1/*6 genotype and CYP2B6*6/*6 genotype."
"CRH caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of << CRH >>-induced ACTH secretion was significantly lower after [[ loperamide ]].","CRH caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of [ENTITY_A]-induced ACTH secretion was significantly lower after [ENTITY_B].",DOWNREGULATOR,CPR:4,1,"CRH caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of CRH-induced ACTH secretion was significantly lower after loperamide."
"Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the << SGLT1 >>-dependent [[ methyl alpha-D-glucopyranoside ]] (AMG) uptake and levels of SGLT1 expression were determined.","Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the [ENTITY_A]-dependent [ENTITY_B] (AMG) uptake and levels of SGLT1 expression were determined.",SUBSTRATE,CPR:9,4,"Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined."
"Risperidone is metabolized to its active metabolite, << 9-hydroxyrisperidone >>, mainly by the [[ cytochrome P450 ]] enzymes CYP2D6 and 3A4.","Risperidone is metabolized to its active metabolite, [ENTITY_A], mainly by the [ENTITY_B] enzymes CYP2D6 and 3A4.",PRODUCT-OF,CPR:9,4,"Risperidone is metabolized to its active metabolite, 9-hydroxyrisperidone, mainly by the cytochrome P450 enzymes CYP2D6 and 3A4."
"As expected, comparison of IC50 indicated that << meloxicam >> and carprofen are more selective inhibitors of [[ COX-2 ]] than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined.","As expected, comparison of IC50 indicated that [ENTITY_A] and carprofen are more selective inhibitors of [ENTITY_B] than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined.",INHIBITOR,CPR:4,1,"As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of COX-2 than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined."
"Moreover, protein and mRNA levels of DSS-induced proinflammatory << cytokines >> in colon, including TNF-α, IL-1β, IL-18, IL-17A and IFN-γ, were markedly suppressed by [[ Fc11a-2 ]].","Moreover, protein and mRNA levels of DSS-induced proinflammatory [ENTITY_A] in colon, including TNF-α, IL-1β, IL-18, IL-17A and IFN-γ, were markedly suppressed by [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-α, IL-1β, IL-18, IL-17A and IFN-γ, were markedly suppressed by Fc11a-2."
"Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the << UCP-3 >> induction achieved after [[ bezafibrate ]] and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.","Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the [ENTITY_A] induction achieved after [ENTITY_B] and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.",INDIRECT-UPREGULATOR,CPR:3,0,"Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the UCP-3 induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides."
<< Levodopa >> is absorbed in the small bowel and is rapidly catabolized by [[ aromatic-L-amino-acid decarboxylase ]] (AADC) and catechol-O-methyltransferase (COMT).,[ENTITY_A] is absorbed in the small bowel and is rapidly catabolized by [ENTITY_B] (AADC) and catechol-O-methyltransferase (COMT).,SUBSTRATE,CPR:9,4,Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol-O-methyltransferase (COMT).
"CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for << CYP2B6 >> in clinical [[ methadone ]] disposition.","CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for [ENTITY_A] in clinical [ENTITY_B] disposition.",SUBSTRATE,CPR:9,4,"CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition."
Structural basis of inhibition of the << human NAD+-dependent deacetylase SIRT5 >> by [[ suramin ]].,Structural basis of inhibition of the [ENTITY_A] by [ENTITY_B].,INHIBITOR,CPR:4,1,Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin.
"Pretreatment with the << 5-HT1A >> antagonist [[ WAY-100,635 ]] (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine.","Pretreatment with the [ENTITY_A] antagonist [ENTITY_B] (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine.",ANTAGONIST,CPR:6,3,"Pretreatment with the 5-HT1A antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine."
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, << formoterol >>, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [[ human beta-adrenergic receptors ]] in an identical cellular background.","The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, [ENTITY_A], broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [ENTITY_B] in an identical cellular background.",AGONIST,CPR:5,2,"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background."
"These << polyphenols >>, but not GvEx, showed a certain level of inhibition of human-cDNA-expressed [[ CYPs ]].","These [ENTITY_A], but not GvEx, showed a certain level of inhibition of human-cDNA-expressed [ENTITY_B].",INHIBITOR,CPR:4,1,"These polyphenols, but not GvEx, showed a certain level of inhibition of human-cDNA-expressed CYPs."
"Furthermore, << N >>-BPs decreased the levels of [[ phosphorylated extracellular signal-regulated kinase ]] (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression.","Furthermore, [ENTITY_A]-BPs decreased the levels of [ENTITY_B] (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, N-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression."
Treatment with << TSA >> and the Nrf2-ARE activator resulted in increased inhibition of the [[ TGF-β ]]-induced myofibroblast differentiation as compared with treatment with DPI or NAC.,Treatment with [ENTITY_A] and the Nrf2-ARE activator resulted in increased inhibition of the [ENTITY_B]-induced myofibroblast differentiation as compared with treatment with DPI or NAC.,INHIBITOR,CPR:4,1,Treatment with TSA and the Nrf2-ARE activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or NAC.
<< c-fos >> expression was induced in urethane-anaesthetized rats by intracisternal [[ capsaicin ]] administration.,[ENTITY_A] expression was induced in urethane-anaesthetized rats by intracisternal [ENTITY_B] administration.,INDIRECT-UPREGULATOR,CPR:3,0,c-fos expression was induced in urethane-anaesthetized rats by intracisternal capsaicin administration.
"Troglitazone, bosentan and glibenclamide inhibit the << bile salt export pump >> (Bsep) which transports [[ taurocholate ]] into bile.","Troglitazone, bosentan and glibenclamide inhibit the [ENTITY_A] (Bsep) which transports [ENTITY_B] into bile.",SUBSTRATE,CPR:9,4,"Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (Bsep) which transports taurocholate into bile."
"The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as << dehydrogenase >> from inactivation by [[ FSA ]].","The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as [ENTITY_A] from inactivation by [ENTITY_B].",INHIBITOR,CPR:4,1,"The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as dehydrogenase from inactivation by FSA."
<< Aspirin >> and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its [[ ATPase ]] activity in human fibroblasts.,[ENTITY_A] and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its [ENTITY_B] activity in human fibroblasts.,INHIBITOR,CPR:4,1,Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its ATPase activity in human fibroblasts.
<< LB-4b >> is the first synthetic [[ APN ]] inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects.,[ENTITY_A] is the first synthetic [ENTITY_B] inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects.,INHIBITOR,CPR:4,1,LB-4b is the first synthetic APN inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects.
<< Methylphenidate >> increased DAT Vmax in SHR mPFC and decreased [[ DAT ]] Vmax in WKY OFC.,[ENTITY_A] increased DAT Vmax in SHR mPFC and decreased [ENTITY_B] Vmax in WKY OFC.,INHIBITOR,CPR:4,1,Methylphenidate increased DAT Vmax in SHR mPFC and decreased DAT Vmax in WKY OFC.
"2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a << P-gp >> substrate, [[ risperidone ]], and its major metabolite, 9-hydroxyrisperidone, in rats.","2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a [ENTITY_A] substrate, [ENTITY_B], and its major metabolite, 9-hydroxyrisperidone, in rats.",SUBSTRATE,CPR:9,4,"2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats."
"The << sigma-receptor >> antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of [[ dextromethorphan ]] (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122.","The [ENTITY_A] antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of [ENTITY_B] (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122.",AGONIST,CPR:5,2,"The sigma-receptor antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122."
Our results have shown that << MMP-9 >> messenger ribonucleic acid (mRNA) expression was inhibited by [[ doxycycline ]] starting at 10 mg/kg/day (P<0.02).,Our results have shown that [ENTITY_A] messenger ribonucleic acid (mRNA) expression was inhibited by [ENTITY_B] starting at 10 mg/kg/day (P<0.02).,INDIRECT-DOWNREGULATOR,CPR:4,1,Our results have shown that MMP-9 messenger ribonucleic acid (mRNA) expression was inhibited by doxycycline starting at 10 mg/kg/day (P<0.02).
The herbicide << paraquat >> (PQ) is a [[ P-gp ]] substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote.,The herbicide [ENTITY_A] (PQ) is a [ENTITY_B] substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote.,SUBSTRATE,CPR:9,4,The herbicide paraquat (PQ) is a P-gp substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote.
"In conclusion, << nobiletin >> attenuates [[ HGF ]]-induced HepG2 cells metastasis involving both ERK and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.","In conclusion, [ENTITY_A] attenuates [ENTITY_B]-induced HepG2 cells metastasis involving both ERK and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.",INHIBITOR,CPR:4,1,"In conclusion, nobiletin attenuates HGF-induced HepG2 cells metastasis involving both ERK and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma."
"The outflow of << [3H]-MPP+ >> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for [[ OCT ]]-related transmembrane transporters.","The outflow of [ENTITY_A] was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for [ENTITY_B]-related transmembrane transporters.",SUBSTRATE,CPR:9,4,"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related transmembrane transporters."
"Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect << methyltransferase >> inhibitor periodate-oxidized [[ adenosine ]] was without effect.","Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect [ENTITY_A] inhibitor periodate-oxidized [ENTITY_B] was without effect.",INHIBITOR,CPR:4,1,"Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect methyltransferase inhibitor periodate-oxidized adenosine was without effect."
"Commercially-available << 5-HT2C >> agonists ([[ CP 809101 ]], Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.","Commercially-available [ENTITY_A] agonists ([ENTITY_B], Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.",AGONIST,CPR:5,2,"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR."
"Furthermore, << DOX >>-treated WT and p65(-/-) MEFs differed in their expression of various apoptosis-associated molecules, when the former demonstrated a decrease in the percentage of [[ p65 ]]-positive and a more prominent decrease in the percentage of p53-positive cells, while a decreased percentage of IκBα-positive and a more prominent decrease in the percentage of bcl-2-positive cells was detected among the latter.","Furthermore, [ENTITY_A]-treated WT and p65(-/-) MEFs differed in their expression of various apoptosis-associated molecules, when the former demonstrated a decrease in the percentage of [ENTITY_B]-positive and a more prominent decrease in the percentage of p53-positive cells, while a decreased percentage of IκBα-positive and a more prominent decrease in the percentage of bcl-2-positive cells was detected among the latter.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, DOX-treated WT and p65(-/-) MEFs differed in their expression of various apoptosis-associated molecules, when the former demonstrated a decrease in the percentage of p65-positive and a more prominent decrease in the percentage of p53-positive cells, while a decreased percentage of IκBα-positive and a more prominent decrease in the percentage of bcl-2-positive cells was detected among the latter."
"In the present study, we evaluated whether therapeutic doses of << metformin >> increase [[ AMPK ]] activity in vivo in subjects with type 2 diabetes.","In the present study, we evaluated whether therapeutic doses of [ENTITY_A] increase [ENTITY_B] activity in vivo in subjects with type 2 diabetes.",ACTIVATOR,CPR:3,0,"In the present study, we evaluated whether therapeutic doses of metformin increase AMPK activity in vivo in subjects with type 2 diabetes."
Electrical Stimuli Release ATP to Increase << GLUT4 >> Translocation and [[ Glucose ]] Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.,Electrical Stimuli Release ATP to Increase [ENTITY_A] Translocation and [ENTITY_B] Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.,SUBSTRATE,CPR:9,4,Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.
"<< Hydralazine >> dose-dependently inhibited PHD activity and induced nonhydroxylated [[ HIF-1alpha ]], evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.","[ENTITY_A] dose-dependently inhibited PHD activity and induced nonhydroxylated [ENTITY_B], evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.",UPREGULATOR,CPR:3,0,"Hydralazine dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity."
"Moreover, GCs have a synergistic effect on << GW4064 >>-induced [[ FXR ]] activation, whereas chenodeoxycholate and GW4064 have an additive effect.","Moreover, GCs have a synergistic effect on [ENTITY_A]-induced [ENTITY_B] activation, whereas chenodeoxycholate and GW4064 have an additive effect.",ACTIVATOR,CPR:3,0,"Moreover, GCs have a synergistic effect on GW4064-induced FXR activation, whereas chenodeoxycholate and GW4064 have an additive effect."
Inhibition of << 5-lipoxygenase >> pathway of [[ arachidonic acid ]] metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.,Inhibition of [ENTITY_A] pathway of [ENTITY_B] metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.,SUBSTRATE,CPR:9,4,Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.
<< IPI-926 >> is both a substrate and inhibitor (IC50 = 1.9 µM) of [[ P-glycoprotein ]].,[ENTITY_A] is both a substrate and inhibitor (IC50 = 1.9 µM) of [ENTITY_B].,INHIBITOR,CPR:4,1,IPI-926 is both a substrate and inhibitor (IC50 = 1.9 µM) of P-glycoprotein.
"RGM-1 cells were treated with << CDCA >> or GW4064, an [[ FXR ]] agonist, in the presence or absence of guggulsterone, an FXR antagonist.","RGM-1 cells were treated with [ENTITY_A] or GW4064, an [ENTITY_B] agonist, in the presence or absence of guggulsterone, an FXR antagonist.",AGONIST,CPR:5,2,"RGM-1 cells were treated with CDCA or GW4064, an FXR agonist, in the presence or absence of guggulsterone, an FXR antagonist."
"Recent studies indicate that << tamoxifen >> initially acts as an antagonist, but later functions as an [[ ER ]] agonist, promoting tumor growth.","Recent studies indicate that [ENTITY_A] initially acts as an antagonist, but later functions as an [ENTITY_B] agonist, promoting tumor growth.",AGONIST,CPR:5,2,"Recent studies indicate that tamoxifen initially acts as an antagonist, but later functions as an ER agonist, promoting tumor growth."
<< Decitabine >> inhibits [[ DNA methyltransferase ]] and has shown therapeutic effects in patients with hematologic malignancies.,[ENTITY_A] inhibits [ENTITY_B] and has shown therapeutic effects in patients with hematologic malignancies.,INHIBITOR,CPR:4,1,Decitabine inhibits DNA methyltransferase and has shown therapeutic effects in patients with hematologic malignancies.
In vitro metabolism of the << 5-hydroxytryptamine1B >> receptor antagonist [[ elzasonan ]].,In vitro metabolism of the [ENTITY_A] receptor antagonist [ENTITY_B].,ANTAGONIST,CPR:6,3,In vitro metabolism of the 5-hydroxytryptamine1B receptor antagonist elzasonan.
"The smooth muscle relaxant, << W-7 >>, which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced [[ PRL ]] secretion in a dose-dependent manner (r = -0.991, p less than 0.01).","The smooth muscle relaxant, [ENTITY_A], which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced [ENTITY_B] secretion in a dose-dependent manner (r = -0.991, p less than 0.01).",INDIRECT-DOWNREGULATOR,CPR:4,1,"The smooth muscle relaxant, W-7, which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced PRL secretion in a dose-dependent manner (r = -0.991, p less than 0.01)."
"In activated microglia, << 15d-PGJ2 >> suppressed iNOS promoter activity, [[ iNOS ]] mRNA, and protein levels.","In activated microglia, [ENTITY_A] suppressed iNOS promoter activity, [ENTITY_B] mRNA, and protein levels.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In activated microglia, 15d-PGJ2 suppressed iNOS promoter activity, iNOS mRNA, and protein levels."
"The << flavonoids >> inhibited [[ DGAT ]] activity in a dose-dependent manner with IC50 values of 10.9 microM ( 1), 9.8 microM ( 2), 8.6 microM ( 3), 142.0 microM ( 4) and 250 microM ( 5).","The [ENTITY_A] inhibited [ENTITY_B] activity in a dose-dependent manner with IC50 values of 10.9 microM ( 1), 9.8 microM ( 2), 8.6 microM ( 3), 142.0 microM ( 4) and 250 microM ( 5).",INHIBITOR,CPR:4,1,"The flavonoids inhibited DGAT activity in a dose-dependent manner with IC50 values of 10.9 microM ( 1), 9.8 microM ( 2), 8.6 microM ( 3), 142.0 microM ( 4) and 250 microM ( 5)."
High throughput screening led to the identification of a novel series of << quinolone >> α7 nicotinic acetylcholine receptor ([[ nAChR ]]) agonists.,High throughput screening led to the identification of a novel series of [ENTITY_A] α7 nicotinic acetylcholine receptor ([ENTITY_B]) agonists.,AGONIST,CPR:5,2,High throughput screening led to the identification of a novel series of quinolone α7 nicotinic acetylcholine receptor (nAChR) agonists.
"Moreover, BH(4) treatment of the << fructose >>-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, [[ nuclear factor-kappaB ]] and activating protein-1, which were increased in fructose-fed rats.","Moreover, BH(4) treatment of the [ENTITY_A]-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, [ENTITY_B] and activating protein-1, which were increased in fructose-fed rats.",UPREGULATOR,CPR:3,0,"Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and activating protein-1, which were increased in fructose-fed rats."
<< Quercetin >> and rutin also increased [[ alkaline phosphatase ]] activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).,[ENTITY_A] and rutin also increased [ENTITY_B] activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).,ACTIVATOR,CPR:3,0,Quercetin and rutin also increased alkaline phosphatase activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).
"Accordingly, loss of << pip5k1β >> function in FRDA cells was accompanied by decreased [[ PI(4,5)P2 ]] levels and was shown instrumental for destabilization of the actin network and delayed cell spreading.","Accordingly, loss of [ENTITY_A] function in FRDA cells was accompanied by decreased [ENTITY_B] levels and was shown instrumental for destabilization of the actin network and delayed cell spreading.",PRODUCT-OF,CPR:9,4,"Accordingly, loss of pip5k1β function in FRDA cells was accompanied by decreased PI(4,5)P2 levels and was shown instrumental for destabilization of the actin network and delayed cell spreading."
"First, we showed that intracerebroventricular administration of << glucose >> in rats increases [[ DBI ]] expression in hypothalamic glial-like tanycytes.","First, we showed that intracerebroventricular administration of [ENTITY_A] in rats increases [ENTITY_B] expression in hypothalamic glial-like tanycytes.",INDIRECT-UPREGULATOR,CPR:3,0,"First, we showed that intracerebroventricular administration of glucose in rats increases DBI expression in hypothalamic glial-like tanycytes."
"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against << alpha 1a-adrenoceptor >>-selective agonist [[ methoxamine ]]-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.","The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against [ENTITY_A]-selective agonist [ENTITY_B]-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",AGONIST,CPR:5,2,"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against alpha 1a-adrenoceptor-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil."
"<< Proline oxidase >> (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to [[ pyrroline- 5-carboxylate ]] (P5C).","[ENTITY_A] (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to [ENTITY_B] (P5C).",PRODUCT-OF,CPR:9,4,"Proline oxidase (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C)."
"In distinction, the preferential << beta 1-AR >> antagonist, [[ betaxolol ]], and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT.","In distinction, the preferential [ENTITY_A] antagonist, [ENTITY_B], and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT.",ANTAGONIST,CPR:6,3,"In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT."
<< Oxybutynin >> (1) is a non-selective [[ muscarinic receptor ]] antagonist that is used clinically for the treatment of urinary incontinence.,[ENTITY_A] (1) is a non-selective [ENTITY_B] antagonist that is used clinically for the treatment of urinary incontinence.,ANTAGONIST,CPR:6,3,Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence.
Subsequent optimization led to several novel << 3HPT >>-based [[ HDAC ]]i that are selective for HDAC 6 and HDAC 8.,Subsequent optimization led to several novel [ENTITY_A]-based [ENTITY_B]i that are selective for HDAC 6 and HDAC 8.,INHIBITOR,CPR:4,1,Subsequent optimization led to several novel 3HPT-based HDACi that are selective for HDAC 6 and HDAC 8.
"Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the << ERbeta >> agonist, [[ DPN ]], protected against dopamine cell loss.","Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the [ENTITY_A] agonist, [ENTITY_B], protected against dopamine cell loss.",AGONIST,CPR:5,2,"Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the ERbeta agonist, DPN, protected against dopamine cell loss."
A series of << xanthine >> derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of [[ dipeptidyl peptidase 4 ]] (DPP-4) for the treatment of type 2 diabetes.,A series of [ENTITY_A] derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of [ENTITY_B] (DPP-4) for the treatment of type 2 diabetes.,INHIBITOR,CPR:4,1,A series of xanthine derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (DPP-4) for the treatment of type 2 diabetes.
Functional and bioenergetic consequences of << AT1 >> antagonist [[ olmesartan medoxomil ]] in hearts with postinfarction LV remodeling.,Functional and bioenergetic consequences of [ENTITY_A] antagonist [ENTITY_B] in hearts with postinfarction LV remodeling.,ANTAGONIST,CPR:6,3,Functional and bioenergetic consequences of AT1 antagonist olmesartan medoxomil in hearts with postinfarction LV remodeling.
The demonstration that << sorafenib >> exhibits potent target inhibition and efficacy in [[ FLT3 ]]-driven models suggests that this compound may have a therapeutic benefit for patients with FLT3-driven leukemias.,The demonstration that [ENTITY_A] exhibits potent target inhibition and efficacy in [ENTITY_B]-driven models suggests that this compound may have a therapeutic benefit for patients with FLT3-driven leukemias.,INHIBITOR,CPR:4,1,The demonstration that sorafenib exhibits potent target inhibition and efficacy in FLT3-driven models suggests that this compound may have a therapeutic benefit for patients with FLT3-driven leukemias.
"Ras-CM and TGF-alpha also increase << PI3-K >> activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by [[ GW572016 ]].","Ras-CM and TGF-alpha also increase [ENTITY_A] activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by [ENTITY_B].",INHIBITOR,CPR:4,1,"Ras-CM and TGF-alpha also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by GW572016."
"In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation << ALK >> inhibitor 4 ([[ TAE684 ]]).","In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation [ENTITY_A] inhibitor 4 ([ENTITY_B]).",INHIBITOR,CPR:4,1,"In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684)."
"Using surface biotinylation, we observed that treatment of N-38 neurons with estradiol or with a membrane impermeant << estradiol >> elevated plasma membrane [[ ERα ]] protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane.","Using surface biotinylation, we observed that treatment of N-38 neurons with estradiol or with a membrane impermeant [ENTITY_A] elevated plasma membrane [ENTITY_B] protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane.",INDIRECT-UPREGULATOR,CPR:3,0,"Using surface biotinylation, we observed that treatment of N-38 neurons with estradiol or with a membrane impermeant estradiol elevated plasma membrane ERα protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane."
<< Monosodium urate >> crystals stimulate monocytes and macrophages to release [[ IL-1beta ]] through the NALP3 component of the inflammasome.,[ENTITY_A] crystals stimulate monocytes and macrophages to release [ENTITY_B] through the NALP3 component of the inflammasome.,INDIRECT-UPREGULATOR,CPR:3,0,Monosodium urate crystals stimulate monocytes and macrophages to release IL-1beta through the NALP3 component of the inflammasome.
<< Geldanamycin >> also disrupts the [[ T-cell receptor ]]-mediated activation of nuclear factor of activated T-cells (NF-AT).,[ENTITY_A] also disrupts the [ENTITY_B]-mediated activation of nuclear factor of activated T-cells (NF-AT).,INHIBITOR,CPR:4,1,Geldanamycin also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells (NF-AT).
"Even though the activities of << MAT >> and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and [[ S-adenosylhomocysteine ]] increased (113%, p<0.001) in the dwarf mice.","Even though the activities of [ENTITY_A] and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and [ENTITY_B] increased (113%, p<0.001) in the dwarf mice.",PRODUCT-OF,CPR:9,4,"Even though the activities of MAT and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice."
<< Phenformin >> reduced the open probability of [[ Kir6.1 ]]/SUR2B channels by approximately 90% in inside-out patches.,[ENTITY_A] reduced the open probability of [ENTITY_B]/SUR2B channels by approximately 90% in inside-out patches.,DOWNREGULATOR,CPR:4,1,Phenformin reduced the open probability of Kir6.1/SUR2B channels by approximately 90% in inside-out patches.
"1. The disposition of << anagliptin >>, an orally active, highly selective [[ dipeptidyl peptidase-4 ]] inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq [(14)C]anagliptin to six healthy men.","1. The disposition of [ENTITY_A], an orally active, highly selective [ENTITY_B] inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq [(14)C]anagliptin to six healthy men.",INHIBITOR,CPR:4,1,"1. The disposition of anagliptin, an orally active, highly selective dipeptidyl peptidase-4 inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq [(14)C]anagliptin to six healthy men."
"BACKGROUND AND AIMS: << Glutamic acid decarboxylase >> (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to [[ gamma-aminobutyric acid ]] (GABA).","BACKGROUND AND AIMS: [ENTITY_A] (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to [ENTITY_B] (GABA).",PRODUCT-OF,CPR:9,4,"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (GABA)."
"However, when coapplied with 10 micro m GABA, << ivermectin >> potentiated the GABA-evoked current of the [[ GAB-1 ]]/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.","However, when coapplied with 10 micro m GABA, [ENTITY_A] potentiated the GABA-evoked current of the [ENTITY_B]/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.",UPREGULATOR,CPR:3,0,"However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor."
"These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to << DeltaNK(ATP) channels >> decreased their P(O(max)) and apparent IC(50) for [[ ATP ]] in the absence of Mg(2+).","These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to [ENTITY_A] decreased their P(O(max)) and apparent IC(50) for [ENTITY_B] in the absence of Mg(2+).",INHIBITOR,CPR:4,1,"These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to DeltaNK(ATP) channels decreased their P(O(max)) and apparent IC(50) for ATP in the absence of Mg(2+)."
<< (125)I-Cyanopindolol >> saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in [[ beta(1)-adrenoceptors ]].,[ENTITY_A] saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,(125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in beta(1)-adrenoceptors.
"NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that << PSE >> inhibited both [[ JNK ]] activation and AP-1 transcriptional activity.","NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that [ENTITY_A] inhibited both [ENTITY_B] activation and AP-1 transcriptional activity.",INHIBITOR,CPR:4,1,"NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that PSE inhibited both JNK activation and AP-1 transcriptional activity."
"Similar to << AMR >> and AMROH, adriamycin and etoposide (VP-16) are [[ DNA topoisomerase II ]] inhibitors.","Similar to [ENTITY_A] and AMROH, adriamycin and etoposide (VP-16) are [ENTITY_B] inhibitors.",INHIBITOR,CPR:4,1,"Similar to AMR and AMROH, adriamycin and etoposide (VP-16) are DNA topoisomerase II inhibitors."
"Furthermore, << galangin >> attenuated [[ IgE ]]-mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue.","Furthermore, [ENTITY_A] attenuated [ENTITY_B]-mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue.",DOWNREGULATOR,CPR:4,1,"Furthermore, galangin attenuated IgE-mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue."
"<< Nateglinide >> inhibits [[ Kir6.2 ]]/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM).","[ENTITY_A] inhibits [ENTITY_B]/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM).",INHIBITOR,CPR:4,1,"Nateglinide inhibits Kir6.2/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM)."
"<< IRF3 >> activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by [[ auranofin ]].","[ENTITY_A] activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by [ENTITY_B].",DOWNREGULATOR,CPR:4,1,"IRF3 activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by auranofin."
"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors << survivin >>, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by [[ BZA ]].","Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors [ENTITY_A], Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by BZA."
"In contrast, the administration of 7.5 and 15 mg of << meloxicam >> caused dose-dependent reductions in monocyte [[ COX-2 ]] activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively.","In contrast, the administration of 7.5 and 15 mg of [ENTITY_A] caused dose-dependent reductions in monocyte [ENTITY_B] activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively.",INHIBITOR,CPR:4,1,"In contrast, the administration of 7.5 and 15 mg of meloxicam caused dose-dependent reductions in monocyte COX-2 activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively."
"Mitochondrial << glutathione (GSH) reductase >> activity and the GSH/glutathione disulfide ratio were decreased by [[ TCDD ]], ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide.","Mitochondrial [ENTITY_A] activity and the GSH/glutathione disulfide ratio were decreased by [ENTITY_B], ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide.",INHIBITOR,CPR:4,1,"Mitochondrial glutathione (GSH) reductase activity and the GSH/glutathione disulfide ratio were decreased by TCDD, ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide."
"Taken together, our study for the first time suggests that << 2-hydroxy-3-methylanthraquinone >> is able to enhance apoptosis of U937 cells, at least in part, through activation of [[ p-p38MAPK ]] and downregulation of p-ERK1/2.","Taken together, our study for the first time suggests that [ENTITY_A] is able to enhance apoptosis of U937 cells, at least in part, through activation of [ENTITY_B] and downregulation of p-ERK1/2.",ACTIVATOR,CPR:3,0,"Taken together, our study for the first time suggests that 2-hydroxy-3-methylanthraquinone is able to enhance apoptosis of U937 cells, at least in part, through activation of p-p38MAPK and downregulation of p-ERK1/2."
"Additionally, in SH-SY5Y cells, << MPP(+) >>-induced demethylation of [[ phosphoprotein phosphatase 2A ]] (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT.","Additionally, in SH-SY5Y cells, [ENTITY_A]-induced demethylation of [ENTITY_B] (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT.",DOWNREGULATOR,CPR:4,1,"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT."
While SP600125 (a << JNK >> inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by [[ ISO ]].,While SP600125 (a [ENTITY_A] inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,While SP600125 (a JNK inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.
"Treatment of HDP cells with a c-Jun NH2-terminal kinase (JNK) inhibitor also reduced butein-induced HO-1 expression, and << butein >> treatment led to increased [[ JNK ]] phosphorylation.","Treatment of HDP cells with a c-Jun NH2-terminal kinase (JNK) inhibitor also reduced butein-induced HO-1 expression, and [ENTITY_A] treatment led to increased [ENTITY_B] phosphorylation.",ACTIVATOR,CPR:3,0,"Treatment of HDP cells with a c-Jun NH2-terminal kinase (JNK) inhibitor also reduced butein-induced HO-1 expression, and butein treatment led to increased JNK phosphorylation."
"The compounds identified as 5-LO inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where << hydroxamic acids >> are potent and more selective inhibitors of [[ 5-LO ]].","The compounds identified as 5-LO inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where [ENTITY_A] are potent and more selective inhibitors of [ENTITY_B].",INHIBITOR,CPR:4,1,"The compounds identified as 5-LO inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where hydroxamic acids are potent and more selective inhibitors of 5-LO."
There was also an increase in << γ-GCS >> and HO-1 levels in [[ calycopterin ]] pretreated cells.,There was also an increase in [ENTITY_A] and HO-1 levels in [ENTITY_B] pretreated cells.,INDIRECT-UPREGULATOR,CPR:3,0,There was also an increase in γ-GCS and HO-1 levels in calycopterin pretreated cells.
"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific << renin >>-angiotensin-aldosterone system (RAAS) blockade by renin-inhibitor [[ remikiren ]] could be predicted from pretreatment renal vascular tone.","This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific [ENTITY_A]-angiotensin-aldosterone system (RAAS) blockade by renin-inhibitor [ENTITY_B] could be predicted from pretreatment renal vascular tone.",INHIBITOR,CPR:4,1,"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin-angiotensin-aldosterone system (RAAS) blockade by renin-inhibitor remikiren could be predicted from pretreatment renal vascular tone."
"It has been known for decades that << lithium chloride >> (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting [[ inositol monophosphatase ]], the final enzyme of the IP3 metabolic cascade.","It has been known for decades that [ENTITY_A] (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting [ENTITY_B], the final enzyme of the IP3 metabolic cascade.",INHIBITOR,CPR:4,1,"It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade."
"Furthermore, cAMP production and << protein kinase A >> (PKA) activity were suppressed by [[ artemisinic acid ]].","Furthermore, cAMP production and [ENTITY_A] (PKA) activity were suppressed by [ENTITY_B].",INHIBITOR,CPR:4,1,"Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by artemisinic acid."
"Dimemorfan pre-treatment also attenuated the << KA >>-induced increases in c-fos/c-jun expression, [[ activator protein (AP)-1 ]] DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.","Dimemorfan pre-treatment also attenuated the [ENTITY_A]-induced increases in c-fos/c-jun expression, [ENTITY_B] DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.",ACTIVATOR,CPR:3,0,"Dimemorfan pre-treatment also attenuated the KA-induced increases in c-fos/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus."
"The << BuChE >> inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than [[ tacrine ]].","The [ENTITY_A] inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than [ENTITY_B].",INHIBITOR,CPR:4,1,"The BuChE inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than tacrine."
"These events are stimulated by << NE >> and by guanethidine, an [[ hNET ]] substrate, and they are blocked by cocaine and the antidepressant desipramine.","These events are stimulated by [ENTITY_A] and by guanethidine, an [ENTITY_B] substrate, and they are blocked by cocaine and the antidepressant desipramine.",SUBSTRATE,CPR:9,4,"These events are stimulated by NE and by guanethidine, an hNET substrate, and they are blocked by cocaine and the antidepressant desipramine."
<< Voltage-gated sodium (Na) channels >>[[ sodium ]] (Na) channels are a critical component of electrically excitable cells.,[ENTITY_A][ENTITY_B] (Na) channels are a critical component of electrically excitable cells.,SUBSTRATE,CPR:9,4,Voltage-gated sodium (Na) channelssodium (Na) channels are a critical component of electrically excitable cells.
"Both << 5'-AMN >> and 5'-MABN had high affinity for κ-receptors (K (i) 1.36 ± 0.98 and 0.27 ± 0.08, respectively) and were revealed as potent κ-antagonists (pA(2) 7.43 and 8.18, respectively) and [[ μ-receptor ]] antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.","Both [ENTITY_A] and 5'-MABN had high affinity for κ-receptors (K (i) 1.36 ± 0.98 and 0.27 ± 0.08, respectively) and were revealed as potent κ-antagonists (pA(2) 7.43 and 8.18, respectively) and [ENTITY_B] antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.",ANTAGONIST,CPR:6,3,"Both 5'-AMN and 5'-MABN had high affinity for κ-receptors (K (i) 1.36 ± 0.98 and 0.27 ± 0.08, respectively) and were revealed as potent κ-antagonists (pA(2) 7.43 and 8.18, respectively) and μ-receptor antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum."
Further investigation demonstrated that 8k reduced << H2O2 >>-induced activation of mitochondrial apoptosis by inhibiting the expression of [[ Bax ]] and elevating the expression of Bcl-2.,Further investigation demonstrated that 8k reduced [ENTITY_A]-induced activation of mitochondrial apoptosis by inhibiting the expression of [ENTITY_B] and elevating the expression of Bcl-2.,INDIRECT-UPREGULATOR,CPR:3,0,Further investigation demonstrated that 8k reduced H2O2-induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of Bcl-2.
"The signaling of both << Sox9 >> and Runx2, key regulators of chondrogenesis, was downregulated by [[ VPA ]].","The signaling of both [ENTITY_A] and Runx2, key regulators of chondrogenesis, was downregulated by [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"The signaling of both Sox9 and Runx2, key regulators of chondrogenesis, was downregulated by VPA."
"Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors (<< proteasome >> inhibitor I, [[ MG-132 ]], or lactacystin) decreased the extent of U50,488H-induced down-regulation.","Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors ([ENTITY_A] inhibitor I, [ENTITY_B], or lactacystin) decreased the extent of U50,488H-induced down-regulation.",INHIBITOR,CPR:4,1,"Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors (proteasome inhibitor I, MG-132, or lactacystin) decreased the extent of U50,488H-induced down-regulation."
"This effect was potentiated by << isobutylmethylxanthine >>, an inhibitor of [[ phosphodiesterase ]].","This effect was potentiated by [ENTITY_A], an inhibitor of [ENTITY_B].",INHIBITOR,CPR:4,1,"This effect was potentiated by isobutylmethylxanthine, an inhibitor of phosphodiesterase."
Protein expression of << Ugt1a6 >> also decreased and corresponded with reduced in vitro glucuronidation of [[ bisphenol A ]] in S9 fractions from livers of pregnant mice.,Protein expression of [ENTITY_A] also decreased and corresponded with reduced in vitro glucuronidation of [ENTITY_B] in S9 fractions from livers of pregnant mice.,INDIRECT-DOWNREGULATOR,CPR:4,1,Protein expression of Ugt1a6 also decreased and corresponded with reduced in vitro glucuronidation of bisphenol A in S9 fractions from livers of pregnant mice.
"Among the possible transporters involved in the uptake of << Cd(2+) >> and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by [[ Slc39a8 ]], showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.","Among the possible transporters involved in the uptake of [ENTITY_A] and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by [ENTITY_B], showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.",SUBSTRATE,CPR:9,4,"Among the possible transporters involved in the uptake of Cd(2+) and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells."
"Together, these results suggested that << imatinib >> affects EGFR activation and signaling pathways through rapid release and increased expression of endogenous [[ EGFR ]]-activating ligands.","Together, these results suggested that [ENTITY_A] affects EGFR activation and signaling pathways through rapid release and increased expression of endogenous [ENTITY_B]-activating ligands.",INDIRECT-UPREGULATOR,CPR:3,0,"Together, these results suggested that imatinib affects EGFR activation and signaling pathways through rapid release and increased expression of endogenous EGFR-activating ligands."
"Taken together, these findings indicate that << antofine >> induces Cx43 gap junction disassembly by the [[ PKCβ ]] signaling pathway.","Taken together, these findings indicate that [ENTITY_A] induces Cx43 gap junction disassembly by the [ENTITY_B] signaling pathway.",ACTIVATOR,CPR:3,0,"Taken together, these findings indicate that antofine induces Cx43 gap junction disassembly by the PKCβ signaling pathway."
"<< Acetylcholinesterase >> (AChE) inhibited by the [[ organophosphate ]] soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.","[ENTITY_A] (AChE) inhibited by the [ENTITY_B] soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.",INHIBITOR,CPR:4,1,"Acetylcholinesterase (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex."
"In healthy rats, << ATB-429 >> dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal [[ c-FOS ]] mRNA, whereas mesalamine had no effect.","In healthy rats, [ENTITY_A] dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal [ENTITY_B] mRNA, whereas mesalamine had no effect.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In healthy rats, ATB-429 dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal c-FOS mRNA, whereas mesalamine had no effect."
It was found that expression of << Sim2 >> protein in cortical neurons was increased in [[ streptozotocin ]]-induced diabetes mellitus rat model.,It was found that expression of [ENTITY_A] protein in cortical neurons was increased in [ENTITY_B]-induced diabetes mellitus rat model.,INDIRECT-UPREGULATOR,CPR:3,0,It was found that expression of Sim2 protein in cortical neurons was increased in streptozotocin-induced diabetes mellitus rat model.
"In the current project, we found that the selective << H(1) >> antagonist pyrilamine also reversed the [[ dizocilpine ]]-induced impairment in PPI of tactile startle with an auditory prepulse.","In the current project, we found that the selective [ENTITY_A] antagonist pyrilamine also reversed the [ENTITY_B]-induced impairment in PPI of tactile startle with an auditory prepulse.",UPREGULATOR,CPR:3,0,"In the current project, we found that the selective H(1) antagonist pyrilamine also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse."
"Immunohistochemical characterization of << pyrimidine >> synthetic enzymes, [[ thymidine kinase-1 ]] and thymidylate synthase, in various types of cancer.","Immunohistochemical characterization of [ENTITY_A] synthetic enzymes, [ENTITY_B] and thymidylate synthase, in various types of cancer.",PRODUCT-OF,CPR:9,4,"Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer."
"In conclusion, in this cellular model, << DOX >> effectively protects against PQ toxicity by inducing [[ P-gp ]] and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.","In conclusion, in this cellular model, [ENTITY_A] effectively protects against PQ toxicity by inducing [ENTITY_B] and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.",ACTIVATOR,CPR:3,0,"In conclusion, in this cellular model, DOX effectively protects against PQ toxicity by inducing P-gp and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications."
"Finally, << Metformin >> treatment caused a significant increase in the level of [[ phosphorylated (active) AMPK ]].","Finally, [ENTITY_A] treatment caused a significant increase in the level of [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"Finally, Metformin treatment caused a significant increase in the level of phosphorylated (active) AMPK."
"We therefore conclude that << carvedilol >>, at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of [[ calcium channels ]] in vascular smooth muscle.(ABSTRACT TRUNCATED AT 400 WORDS)","We therefore conclude that [ENTITY_A], at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of [ENTITY_B] in vascular smooth muscle.(ABSTRACT TRUNCATED AT 400 WORDS)",ANTAGONIST,CPR:6,3,"We therefore conclude that carvedilol, at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of calcium channels in vascular smooth muscle.(ABSTRACT TRUNCATED AT 400 WORDS)"
This paper describes the identification and synthesis of substituted << benzofurans >> as [[ LTH(4)H ]] inhibitors.,This paper describes the identification and synthesis of substituted [ENTITY_A] as [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,This paper describes the identification and synthesis of substituted benzofurans as LTH(4)H inhibitors.
"Polyclonal antisera to either << b5R >> or cyt b5 significantly inhibited [[ N-hydroxy-4-aminobiphenyl ]] (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).","Polyclonal antisera to either [ENTITY_A] or cyt b5 significantly inhibited [ENTITY_B] (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).",SUBSTRATE,CPR:9,4,"Polyclonal antisera to either b5R or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)."
"The latter reaction, catalyzed by << aspartoacylase >> (ASPA), produces [[ acetyl ]] groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter.","The latter reaction, catalyzed by [ENTITY_A] (ASPA), produces [ENTITY_B] groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter.",PRODUCT-OF,CPR:9,4,"The latter reaction, catalyzed by aspartoacylase (ASPA), produces acetyl groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter."
"In a recent study using protein-specific anti-acetyl lysine antibodies and immunological methods, we demonstrated the ability of << aspirin >> to acetylate the [[ tumor suppressor protein p53 ]].","In a recent study using protein-specific anti-acetyl lysine antibodies and immunological methods, we demonstrated the ability of [ENTITY_A] to acetylate the [ENTITY_B].",ACTIVATOR,CPR:3,0,"In a recent study using protein-specific anti-acetyl lysine antibodies and immunological methods, we demonstrated the ability of aspirin to acetylate the tumor suppressor protein p53."
These results suggest that << pitavastatin >> efficiently increases [[ apoA-I ]] in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.,These results suggest that [ENTITY_A] efficiently increases [ENTITY_B] in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.,INDIRECT-UPREGULATOR,CPR:3,0,These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.
The in vitro kinase activity of << PKC-alpha >> induced by [[ I3A ]] was lower than that induced by PMA.,The in vitro kinase activity of [ENTITY_A] induced by [ENTITY_B] was lower than that induced by PMA.,ACTIVATOR,CPR:3,0,The in vitro kinase activity of PKC-alpha induced by I3A was lower than that induced by PMA.
"METHODS: The effect of leukotriene D(4) and the << leukotriene receptor >> antagonist, [[ pranlukast hydrate ]] (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.","METHODS: The effect of leukotriene D(4) and the [ENTITY_A] antagonist, [ENTITY_B] (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.",ANTAGONIST,CPR:6,3,"METHODS: The effect of leukotriene D(4) and the leukotriene receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells."
alpha(1)-Adrenoceptor antagonists were tested against the << phenylephrine >> ([[ alpha(1)-adrenoceptor ]] agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach.,alpha(1)-Adrenoceptor antagonists were tested against the [ENTITY_A] ([ENTITY_B] agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach.,AGONIST,CPR:5,2,alpha(1)-Adrenoceptor antagonists were tested against the phenylephrine (alpha(1)-adrenoceptor agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach.
"Staining around the edges of the brown fat cells was observed with the << SSAO >> substrates, [[ tyramine ]] and benzylamine.","Staining around the edges of the brown fat cells was observed with the [ENTITY_A] substrates, [ENTITY_B] and benzylamine.",SUBSTRATE,CPR:9,4,"Staining around the edges of the brown fat cells was observed with the SSAO substrates, tyramine and benzylamine."
"Known VR1 antagonists (<< BCTC >>, thio-BCTC and capsazepine) were also able to block the response of [[ TRPM8 ]] to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).","Known VR1 antagonists ([ENTITY_A], thio-BCTC and capsazepine) were also able to block the response of [ENTITY_B] to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).",INHIBITOR,CPR:4,1,"Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively)."
Derivatives of << 5-(dipentylamino)-5-oxo-pentanoic acid >> are a new class of non-peptide cholecystokinin ([[ CCK ]]) antagonists.,Derivatives of [ENTITY_A] are a new class of non-peptide cholecystokinin ([ENTITY_B]) antagonists.,ANTAGONIST,CPR:6,3,Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists.
"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the << CB(1) >> agonist [[ Δ(9)-tetrahydrocannabinol ]], and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.","Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the [ENTITY_A] agonist [ENTITY_B], and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.",AGONIST,CPR:5,2,"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054."
RESULTS: << Aspirin >> reduced [[ mTOR ]] signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1.,RESULTS: [ENTITY_A] reduced [ENTITY_B] signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1.,INDIRECT-DOWNREGULATOR,CPR:4,1,RESULTS: Aspirin reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1.
<< DBDCT >> also caused the phosphorylation of [[ JNK ]] and p38(MAPK).,[ENTITY_A] also caused the phosphorylation of [ENTITY_B] and p38(MAPK).,ACTIVATOR,CPR:3,0,DBDCT also caused the phosphorylation of JNK and p38(MAPK).
"In the present study we tested whether << propranolol >>, a [[ β-receptor ]] antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8).","In the present study we tested whether [ENTITY_A], a [ENTITY_B] antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8).",ANTAGONIST,CPR:6,3,"In the present study we tested whether propranolol, a β-receptor antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8)."
"Upon << nicotine >> pre-exposure, brain [[ acetylcholinesterase ]] increased, while monoamine oxidase (MAO) decreased.","Upon [ENTITY_A] pre-exposure, brain [ENTITY_B] increased, while monoamine oxidase (MAO) decreased.",UPREGULATOR,CPR:3,0,"Upon nicotine pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase (MAO) decreased."
"In conclusion, early application of << amiloride >> inhibited [[ u-PA ]] activity in UVB-irradiated corneas as well as in tear fluid and diminished the development of corneal pathology.","In conclusion, early application of [ENTITY_A] inhibited [ENTITY_B] activity in UVB-irradiated corneas as well as in tear fluid and diminished the development of corneal pathology.",INHIBITOR,CPR:4,1,"In conclusion, early application of amiloride inhibited u-PA activity in UVB-irradiated corneas as well as in tear fluid and diminished the development of corneal pathology."
"OBJECTIVES: This study examined the effect of a small-molecule, direct << thrombin >> inhibitor, [[ argatroban ]], on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).","OBJECTIVES: This study examined the effect of a small-molecule, direct [ENTITY_A] inhibitor, [ENTITY_B], on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).",INHIBITOR,CPR:4,1,"OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI)."
"Unique binding interactions of << valdecoxib >> with COX-2 translate into a fast rate of inactivation of [[ COX-2 ]] (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib).","Unique binding interactions of [ENTITY_A] with COX-2 translate into a fast rate of inactivation of [ENTITY_B] (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib).",DOWNREGULATOR,CPR:4,1,"Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib)."
"In leukemia cell lines MV4-11 and EOL-1, << sorafenib >> treatment resulted in decreased cell proliferation and inhibition of [[ FLT3 ]] signaling.","In leukemia cell lines MV4-11 and EOL-1, [ENTITY_A] treatment resulted in decreased cell proliferation and inhibition of [ENTITY_B] signaling.",INHIBITOR,CPR:4,1,"In leukemia cell lines MV4-11 and EOL-1, sorafenib treatment resulted in decreased cell proliferation and inhibition of FLT3 signaling."
We evaluated the effects of << angiotensin II >> and an angiotensin-converting enzyme inhibitor ([[ cilazapril ]]) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.,We evaluated the effects of [ENTITY_A] and an angiotensin-converting enzyme inhibitor ([ENTITY_B]) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.,INHIBITOR,CPR:4,1,We evaluated the effects of angiotensin II and an angiotensin-converting enzyme inhibitor (cilazapril) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.
Results of RT-PCR analysis showed decrease of << p53 >> mRNA level and no significant difference in Bcl-2 and Bax mRNA expressions in [[ DEX ]]-treated rats.,Results of RT-PCR analysis showed decrease of [ENTITY_A] mRNA level and no significant difference in Bcl-2 and Bax mRNA expressions in [ENTITY_B]-treated rats.,INDIRECT-DOWNREGULATOR,CPR:4,1,Results of RT-PCR analysis showed decrease of p53 mRNA level and no significant difference in Bcl-2 and Bax mRNA expressions in DEX-treated rats.
<< AlCl3 >> markedly reduced AA performance and activities of [[ cytochrome c oxidase ]] (COX) and acetylcholinesterase (AChE) in all regions.,[ENTITY_A] markedly reduced AA performance and activities of [ENTITY_B] (COX) and acetylcholinesterase (AChE) in all regions.,INHIBITOR,CPR:4,1,AlCl3 markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (AChE) in all regions.
SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors << doxorubicin >> and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in [[ FAS promoter ]] activity when compared with control cells growing in drug-free culture conditions.,SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors [ENTITY_A] and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in [ENTITY_B] activity when compared with control cells growing in drug-free culture conditions.,ACTIVATOR,CPR:3,0,SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.
"<< MNU >>-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high [[ MGMT ]] staining.","[ENTITY_A]-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high [ENTITY_B] staining.",INDIRECT-UPREGULATOR,CPR:3,0,"MNU-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high MGMT staining."
Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced << iNOS >> expression and [[ NO ]] production.,Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced [ENTITY_A] expression and [ENTITY_B] production.,PRODUCT-OF,CPR:9,4,Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced iNOS expression and NO production.
Association of PGE2 or << acetazolamide >> to NSAIDs reduced NSAID-induced activation of [[ CA I ]] and CA II.,Association of PGE2 or [ENTITY_A] to NSAIDs reduced NSAID-induced activation of [ENTITY_B] and CA II.,DOWNREGULATOR,CPR:4,1,Association of PGE2 or acetazolamide to NSAIDs reduced NSAID-induced activation of CA I and CA II.
The pretreatment with << salbutamol >> induced a 59% down-regulation of left ventricular [[ beta(2)-adrenoceptors ]] compared to control.,The pretreatment with [ENTITY_A] induced a 59% down-regulation of left ventricular [ENTITY_B] compared to control.,DOWNREGULATOR,CPR:4,1,The pretreatment with salbutamol induced a 59% down-regulation of left ventricular beta(2)-adrenoceptors compared to control.
Fumarate reductase (<< FRD >>) is the key enzyme in [[ fumarate ]] respiration induced by anaerobic growth of bacteria.,Fumarate reductase ([ENTITY_A]) is the key enzyme in [ENTITY_B] respiration induced by anaerobic growth of bacteria.,SUBSTRATE,CPR:9,4,Fumarate reductase (FRD) is the key enzyme in fumarate respiration induced by anaerobic growth of bacteria.
These results suggest that << Cat3 >> compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity [[ arginine ]] transport.,These results suggest that [ENTITY_A] compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity [ENTITY_B] transport.,SUBSTRATE,CPR:9,4,These results suggest that Cat3 compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity arginine transport.
<< Sophocarpine >> alleviates hepatocyte steatosis through activating [[ AMPK ]] signaling pathway.,[ENTITY_A] alleviates hepatocyte steatosis through activating [ENTITY_B] signaling pathway.,ACTIVATOR,CPR:3,0,Sophocarpine alleviates hepatocyte steatosis through activating AMPK signaling pathway.
We have expressed << VIAAT >> and the plasmalemmal transporters for glycine and [[ GABA ]] in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.,We have expressed [ENTITY_A] and the plasmalemmal transporters for glycine and [ENTITY_B] in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.,SUBSTRATE,CPR:9,4,We have expressed VIAAT and the plasmalemmal transporters for glycine and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.
"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on << mucin >> secretion was inhibited by EGFR kinase inhibitor, [[ PD153035 ]], as well as wortmannin, a specific inhibitor of PI3K.","Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on [ENTITY_A] secretion was inhibited by EGFR kinase inhibitor, [ENTITY_B], as well as wortmannin, a specific inhibitor of PI3K.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K."
"<< Thymidylate synthase >> and thymidine kinase are key enzymes involved in the de novo and salvage pathways for [[ pyrimidine nucleotide ]] synthesis, respectively.","[ENTITY_A] and thymidine kinase are key enzymes involved in the de novo and salvage pathways for [ENTITY_B] synthesis, respectively.",PRODUCT-OF,CPR:9,4,"Thymidylate synthase and thymidine kinase are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively."
These data support the concept that adipose tissue << NNMT >> contributes to the increased plasma [[ homocysteine ]] levels in patients treated with NA.,These data support the concept that adipose tissue [ENTITY_A] contributes to the increased plasma [ENTITY_B] levels in patients treated with NA.,PRODUCT-OF,CPR:9,4,These data support the concept that adipose tissue NNMT contributes to the increased plasma homocysteine levels in patients treated with NA.
"Most of the tested H(2)R agonists and << imidazole >>-based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic [[ hH(4)R ]] activities, ranging from full agonists to inverse agonists.","Most of the tested H(2)R agonists and [ENTITY_A]-based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic [ENTITY_B] activities, ranging from full agonists to inverse agonists.",AGONIST-ACTIVATOR,CPR:5,2,"Most of the tested H(2)R agonists and imidazole-based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists."
Galanin attenuates << cyclic AMP regulatory element-binding protein >> (CREB) phosphorylation induced by chronic [[ morphine ]] and naloxone challenge in Cath.a cells and primary striatal cultures.,Galanin attenuates [ENTITY_A] (CREB) phosphorylation induced by chronic [ENTITY_B] and naloxone challenge in Cath.a cells and primary striatal cultures.,ACTIVATOR,CPR:3,0,Galanin attenuates cyclic AMP regulatory element-binding protein (CREB) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures.
Western blot assay demonstrated that << DICO >> decreased Bcl-2 level and induced [[ Bax ]] translocation to cause cytochrome c release.,Western blot assay demonstrated that [ENTITY_A] decreased Bcl-2 level and induced [ENTITY_B] translocation to cause cytochrome c release.,INDIRECT-UPREGULATOR,CPR:3,0,Western blot assay demonstrated that DICO decreased Bcl-2 level and induced Bax translocation to cause cytochrome c release.
<< Phenylephrine >> elicited a concentration-dependent positive inotropic effect via [[ alpha 1-adrenoceptors ]] in the presence of either (+/-)-bupranolol or S(-)-timolol.,[ENTITY_A] elicited a concentration-dependent positive inotropic effect via [ENTITY_B] in the presence of either (+/-)-bupranolol or S(-)-timolol.,AGONIST-ACTIVATOR,CPR:5,2,Phenylephrine elicited a concentration-dependent positive inotropic effect via alpha 1-adrenoceptors in the presence of either (+/-)-bupranolol or S(-)-timolol.
"In addition, another drug that is both a substrate of << uptake1 >> and a MAO inhibitor, [[ debrisoquine ]], was investigated in the study.","In addition, another drug that is both a substrate of [ENTITY_A] and a MAO inhibitor, [ENTITY_B], was investigated in the study.",SUBSTRATE,CPR:9,4,"In addition, another drug that is both a substrate of uptake1 and a MAO inhibitor, debrisoquine, was investigated in the study."
The irreversible complex between << phenoxybenzamine >> and calmodulin may be useful for inhibiting certain [[ calmodulin ]]-dependent reactions and for studying the various biological functions of calmodulin.,The irreversible complex between [ENTITY_A] and calmodulin may be useful for inhibiting certain [ENTITY_B]-dependent reactions and for studying the various biological functions of calmodulin.,INHIBITOR,CPR:4,1,The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.
Analysis of tumour-conditioned medium indicated that << bexarotene >> decreased the secretion of angiogenic factors and [[ matrix metalloproteinases ]] and increased the tissue inhibitor of matrix metalloproteinases.,Analysis of tumour-conditioned medium indicated that [ENTITY_A] decreased the secretion of angiogenic factors and [ENTITY_B] and increased the tissue inhibitor of matrix metalloproteinases.,INDIRECT-DOWNREGULATOR,CPR:4,1,Analysis of tumour-conditioned medium indicated that bexarotene decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of matrix metalloproteinases.
We find that << minocycline >> inhibits mitochondrial permeability-transition-mediated [[ cytochrome c ]] release.,We find that [ENTITY_A] inhibits mitochondrial permeability-transition-mediated [ENTITY_B] release.,INDIRECT-DOWNREGULATOR,CPR:4,1,We find that minocycline inhibits mitochondrial permeability-transition-mediated cytochrome c release.
"CONCLUSION: << Imidapril >> and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of [[ TGF-beta1 ]], c-Jun in SHR.","CONCLUSION: [ENTITY_A] and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of [ENTITY_B], c-Jun in SHR.",INDIRECT-DOWNREGULATOR,CPR:4,1,"CONCLUSION: Imidapril and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, c-Jun in SHR."
"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of << insulin >> (achieved by administering insulin plus [[ glucose ]], glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine).","Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of [ENTITY_A] (achieved by administering insulin plus [ENTITY_B], glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine).",INDIRECT-UPREGULATOR,CPR:3,0,"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine)."
"The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide (BPDE) can be detoxified by << glutathione >> conjugate formation catalyzed by [[ glutathione S-transferases ]].","The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide (BPDE) can be detoxified by [ENTITY_A] conjugate formation catalyzed by [ENTITY_B].",PRODUCT-OF,CPR:9,4,"The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide (BPDE) can be detoxified by glutathione conjugate formation catalyzed by glutathione S-transferases."
"Structure-based design, synthesis and evaluation of novel << anthra[1,2-d]imidazole-6,11-dione >> derivatives as [[ telomerase ]] inhibitors and potential for cancer polypharmacology.","Structure-based design, synthesis and evaluation of novel [ENTITY_A] derivatives as [ENTITY_B] inhibitors and potential for cancer polypharmacology.",INHIBITOR,CPR:4,1,"Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology."
"The current comprehensive losartan clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the << AT(1) receptor >> with [[ losartan ]] compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.","The current comprehensive losartan clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the [ENTITY_A] with [ENTITY_B] compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.",INHIBITOR,CPR:4,1,"The current comprehensive losartan clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the AT(1) receptor with losartan compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL."
"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of << linoleic acid >> (LA) and alpha-linolenic acid (LNA) and the expression of PBMC [[ D6D ]] and D5D genes.","A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of [ENTITY_A] (LA) and alpha-linolenic acid (LNA) and the expression of PBMC [ENTITY_B] and D5D genes.",INDIRECT-DOWNREGULATOR,CPR:4,1,"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes."
"Binding of the agonist angiotensin II (AngII) and inverse agonist << losartan >> in wild-type [[ AT1R ]] changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific ""lid"" conformations of ECL2.","Binding of the agonist angiotensin II (AngII) and inverse agonist [ENTITY_A] in wild-type [ENTITY_B] changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific ""lid"" conformations of ECL2.",AGONIST-INHIBITOR,CPR:5,2,"Binding of the agonist angiotensin II (AngII) and inverse agonist losartan in wild-type AT1R changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific ""lid"" conformations of ECL2."
The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic << CYP3A >> subfamily-mediated metabolism (21.9% decrease) of [[ doxorubicin ]].,The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic [ENTITY_A] subfamily-mediated metabolism (21.9% decrease) of [ENTITY_B].,SUBSTRATE,CPR:9,4,The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic CYP3A subfamily-mediated metabolism (21.9% decrease) of doxorubicin.
"First, addition of << apolipoprotein A-I >> (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased [[ alpha-tocopherol ]] secretion in a dose-dependent manner.","First, addition of [ENTITY_A] (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased [ENTITY_B] secretion in a dose-dependent manner.",PRODUCT-OF,CPR:9,4,"First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased alpha-tocopherol secretion in a dose-dependent manner."
"Thus, << H(1) >> antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as [[ clozapine ]].","Thus, [ENTITY_A] antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as [ENTITY_B].",ANTAGONIST,CPR:6,3,"Thus, H(1) antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as clozapine."
"Mice given daily injections of high dose << JZL184 >> (≥16 mg/kg) for six days displayed decreased [[ CB(1) ]] receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTPγS binding assays, respectively.","Mice given daily injections of high dose [ENTITY_A] (≥16 mg/kg) for six days displayed decreased [ENTITY_B] receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTPγS binding assays, respectively.",DOWNREGULATOR,CPR:4,1,"Mice given daily injections of high dose JZL184 (≥16 mg/kg) for six days displayed decreased CB(1) receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTPγS binding assays, respectively."
Structure-based design of novel << dihydroisoquinoline >> [[ BACE-1 ]] inhibitors that do not engage the catalytic aspartates.,Structure-based design of novel [ENTITY_A] [ENTITY_B] inhibitors that do not engage the catalytic aspartates.,INHIBITOR,CPR:4,1,Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates.
"In the presence of H2O2, << calycopterin >> inhibited decrease in GSH level and [[ SOD ]] activity.","In the presence of H2O2, [ENTITY_A] inhibited decrease in GSH level and [ENTITY_B] activity.",ACTIVATOR,CPR:3,0,"In the presence of H2O2, calycopterin inhibited decrease in GSH level and SOD activity."
"Moreover, co-treatment with << antofine >> and a specific PKCβ inhibitor prevented endocytosis of gap junctions, downregulation of [[ Cx43 ]], and inhibition of GJIC.","Moreover, co-treatment with [ENTITY_A] and a specific PKCβ inhibitor prevented endocytosis of gap junctions, downregulation of [ENTITY_B], and inhibition of GJIC.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, co-treatment with antofine and a specific PKCβ inhibitor prevented endocytosis of gap junctions, downregulation of Cx43, and inhibition of GJIC."
"The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to << Na+ >>-H+ exchange ([[ NHE1 ]] isoform).","The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to [ENTITY_A]-H+ exchange ([ENTITY_B] isoform).",SUBSTRATE,CPR:9,4,"The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+-H+ exchange (NHE1 isoform)."
"We searched for inhibitors of << HDC >> from the [[ ethyl acetate ]] extract of the petal of Filipendula ulmaria, also called meadowsweet.","We searched for inhibitors of [ENTITY_A] from the [ENTITY_B] extract of the petal of Filipendula ulmaria, also called meadowsweet.",INHIBITOR,CPR:4,1,"We searched for inhibitors of HDC from the ethyl acetate extract of the petal of Filipendula ulmaria, also called meadowsweet."
"PURPOSE: << Omeprazole >> has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with [[ cytochrome P450 (CYP) 2C19 ]] genotype groups.","PURPOSE: [ENTITY_A] has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with [ENTITY_B] genotype groups.",SUBSTRATE,CPR:9,4,"PURPOSE: Omeprazole has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with cytochrome P450 (CYP) 2C19 genotype groups."
High-affinity blockade of << voltage-operated skeletal muscle and neuronal sodium channels >> by [[ halogenated propofol ]] analogues.,High-affinity blockade of [ENTITY_A] by [ENTITY_B] analogues.,INHIBITOR,CPR:4,1,High-affinity blockade of voltage-operated skeletal muscle and neuronal sodium channels by halogenated propofol analogues.
"Importantly, expression of the acute-phase reactant << serum amyloid A >> (SAA) significantly increased after [[ ritodrine ]] injection, with values indicating the largest fold-change.","Importantly, expression of the acute-phase reactant [ENTITY_A] (SAA) significantly increased after [ENTITY_B] injection, with values indicating the largest fold-change.",INDIRECT-UPREGULATOR,CPR:3,0,"Importantly, expression of the acute-phase reactant serum amyloid A (SAA) significantly increased after ritodrine injection, with values indicating the largest fold-change."
"A selective << retinoid X receptor >> agonist [[ bexarotene ]] (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.","A selective [ENTITY_A] agonist [ENTITY_B] (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.",AGONIST,CPR:5,2,"A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours."
Binding of << cGMP >> to GAF-A increases [[ cNPK ]] phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors.,Binding of [ENTITY_A] to GAF-A increases [ENTITY_B] phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors.,INDIRECT-UPREGULATOR,CPR:3,0,Binding of cGMP to GAF-A increases cNPK phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors.
"Since the suppression of << AT1R >> expression was prevented by pretreatment with [[ GW9662 ]], a PPARgamma antagonist, PPARgamma should have participated in the process.","Since the suppression of [ENTITY_A] expression was prevented by pretreatment with [ENTITY_B], a PPARgamma antagonist, PPARgamma should have participated in the process.",INDIRECT-UPREGULATOR,CPR:3,0,"Since the suppression of AT1R expression was prevented by pretreatment with GW9662, a PPARgamma antagonist, PPARgamma should have participated in the process."
"<< Hexahydrochromeno[4,3-b]pyrrole >> derivatives as [[ acetylcholinesterase ]] inhibitors.",[ENTITY_A] derivatives as [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,"Hexahydrochromeno[4,3-b]pyrrole derivatives as acetylcholinesterase inhibitors."
"No influence of moderate hepatic impairment on the pharmacokinetics of << lumiracoxib >>, an oral [[ COX-2 ]] selective inhibitor.","No influence of moderate hepatic impairment on the pharmacokinetics of [ENTITY_A], an oral [ENTITY_B] selective inhibitor.",INHIBITOR,CPR:4,1,"No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor."
"<< Thalidomide >>--removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of [[ TNF alpha ]].","[ENTITY_A]--removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of [ENTITY_B].",INHIBITOR,CPR:4,1,"Thalidomide--removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of TNF alpha."
"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), << 17-phenyl-trinor-PGE2 >> (an [[ EP1 ]]-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.","Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), [ENTITY_A] (an [ENTITY_B]-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.",AGONIST,CPR:5,2,"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2."
"<< LY294002 >>, a specific [[ PI3K ]]/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.","[ENTITY_A], a specific [ENTITY_B]/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.",INHIBITOR,CPR:4,1,"LY294002, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK."
"Synergistic cytotoxicity was demonstrated, and << pemetrexed >> significantly decreased the amount of [[ phosphorylated Akt ]], enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines.","Synergistic cytotoxicity was demonstrated, and [ENTITY_A] significantly decreased the amount of [ENTITY_B], enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines.",INHIBITOR,CPR:4,1,"Synergistic cytotoxicity was demonstrated, and pemetrexed significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines."
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of << prostaglandin E2 >> (PGE2; a product of both [[ COX-1 ]] and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.,Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of [ENTITY_A] (PGE2; a product of both [ENTITY_B] and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.,PRODUCT-OF,CPR:9,4,Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2; a product of both COX-1 and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.
"Pre-irradiation administration of RP-1 enhanced levels of << GSH >> induced increase in [[ complex I ]] (upto 16 h), complex I/III (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).","Pre-irradiation administration of RP-1 enhanced levels of [ENTITY_A] induced increase in [ENTITY_B] (upto 16 h), complex I/III (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).",ACTIVATOR,CPR:3,0,"Pre-irradiation administration of RP-1 enhanced levels of GSH induced increase in complex I (upto 16 h), complex I/III (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01)."
<< Allicin >> treatment showed reduced production of pro-inflammatory [[ cytokines ]] and NO and increased HO-1 activity.,[ENTITY_A] treatment showed reduced production of pro-inflammatory [ENTITY_B] and NO and increased HO-1 activity.,INDIRECT-DOWNREGULATOR,CPR:4,1,Allicin treatment showed reduced production of pro-inflammatory cytokines and NO and increased HO-1 activity.
"We discovered << sergliflozin etabonate >>, a novel selective [[ SGLT2 ]] inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels.","We discovered [ENTITY_A], a novel selective [ENTITY_B] inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels.",INHIBITOR,CPR:4,1,"We discovered sergliflozin etabonate, a novel selective SGLT2 inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels."
Acetylation of << phenelzine >> at the N2 position presumably interferes with the inhibition of the [[ transaminase ]] enzymes for gamma-aminobutyric acid and alanine.,Acetylation of [ENTITY_A] at the N2 position presumably interferes with the inhibition of the [ENTITY_B] enzymes for gamma-aminobutyric acid and alanine.,INHIBITOR,CPR:4,1,Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the transaminase enzymes for gamma-aminobutyric acid and alanine.
Sulfhydration of << sulfonylurea receptor 2B >> (SUR2B) was induced by [[ NaHS ]] and colonic inflammation.,Sulfhydration of [ENTITY_A] (SUR2B) was induced by [ENTITY_B] and colonic inflammation.,ACTIVATOR,CPR:3,0,Sulfhydration of sulfonylurea receptor 2B (SUR2B) was induced by NaHS and colonic inflammation.
"<< Nisoldipine >> (a DHP antagonist) blocks the [[ smooth muscle channel ]] more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels.","[ENTITY_A] (a DHP antagonist) blocks the [ENTITY_B] more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels.",INHIBITOR,CPR:4,1,"Nisoldipine (a DHP antagonist) blocks the smooth muscle channel more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels."
"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of << voltage dependent calcium channels >> and the subsequent translocation of extracellular calcium, was significantly inhibited by [[ carvedilol ]] (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.","The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of [ENTITY_A] and the subsequent translocation of extracellular calcium, was significantly inhibited by [ENTITY_B] (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.",INHIBITOR,CPR:4,1,"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies."
"However, their inhibitory effect was markedly reduced if clots were formed in the presence of << t-PA >> and then exposed to either of the [[ lysine ]] analogues.","However, their inhibitory effect was markedly reduced if clots were formed in the presence of [ENTITY_A] and then exposed to either of the [ENTITY_B] analogues.",INHIBITOR,CPR:4,1,"However, their inhibitory effect was markedly reduced if clots were formed in the presence of t-PA and then exposed to either of the lysine analogues."
"Taken together, << PTE >> is a potent inhibitor of osteosarcoma cell growth that targets the [[ JAK2 ]]/STAT3 signaling pathway.","Taken together, [ENTITY_A] is a potent inhibitor of osteosarcoma cell growth that targets the [ENTITY_B]/STAT3 signaling pathway.",INHIBITOR,CPR:4,1,"Taken together, PTE is a potent inhibitor of osteosarcoma cell growth that targets the JAK2/STAT3 signaling pathway."
<< Glufosinate >> inhibits [[ glutamine synthetase ]] and blocks biosynthesis of glutamine.,[ENTITY_A] inhibits [ENTITY_B] and blocks biosynthesis of glutamine.,INHIBITOR,CPR:4,1,Glufosinate inhibits glutamine synthetase and blocks biosynthesis of glutamine.
"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of << PLZ >> on [[ alanine transaminase ]] (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.","The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of [ENTITY_A] on [ENTITY_B] (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.",INHIBITOR,CPR:4,1,"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced."
"After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of << haloperidol >> (HAL; 0.01 microM), a [[ dopamine D2 ]] antagonist.","After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of [ENTITY_A] (HAL; 0.01 microM), a [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a dopamine D2 antagonist."
"In non-pre-treated cells, << HMG-CoA >> was up-regulated by both [[ 7-ketosterols ]].","In non-pre-treated cells, [ENTITY_A] was up-regulated by both [ENTITY_B].",UPREGULATOR,CPR:3,0,"In non-pre-treated cells, HMG-CoA was up-regulated by both 7-ketosterols."
"Cotreatment with << U0126 >> and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, [[ JNK ]], and beta-catenin.","Cotreatment with [ENTITY_A] and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, [ENTITY_B], and beta-catenin.",ACTIVATOR,CPR:3,0,"Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, JNK, and beta-catenin."
"Moreover, activities of << caspase-3 >> and caspase-9 enzymes were also significantly higher in both kinds of cells exposed to [[ SiO(2) ]] NPs.","Moreover, activities of [ENTITY_A] and caspase-9 enzymes were also significantly higher in both kinds of cells exposed to [ENTITY_B] NPs.",ACTIVATOR,CPR:3,0,"Moreover, activities of caspase-3 and caspase-9 enzymes were also significantly higher in both kinds of cells exposed to SiO(2) NPs."
"Additionally, << phenformin >> inhibited the current elicited through the [[ Kir6.2DeltaC26 ]] (functional without SUR) channel with an IC50 of 1.78 mM.","Additionally, [ENTITY_A] inhibited the current elicited through the [ENTITY_B] (functional without SUR) channel with an IC50 of 1.78 mM.",INHIBITOR,CPR:4,1,"Additionally, phenformin inhibited the current elicited through the Kir6.2DeltaC26 (functional without SUR) channel with an IC50 of 1.78 mM."
RESULTS: << Leukotriene D(4) >> upregulated [[ MUC2/5AC ]] gene expression and mucin secretion in a dose dependent pattern.,RESULTS: [ENTITY_A] upregulated [ENTITY_B] gene expression and mucin secretion in a dose dependent pattern.,INDIRECT-UPREGULATOR,CPR:3,0,RESULTS: Leukotriene D(4) upregulated MUC2/5AC gene expression and mucin secretion in a dose dependent pattern.
Processing of polysialylated NCAM was reproduced in a mouse model by << bleomycin >> administration leading to an activation of the inflammasome and secretion of [[ interleukin (IL)-1β ]].,Processing of polysialylated NCAM was reproduced in a mouse model by [ENTITY_A] administration leading to an activation of the inflammasome and secretion of [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,Processing of polysialylated NCAM was reproduced in a mouse model by bleomycin administration leading to an activation of the inflammasome and secretion of interleukin (IL)-1β.
"When combined, << mianserin >> antagonized the effects of the full [[ kappa-opioid receptor ]] agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A.","When combined, [ENTITY_A] antagonized the effects of the full [ENTITY_B] agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A.",ANTAGONIST,CPR:6,3,"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A."
"This study identified four clinically approved antihypertensive drugs (<< efonidipine >>, felodipine, isradipine, and nitrendipine) as potent [[ T-channel ]] blockers (IC(50) < 3 microM).","This study identified four clinically approved antihypertensive drugs ([ENTITY_A], felodipine, isradipine, and nitrendipine) as potent [ENTITY_B] blockers (IC(50) < 3 microM).",INHIBITOR,CPR:4,1,"This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, isradipine, and nitrendipine) as potent T-channel blockers (IC(50) < 3 microM)."
Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to << L-BOAA >> toxicity seen as [[ mitochondrial complex I ]] loss.,Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to [ENTITY_A] toxicity seen as [ENTITY_B] loss.,DOWNREGULATOR,CPR:4,1,Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to L-BOAA toxicity seen as mitochondrial complex I loss.
Cellular << zinc >> is controlled by [[ zinc-chelating proteins ]] and by zinc transporters.,Cellular [ENTITY_A] is controlled by [ENTITY_B] and by zinc transporters.,SUBSTRATE,CPR:9,4,Cellular zinc is controlled by zinc-chelating proteins and by zinc transporters.
"<< NFD >> suppressed [[ EGF ]]-mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.","[ENTITY_A] suppressed [ENTITY_B]-mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.",DOWNREGULATOR,CPR:4,1,"NFD suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity."
"The irreversible << MAO-B >> inhibitors, [[ pargyline ]] (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice.","The irreversible [ENTITY_A] inhibitors, [ENTITY_B] (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice.",INHIBITOR,CPR:4,1,"The irreversible MAO-B inhibitors, pargyline (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice."
"In the present study, << hinokitiol >> (1 and 2μM) inhibited the [[ collagen ]]-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP.","In the present study, [ENTITY_A] (1 and 2μM) inhibited the [ENTITY_B]-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP.",INHIBITOR,CPR:4,1,"In the present study, hinokitiol (1 and 2μM) inhibited the collagen-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP."
"With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) << PhIP >> at the doses of 10mg/kg and/or 15mg/kg significantly inhibited [[ p16 ]] mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control.","With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) [ENTITY_A] at the doses of 10mg/kg and/or 15mg/kg significantly inhibited [ENTITY_B] mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control.",INDIRECT-DOWNREGULATOR,CPR:4,1,"With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) PhIP at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control."
"Through immunoblotting analysis, it was found that << AdOx >> was capable of indirectly diminishing the phosphorylation of oncogenic [[ Src ]] and its kinase activity.","Through immunoblotting analysis, it was found that [ENTITY_A] was capable of indirectly diminishing the phosphorylation of oncogenic [ENTITY_B] and its kinase activity.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Through immunoblotting analysis, it was found that AdOx was capable of indirectly diminishing the phosphorylation of oncogenic Src and its kinase activity."
"METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [<< buspirone >> (partial [[ 5-HT1A ]] agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.","METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [[ENTITY_A] (partial [ENTITY_B] agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.",AGONIST,CPR:5,2,"METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test."
<< Protein tyrosine phosphatase 1B >> inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum [[ saponins ]].,[ENTITY_A] inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum [ENTITY_B].,INHIBITOR,CPR:4,1,Protein tyrosine phosphatase 1B inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins.
Synthesis and in-silico studies of some << diaryltriazole >> derivatives as potential [[ cyclooxygenase ]] inhibitors.,Synthesis and in-silico studies of some [ENTITY_A] derivatives as potential [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Synthesis and in-silico studies of some diaryltriazole derivatives as potential cyclooxygenase inhibitors.
"We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of << (R)-(alpha)-(-)-methylhistamine dihydrobromide >> (RAMH) ([[ H3R ]] agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats.","We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of [ENTITY_A] (RAMH) ([ENTITY_B] agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats.",AGONIST,CPR:5,2,"We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats."
"These results suggest that prostacyclin may play a role in downregulating << tissue factor >> expression in monocytes, at least in part via elevation of intracellular levels of [[ cyclic AMP ]].","These results suggest that prostacyclin may play a role in downregulating [ENTITY_A] expression in monocytes, at least in part via elevation of intracellular levels of [ENTITY_B].",DOWNREGULATOR,CPR:4,1,"These results suggest that prostacyclin may play a role in downregulating tissue factor expression in monocytes, at least in part via elevation of intracellular levels of cyclic AMP."
"Western blotting demonstrated that << DMBT >> effectively suppressed the expression of [[ VEGF ]], p-VEGFR-2, p-EGFR, and p-Akt.","Western blotting demonstrated that [ENTITY_A] effectively suppressed the expression of [ENTITY_B], p-VEGFR-2, p-EGFR, and p-Akt.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Western blotting demonstrated that DMBT effectively suppressed the expression of VEGF, p-VEGFR-2, p-EGFR, and p-Akt."
"The broad-spectrum anti-emetic activity of << AS-8112 >>, a novel dopamine D2, D3 and [[ 5-HT3 receptors ]] antagonist.","The broad-spectrum anti-emetic activity of [ENTITY_A], a novel dopamine D2, D3 and [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist."
"CONCLUSION: ACE inhibitors, such as << captopril >>, may be applied as important compounds for [[ MMP-2 ]] inhibition in inflammation caused by CAPD.","CONCLUSION: ACE inhibitors, such as [ENTITY_A], may be applied as important compounds for [ENTITY_B] inhibition in inflammation caused by CAPD.",INHIBITOR,CPR:4,1,"CONCLUSION: ACE inhibitors, such as captopril, may be applied as important compounds for MMP-2 inhibition in inflammation caused by CAPD."
<< Pasireotide >> (Signifor(®)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of [[ corticotropin ]] from the pituitary adenoma in patients with Cushing's disease.,[ENTITY_A] (Signifor(®)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of [ENTITY_B] from the pituitary adenoma in patients with Cushing's disease.,INDIRECT-DOWNREGULATOR,CPR:4,1,Pasireotide (Signifor(®)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease.
The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the << MAO >> inhibitor [[ tranylcypromine ]].,The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the [ENTITY_A] inhibitor [ENTITY_B].,INHIBITOR,CPR:4,1,The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the MAO inhibitor tranylcypromine.
"<< TAS-102 >> is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit [[ TS ]].","[ENTITY_A] is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"TAS-102 is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit TS."
"This shows that << CPT2 >> and CACT are crucial for mitochondrial [[ acylcarnitine ]] formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R.","This shows that [ENTITY_A] and CACT are crucial for mitochondrial [ENTITY_B] formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R.",PRODUCT-OF,CPR:9,4,"This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R."
"All four << DCK >> proteins yielded comparable metabolic activity for [[ Ara-C ]] and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).","All four [ENTITY_A] proteins yielded comparable metabolic activity for [ENTITY_B] and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).",SUBSTRATE,CPR:9,4,"All four DCK proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05)."
"Accordingly, in transfection experiments performed in TPC1 cells, treatment with << PJ34 >> increased [[ NIS promoter ]] activity without affecting PARP-1 binding to the promoter sequence.","Accordingly, in transfection experiments performed in TPC1 cells, treatment with [ENTITY_A] increased [ENTITY_B] activity without affecting PARP-1 binding to the promoter sequence.",ACTIVATOR,CPR:3,0,"Accordingly, in transfection experiments performed in TPC1 cells, treatment with PJ34 increased NIS promoter activity without affecting PARP-1 binding to the promoter sequence."
<< Benzenesulfonamides >> incorporating cyanoacrylamide moieties strongly inhibit [[ Saccharomyces cerevisiae β-carbonic anhydrase ]].,[ENTITY_A] incorporating cyanoacrylamide moieties strongly inhibit [ENTITY_B].,INHIBITOR,CPR:4,1,Benzenesulfonamides incorporating cyanoacrylamide moieties strongly inhibit Saccharomyces cerevisiae β-carbonic anhydrase.
<< Ibuprofen >> inhibits [[ cystic fibrosis transmembrane conductance regulator ]]-mediated Cl- secretion.,[ENTITY_A] inhibits [ENTITY_B]-mediated Cl- secretion.,INHIBITOR,CPR:4,1,Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator-mediated Cl- secretion.
"All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only << BDZs >> and pentobarbital induced a negative shift in [[ Ca(v)1.2 ]] channel inactivation.","All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only [ENTITY_A] and pentobarbital induced a negative shift in [ENTITY_B] channel inactivation.",INHIBITOR,CPR:4,1,"All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only BDZs and pentobarbital induced a negative shift in Ca(v)1.2 channel inactivation."
"Thus, << imatinib >> and other [[ c-Abl ]] kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.","Thus, [ENTITY_A] and other [ENTITY_B] kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.",INHIBITOR,CPR:4,1,"Thus, imatinib and other c-Abl kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31."
"<< CCl(4) >> administration triggered inflammatory response in mice livers by activating [[ nuclear factor-kappaB ]] (NF-κB), which coincided with the induction of tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (COX-2).","[ENTITY_A] administration triggered inflammatory response in mice livers by activating [ENTITY_B] (NF-κB), which coincided with the induction of tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (COX-2).",ACTIVATOR,CPR:3,0,"CCl(4) administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-κB), which coincided with the induction of tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (COX-2)."
"Moreover, << paclitaxel >>-induced [[ ERCC1 ]] protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).","Moreover, [ENTITY_A]-induced [ENTITY_B] protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).",INDIRECT-UPREGULATOR,CPR:3,0,"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA)."
<< PKAA >>/anti-TNF-α siRNA nanocomplexes significantly reduced the [[ ALT ]] (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.,[ENTITY_A]/anti-TNF-α siRNA nanocomplexes significantly reduced the [ENTITY_B] (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.,INDIRECT-DOWNREGULATOR,CPR:4,1,PKAA/anti-TNF-α siRNA nanocomplexes significantly reduced the ALT (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.
"<< Progestin >> induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on [[ PR ]] activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.","[ENTITY_A] induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on [ENTITY_B] activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.",ACTIVATOR,CPR:3,0,"Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src."
"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or << AMN082 >> [[[ metabotropic glutamate receptor 7 ]] (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.","Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or [ENTITY_A] [[ENTITY_B] (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.",AGONIST,CPR:5,2,"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice."
"Preincubation for 30 minutes with << iloprost >>, ciprostene, and carbacyclin led to a dose-dependent inhibition of [[ tissue factor ]] expression induced by all three challenging agents.","Preincubation for 30 minutes with [ENTITY_A], ciprostene, and carbacyclin led to a dose-dependent inhibition of [ENTITY_B] expression induced by all three challenging agents.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Preincubation for 30 minutes with iloprost, ciprostene, and carbacyclin led to a dose-dependent inhibition of tissue factor expression induced by all three challenging agents."
"However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the << 5-HT(1A) >> agonist actions of [[ yohimbine ]] suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.","However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the [ENTITY_A] agonist actions of [ENTITY_B] suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.",AGONIST,CPR:5,2,"However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels."
This study focuses on determining whether treatment of TCDD-exposed UGS organ cultures with RSPO2 and/or RSPO3 is capable of rescuing the inhibitory effects of << TCDD >> on canonical [[ Wnt ]] signaling and prostatic bud formation.,This study focuses on determining whether treatment of TCDD-exposed UGS organ cultures with RSPO2 and/or RSPO3 is capable of rescuing the inhibitory effects of [ENTITY_A] on canonical [ENTITY_B] signaling and prostatic bud formation.,INDIRECT-DOWNREGULATOR,CPR:4,1,This study focuses on determining whether treatment of TCDD-exposed UGS organ cultures with RSPO2 and/or RSPO3 is capable of rescuing the inhibitory effects of TCDD on canonical Wnt signaling and prostatic bud formation.
"Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective << cyclooxygenase-2 >> inhibitor, [[ celecoxib ]], improved vascular function, and also attenuated obesity.","Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective [ENTITY_A] inhibitor, [ENTITY_B], improved vascular function, and also attenuated obesity.",INHIBITOR,CPR:4,1,"Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective cyclooxygenase-2 inhibitor, celecoxib, improved vascular function, and also attenuated obesity."
"Our data also indicate that << NMDA receptor >> pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since [[ AP7 ]] microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO.","Our data also indicate that [ENTITY_A] pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since [ENTITY_B] microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO.",INHIBITOR,CPR:4,1,"Our data also indicate that NMDA receptor pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO."
"The influence of sex, ethnicity, and << CYP2B6 >> genotype on [[ bupropion ]] metabolism as an index of hepatic CYP2B6 activity in humans.","The influence of sex, ethnicity, and [ENTITY_A] genotype on [ENTITY_B] metabolism as an index of hepatic CYP2B6 activity in humans.",SUBSTRATE,CPR:9,4,"The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans."
<< MMP-2 >> and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and [[ captopril ]] inhibited them.,[ENTITY_A] and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and [ENTITY_B] inhibited them.,INDIRECT-DOWNREGULATOR,CPR:4,1,MMP-2 and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and captopril inhibited them.
"Therefore, in the present studies, animals were rendered tolerant to the << delta-opioid receptor >>-selective agonist [D-Pen2,D-Pen5]enkephalin ([[ DPDPE ]]), and receptor binding activities were measured.","Therefore, in the present studies, animals were rendered tolerant to the [ENTITY_A]-selective agonist [D-Pen2,D-Pen5]enkephalin ([ENTITY_B]), and receptor binding activities were measured.",AGONIST,CPR:5,2,"Therefore, in the present studies, animals were rendered tolerant to the delta-opioid receptor-selective agonist [D-Pen2,D-Pen5]enkephalin (DPDPE), and receptor binding activities were measured."
"Re-feeding normal chow or a high << sucrose >> diet for 24 h after a 48-h fast increased both [[ ACS1 ]] and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies.","Re-feeding normal chow or a high [ENTITY_A] diet for 24 h after a 48-h fast increased both [ENTITY_B] and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies.",INDIRECT-UPREGULATOR,CPR:3,0,"Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies."
"<< ISO >> is able to induce apoptosis through mitochondrial dysfunction and inhibition of [[ PI3K ]]/Akt signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown.","[ENTITY_A] is able to induce apoptosis through mitochondrial dysfunction and inhibition of [ENTITY_B]/Akt signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown.",INHIBITOR,CPR:4,1,"ISO is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown."
"We demonstrate here that << minoxidil >> is a potent activator of purified [[ PGHS-1 ]] (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production.","We demonstrate here that [ENTITY_A] is a potent activator of purified [ENTITY_B] (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production.",ACTIVATOR,CPR:3,0,"We demonstrate here that minoxidil is a potent activator of purified PGHS-1 (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production."
"The elevation in brain << alanine >> levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on [[ alanine transaminase ]] (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.","The elevation in brain [ENTITY_A] levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on [ENTITY_B] (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.",SUBSTRATE,CPR:9,4,"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced."
The IL-18 production is located upstream of the << cytokine >> cascade activated by [[ simvastatin ]].,The IL-18 production is located upstream of the [ENTITY_A] cascade activated by [ENTITY_B].,ACTIVATOR,CPR:3,0,The IL-18 production is located upstream of the cytokine cascade activated by simvastatin.
<< Propranolol >> treatment (4 X 40 mg/day) increased the density of [[ beta 2-adrenoceptors ]] by 25% after 2 days; concomitantly PRA and heart rate were reduced.,[ENTITY_A] treatment (4 X 40 mg/day) increased the density of [ENTITY_B] by 25% after 2 days; concomitantly PRA and heart rate were reduced.,INDIRECT-UPREGULATOR,CPR:3,0,Propranolol treatment (4 X 40 mg/day) increased the density of beta 2-adrenoceptors by 25% after 2 days; concomitantly PRA and heart rate were reduced.
"Stable << ABCC1 >>, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of [[ BPDE glutathione ]] conjugates.","Stable [ENTITY_A], ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of [ENTITY_B] conjugates.",SUBSTRATE,CPR:9,4,"Stable ABCC1, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of BPDE glutathione conjugates."
"However, as with the human receptor, << maraviroc >> was shown to be a high affinity, potent functional antagonist of [[ macaque CCR5 ]] thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists.","However, as with the human receptor, [ENTITY_A] was shown to be a high affinity, potent functional antagonist of [ENTITY_B] thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists.",ANTAGONIST,CPR:6,3,"However, as with the human receptor, maraviroc was shown to be a high affinity, potent functional antagonist of macaque CCR5 thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists."
A Nanogram Dose of the << CYP3A >> Probe Substrate [[ Midazolam ]] to Evaluate Drug Interactions.,A Nanogram Dose of the [ENTITY_A] Probe Substrate [ENTITY_B] to Evaluate Drug Interactions.,SUBSTRATE,CPR:9,4,A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions.
Identification of << benzofuran >> central cores for the inhibition of [[ leukotriene A(4) hydrolase ]].,Identification of [ENTITY_A] central cores for the inhibition of [ENTITY_B].,INHIBITOR,CPR:4,1,Identification of benzofuran central cores for the inhibition of leukotriene A(4) hydrolase.
"Therefore, we examined whether the << PDE5 >>-I [[ vardenafil ]] improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults.","Therefore, we examined whether the [ENTITY_A]-I [ENTITY_B] improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults.",INHIBITOR,CPR:4,1,"Therefore, we examined whether the PDE5-I vardenafil improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults."
"The specific activity of only << ornithine aminotransferase >> (OAT), the rate-limiting enzyme in the conversion of ornithine to [[ proline ]], increased in 2 weeks of hypertrophy.","The specific activity of only [ENTITY_A] (OAT), the rate-limiting enzyme in the conversion of ornithine to [ENTITY_B], increased in 2 weeks of hypertrophy.",PRODUCT-OF,CPR:9,4,"The specific activity of only ornithine aminotransferase (OAT), the rate-limiting enzyme in the conversion of ornithine to proline, increased in 2 weeks of hypertrophy."
The << kinase >> activity of EGFR was little inhibited by [[ TT-B ]] in a cell-free system.,The [ENTITY_A] activity of EGFR was little inhibited by [ENTITY_B] in a cell-free system.,INHIBITOR,CPR:4,1,The kinase activity of EGFR was little inhibited by TT-B in a cell-free system.
"To explain our observations, we propose that << hNETs >> function as ion-gated ligand channels with an indefinite stoichiometry relating ion flux to [[ NE ]] transport.","To explain our observations, we propose that [ENTITY_A] function as ion-gated ligand channels with an indefinite stoichiometry relating ion flux to [ENTITY_B] transport.",SUBSTRATE,CPR:9,4,"To explain our observations, we propose that hNETs function as ion-gated ligand channels with an indefinite stoichiometry relating ion flux to NE transport."
"The << CYP3A4 >> activity could be induced 2-fold by [[ rifampicin ]], whereas CYP2C9 activity remained equally high.","The [ENTITY_A] activity could be induced 2-fold by [ENTITY_B], whereas CYP2C9 activity remained equally high.",ACTIVATOR,CPR:3,0,"The CYP3A4 activity could be induced 2-fold by rifampicin, whereas CYP2C9 activity remained equally high."
"High << p53 >> protein levels, but not genetic or functional p53 status, were associated with increased [[ topotecan ]]-induced DNA/topoisomerase I complex formation.","High [ENTITY_A] protein levels, but not genetic or functional p53 status, were associated with increased [ENTITY_B]-induced DNA/topoisomerase I complex formation.",INDIRECT-UPREGULATOR,CPR:3,0,"High p53 protein levels, but not genetic or functional p53 status, were associated with increased topotecan-induced DNA/topoisomerase I complex formation."
"Blockade of << JAK >> and ERK pathways with [[ AG490 ]] and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-α-MSH.","Blockade of [ENTITY_A] and ERK pathways with [ENTITY_B] and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-α-MSH.",INHIBITOR,CPR:4,1,"Blockade of JAK and ERK pathways with AG490 and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-α-MSH."
"Furthermore, << PTE >> treatment directly inhibited the phosphorylation of JAK2 at Tyr 1007 and the downstream activation of [[ STAT3 ]].","Furthermore, [ENTITY_A] treatment directly inhibited the phosphorylation of JAK2 at Tyr 1007 and the downstream activation of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, PTE treatment directly inhibited the phosphorylation of JAK2 at Tyr 1007 and the downstream activation of STAT3."
"To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that << PSE >> inhibited [[ NF-kappaB ]]-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity.","To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that [ENTITY_A] inhibited [ENTITY_B]-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity.",INHIBITOR,CPR:4,1,"To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity."
"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of << phosphoprotein phosphatase 2A >> (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by [[ EHT ]].","Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of [ENTITY_A] (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by [ENTITY_B].",UPREGULATOR,CPR:3,0,"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT."
"Chronic treatment with the NET inhibitor, << desipramine >> (DMI), reduced [[ NET ]] levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.","Chronic treatment with the NET inhibitor, [ENTITY_A] (DMI), reduced [ENTITY_B] levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Chronic treatment with the NET inhibitor, desipramine (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs."
We found that the removal of << urea >> with [[ urease ]] is necessary since urea also produces a positive reaction.,We found that the removal of [ENTITY_A] with [ENTITY_B] is necessary since urea also produces a positive reaction.,SUBSTRATE,CPR:9,4,We found that the removal of urea with urease is necessary since urea also produces a positive reaction.
"<< alpha(1A)-Adrenoceptor >> selective antagonists, [[ 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane ]] (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.","[ENTITY_A] selective antagonists, [ENTITY_B] (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.",ANTAGONIST,CPR:6,3,"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved."
"Moreover, << curcumin >> could also down-regulate the expression and activity of [[ matrix metalloproteinase-9 ]] (MMP-9).","Moreover, [ENTITY_A] could also down-regulate the expression and activity of [ENTITY_B] (MMP-9).",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, curcumin could also down-regulate the expression and activity of matrix metalloproteinase-9 (MMP-9)."
"Rifampicin (10 micromol/L) inhibited << OATP8 >>-mediated [[ BSP ]] uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.","Rifampicin (10 micromol/L) inhibited [ENTITY_A]-mediated [ENTITY_B] uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.",SUBSTRATE,CPR:9,4,"Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%."
"<< Methadone >> N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to [[ CYP3A4 ]].","[ENTITY_A] N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to [ENTITY_B].",SUBSTRATE,CPR:9,4,"Methadone N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4."
"Assessment of the abuse liability of << ABT-288 >>, a novel [[ histamine H3 receptor ]] antagonist.","Assessment of the abuse liability of [ENTITY_A], a novel [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"Assessment of the abuse liability of ABT-288, a novel histamine H3 receptor antagonist."
"Altogether, our results suggest that a high dose of << glucosamine >> may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in [[ Rb ]] phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation.","Altogether, our results suggest that a high dose of [ENTITY_A] may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in [ENTITY_B] phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation.",INHIBITOR,CPR:4,1,"Altogether, our results suggest that a high dose of glucosamine may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation."
Licofelone almost abolished << 5-LOX >> activity by inhibiting [[ leukotriene B4 ]] generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.,Licofelone almost abolished [ENTITY_A] activity by inhibiting [ENTITY_B] generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.,PRODUCT-OF,CPR:9,4,Licofelone almost abolished 5-LOX activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.
"Since the suppression of AT1R expression was prevented by pretreatment with << GW9662 >>, a [[ PPARgamma ]] antagonist, PPARgamma should have participated in the process.","Since the suppression of AT1R expression was prevented by pretreatment with [ENTITY_A], a [ENTITY_B] antagonist, PPARgamma should have participated in the process.",ANTAGONIST,CPR:6,3,"Since the suppression of AT1R expression was prevented by pretreatment with GW9662, a PPARgamma antagonist, PPARgamma should have participated in the process."
"Here, we show that siRNA-mediated knockdown of << SSAT2 >> in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of [[ TETA ]] to MAT.","Here, we show that siRNA-mediated knockdown of [ENTITY_A] in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of [ENTITY_B] to MAT.",SUBSTRATE,CPR:9,4,"Here, we show that siRNA-mediated knockdown of SSAT2 in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of TETA to MAT."
"RESULTS: In drug discrimination studies, << lisuride >> fully mimicked the [[ 5-HT(1A) ]] agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine.","RESULTS: In drug discrimination studies, [ENTITY_A] fully mimicked the [ENTITY_B] agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine.",AGONIST,CPR:5,2,"RESULTS: In drug discrimination studies, lisuride fully mimicked the 5-HT(1A) agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine."
These unexpected and intriguing complexities seem likely to have some as yet undefined role in regulating << SSAT >> activity or stability as a part of [[ polyamine ]] homeostasis.,These unexpected and intriguing complexities seem likely to have some as yet undefined role in regulating [ENTITY_A] activity or stability as a part of [ENTITY_B] homeostasis.,PRODUCT-OF,CPR:9,4,These unexpected and intriguing complexities seem likely to have some as yet undefined role in regulating SSAT activity or stability as a part of polyamine homeostasis.
"Among the isolated compounds, << trans-dihydromorin >> (8), oxyresveratrol (9), and steppogenin (12) were found to exhibit significant [[ tyrosinase ]] inhibition activities.","Among the isolated compounds, [ENTITY_A] (8), oxyresveratrol (9), and steppogenin (12) were found to exhibit significant [ENTITY_B] inhibition activities.",INHIBITOR,CPR:4,1,"Among the isolated compounds, trans-dihydromorin (8), oxyresveratrol (9), and steppogenin (12) were found to exhibit significant tyrosinase inhibition activities."
"CONCLUSIONS: The << alpha(2)-adrenoceptor >> agonists [[ brimonidine ]], apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery.","CONCLUSIONS: The [ENTITY_A] agonists [ENTITY_B], apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery.",AGONIST,CPR:5,2,"CONCLUSIONS: The alpha(2)-adrenoceptor agonists brimonidine, apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery."
"Comprehensive review of << rasagiline >>, a second-generation [[ monoamine oxidase ]] inhibitor, for the treatment of Parkinson's disease.","Comprehensive review of [ENTITY_A], a second-generation [ENTITY_B] inhibitor, for the treatment of Parkinson's disease.",INHIBITOR,CPR:4,1,"Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease."
"<< PDE5 >> is the predominant PDE in the corpus cavernosum, and [[ cGMP ]] is its primary substrate.","[ENTITY_A] is the predominant PDE in the corpus cavernosum, and [ENTITY_B] is its primary substrate.",SUBSTRATE,CPR:9,4,"PDE5 is the predominant PDE in the corpus cavernosum, and cGMP is its primary substrate."
Peroxisome proliferator-activated receptor-α (PPARα) activation mimicked the effects of << resveratrol >> while PPARα inhibition prevented the effects of this [[ SIRT1 ]] activator.,Peroxisome proliferator-activated receptor-α (PPARα) activation mimicked the effects of [ENTITY_A] while PPARα inhibition prevented the effects of this [ENTITY_B] activator.,ACTIVATOR,CPR:3,0,Peroxisome proliferator-activated receptor-α (PPARα) activation mimicked the effects of resveratrol while PPARα inhibition prevented the effects of this SIRT1 activator.
In sum the results of the present study indicate that << RA >>-induced expression of [[ blr1 ]] expression depends on a novel RA response element.,In sum the results of the present study indicate that [ENTITY_A]-induced expression of [ENTITY_B] expression depends on a novel RA response element.,INDIRECT-UPREGULATOR,CPR:3,0,In sum the results of the present study indicate that RA-induced expression of blr1 expression depends on a novel RA response element.
"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the << eNOS >> selective antagonists (0.01-10 microM): [[ L-Nomega -monomethyl-L-arginine ]] (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).","These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the [ENTITY_A] selective antagonists (0.01-10 microM): [ENTITY_B] (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).",ANTAGONIST,CPR:6,3,"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)."
"The selective << beta1AR >> antagonists [[ atenolol ]] and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.","The selective [ENTITY_A] antagonists [ENTITY_B] and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.",ANTAGONIST,CPR:6,3,"The selective beta1AR antagonists atenolol and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively."
"<< Glutathione-S-transferase >>, a phase II enzyme, was inhibited by both [[ arsenic ]] and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine.","[ENTITY_A], a phase II enzyme, was inhibited by both [ENTITY_B] and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine.",INHIBITOR,CPR:4,1,"Glutathione-S-transferase, a phase II enzyme, was inhibited by both arsenic and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine."
"Promoter and electromobility shift assays showed that transcriptional activation of << NF-κB >> was significantly reduced by [[ catalpol ]] treatment, while AP-1 was not.","Promoter and electromobility shift assays showed that transcriptional activation of [ENTITY_A] was significantly reduced by [ENTITY_B] treatment, while AP-1 was not.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Promoter and electromobility shift assays showed that transcriptional activation of NF-κB was significantly reduced by catalpol treatment, while AP-1 was not."
"Megalin, a family of << endocytic receptors >> related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular [[ aminoglycoside ]] accumulation.","Megalin, a family of [ENTITY_A] related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular [ENTITY_B] accumulation.",SUBSTRATE,CPR:9,4,"Megalin, a family of endocytic receptors related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular aminoglycoside accumulation."
β-catenin regulates << GnRH >>-induced [[ FSHβ ]] gene expression.,β-catenin regulates [ENTITY_A]-induced [ENTITY_B] gene expression.,INDIRECT-UPREGULATOR,CPR:3,0,β-catenin regulates GnRH-induced FSHβ gene expression.
<< Lintitript >> markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial [[ PP ]] levels (P<0.01) as compared to placebo.,[ENTITY_A] markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial [ENTITY_B] levels (P<0.01) as compared to placebo.,INDIRECT-DOWNREGULATOR,CPR:4,1,Lintitript markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo.
One of the mechanism of << mifepristone >> action on decreasing leiomyomata volume may be related to suppression on expression of [[ PR gene ]].,One of the mechanism of [ENTITY_A] action on decreasing leiomyomata volume may be related to suppression on expression of [ENTITY_B].,INDIRECT-DOWNREGULATOR,CPR:4,1,One of the mechanism of mifepristone action on decreasing leiomyomata volume may be related to suppression on expression of PR gene.
Local << PGE2 >> administration prevented the increase of airway [[ IL-13 ]] and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline.,Local [ENTITY_A] administration prevented the increase of airway [ENTITY_B] and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline.,INHIBITOR,CPR:4,1,Local PGE2 administration prevented the increase of airway IL-13 and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline.
"LPO was increased while as GSH, << CAT >> and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of [[ NAC ]] restored these liver markers to normal levels (p<0.001).","LPO was increased while as GSH, [ENTITY_A] and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of [ENTITY_B] restored these liver markers to normal levels (p<0.001).",INDIRECT-UPREGULATOR,CPR:3,0,"LPO was increased while as GSH, CAT and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of NAC restored these liver markers to normal levels (p<0.001)."
G6pc2 deletion resulted in a leftward shift in the dose-response curve for << glucose >>-stimulated [[ insulin ]] secretion (GSIS).,G6pc2 deletion resulted in a leftward shift in the dose-response curve for [ENTITY_A]-stimulated [ENTITY_B] secretion (GSIS).,UPREGULATOR,CPR:3,0,G6pc2 deletion resulted in a leftward shift in the dose-response curve for glucose-stimulated insulin secretion (GSIS).
"Glutathione-independent prostaglandin D synthase [<< prostaglandin-H2 D-isomerase >>; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of [[ prostaglandin D2 ]] in the central nervous system.","Glutathione-independent prostaglandin D synthase [[ENTITY_A]; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of [ENTITY_B] in the central nervous system.",PRODUCT-OF,CPR:9,4,"Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system."
"Evidence has accumulated in the last few years that the expression of the << microsomal/peroxidase antigen >> (M/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular [[ cAMP ]] accumulation and protein synthesis.","Evidence has accumulated in the last few years that the expression of the [ENTITY_A] (M/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular [ENTITY_B] accumulation and protein synthesis.",UPREGULATOR,CPR:3,0,"Evidence has accumulated in the last few years that the expression of the microsomal/peroxidase antigen (M/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular cAMP accumulation and protein synthesis."
These observations suggest that some of the pharmacological actions of << felodipine >> on smooth muscle may involve inhibition of [[ calmodulin-dependent enzymes ]] which are functionally involved in the regulation of smooth muscle contraction.,These observations suggest that some of the pharmacological actions of [ENTITY_A] on smooth muscle may involve inhibition of [ENTITY_B] which are functionally involved in the regulation of smooth muscle contraction.,INHIBITOR,CPR:4,1,These observations suggest that some of the pharmacological actions of felodipine on smooth muscle may involve inhibition of calmodulin-dependent enzymes which are functionally involved in the regulation of smooth muscle contraction.
"The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported << PAO >> substrate, [[ N (1)-( n -octanesulphonyl)spermine ]], potently inhibited the reaction.","The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported [ENTITY_A] substrate, [ENTITY_B], potently inhibited the reaction.",SUBSTRATE,CPR:9,4,"The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction."
"Only pMPPI [<< 4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride >>], a selective [[ 5-HT(1A) ]] antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD.","Only pMPPI [[ENTITY_A]], a selective [ENTITY_B] antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD.",ANTAGONIST,CPR:6,3,"Only pMPPI [4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride], a selective 5-HT(1A) antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD."
"<< Lumiracoxib >> inhibited purified [[ COX-1 ]] and COX-2 with K(i) values of 3 and 0.06 microM, respectively.","[ENTITY_A] inhibited purified [ENTITY_B] and COX-2 with K(i) values of 3 and 0.06 microM, respectively.",INHIBITOR,CPR:4,1,"Lumiracoxib inhibited purified COX-1 and COX-2 with K(i) values of 3 and 0.06 microM, respectively."
"We propose a model whereby compartmentalized << PDEs >>, rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different [[ cAMP ]] concentrations irrespective of their distance from the site of cAMP synthesis.","We propose a model whereby compartmentalized [ENTITY_A], rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different [ENTITY_B] concentrations irrespective of their distance from the site of cAMP synthesis.",SUBSTRATE,CPR:9,4,"We propose a model whereby compartmentalized PDEs, rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different cAMP concentrations irrespective of their distance from the site of cAMP synthesis."
"The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the << thromboxane A2 receptor >> antagonists [[ GR32191 ]] and ridogrel.","The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the [ENTITY_A] antagonists [ENTITY_B] and ridogrel.",ANTAGONIST,CPR:6,3,"The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the thromboxane A2 receptor antagonists GR32191 and ridogrel."
"Staining was largely absent when substrate was omitted or after pretreatment with the irreversible << SSAO >> inhibitor, [[ hydralazine ]] and the slowly reversible inhibitor, semicarbazide.","Staining was largely absent when substrate was omitted or after pretreatment with the irreversible [ENTITY_A] inhibitor, [ENTITY_B] and the slowly reversible inhibitor, semicarbazide.",INHIBITOR,CPR:4,1,"Staining was largely absent when substrate was omitted or after pretreatment with the irreversible SSAO inhibitor, hydralazine and the slowly reversible inhibitor, semicarbazide."
"Specificity of << zebrafish retinol saturase >>: formation of [[ all-trans-13,14-dihydroretinol ]] and all-trans-7,8- dihydroretinol.","Specificity of [ENTITY_A]: formation of [ENTITY_B] and all-trans-7,8- dihydroretinol.",PRODUCT-OF,CPR:9,4,"Specificity of zebrafish retinol saturase: formation of all-trans-13,14-dihydroretinol and all-trans-7,8- dihydroretinol."
"The effects of two reversible, predominantly << monoamine oxidase-A >> (MAO-A) inhibitors, [[ moclobemide ]] (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects.","The effects of two reversible, predominantly [ENTITY_A] (MAO-A) inhibitors, [ENTITY_B] (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects.",INHIBITOR,CPR:4,1,"The effects of two reversible, predominantly monoamine oxidase-A (MAO-A) inhibitors, moclobemide (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects."
"Lung inflammation, << IL-4 >> production, and airway mast cell activity were also prevented under this early short-term treatment with [[ PGE2 ]].","Lung inflammation, [ENTITY_A] production, and airway mast cell activity were also prevented under this early short-term treatment with [ENTITY_B].",INHIBITOR,CPR:4,1,"Lung inflammation, IL-4 production, and airway mast cell activity were also prevented under this early short-term treatment with PGE2."
"<< Licofelone >> reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, [[ monocyte chemoattractant protein-1 ]] (MCP-1) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma.","[ENTITY_A] reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, [ENTITY_B] (MCP-1) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Licofelone reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 (MCP-1) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma."
"Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or << MS-275 >> ([[ histone deacetylase ]] (HDAC) inhibitor), applied after extinction training.","Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or [ENTITY_A] ([ENTITY_B] (HDAC) inhibitor), applied after extinction training.",INHIBITOR,CPR:4,1,"Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or MS-275 (histone deacetylase (HDAC) inhibitor), applied after extinction training."
"The upregulation of << calpain >>, tBid and caspase-3 activity were further inhibited by treatment with [[ EGTA ]] in the presence of ALD.","The upregulation of [ENTITY_A], tBid and caspase-3 activity were further inhibited by treatment with [ENTITY_B] in the presence of ALD.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The upregulation of calpain, tBid and caspase-3 activity were further inhibited by treatment with EGTA in the presence of ALD."
<< Orlistat >> has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal [[ lipases ]].,[ENTITY_A] has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal [ENTITY_B].,INHIBITOR,CPR:4,1,Orlistat has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal lipases.
<< TSA >> selectively induced [[ uc002mbe.2 ]] in four studied HCC cell lines.,[ENTITY_A] selectively induced [ENTITY_B] in four studied HCC cell lines.,INDIRECT-UPREGULATOR,CPR:3,0,TSA selectively induced uc002mbe.2 in four studied HCC cell lines.
<< Mifepriston'e >> blocks [[ glucocorticoid receptor ]] activation without modifying cortisol synthesis.,[ENTITY_A] blocks [ENTITY_B] activation without modifying cortisol synthesis.,INHIBITOR,CPR:4,1,Mifepriston'e blocks glucocorticoid receptor activation without modifying cortisol synthesis.
"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the << alpha 2-adrenoceptor >> antagonist, [[ idazoxan ]], the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.","In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the [ENTITY_A] antagonist, [ENTITY_B], the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.",ANTAGONIST,CPR:6,3,"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408."
"Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean << isoflavone >> increased gene expression of [[ heme oxygenase-1 ]] (HO-1), a major antioxidative stress enzyme.","Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean [ENTITY_A] increased gene expression of [ENTITY_B] (HO-1), a major antioxidative stress enzyme.",INDIRECT-UPREGULATOR,CPR:3,0,"Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean isoflavone increased gene expression of heme oxygenase-1 (HO-1), a major antioxidative stress enzyme."
"<< (-)-Stepholidine >> (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and [[ D2 ]] antagonist.","[ENTITY_A] (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and [ENTITY_B] antagonist.",ANTAGONIST,CPR:6,3,"(-)-Stepholidine (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and D2 antagonist."
"<< LTC4 synthase >> (LTC4S), the pivotal enzyme for the biosynthesis of [[ LTC4 ]] (ref. 10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref. 13).","[ENTITY_A] (LTC4S), the pivotal enzyme for the biosynthesis of [ENTITY_B] (ref. 10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref. 13).",PRODUCT-OF,CPR:9,4,"LTC4 synthase (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref. 10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref. 13)."
"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or << p-ERK >> inhibitor [[ U0126 ]] rather than estrogen receptor α antagonist ICI 82,780.","These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or [ENTITY_A] inhibitor [ENTITY_B] rather than estrogen receptor α antagonist ICI 82,780.",INHIBITOR,CPR:4,1,"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780."
<< 24(S)-hydroxycholesterol >> is actively eliminated from neuronal cells by [[ ABCA1 ]].,[ENTITY_A] is actively eliminated from neuronal cells by [ENTITY_B].,SUBSTRATE,CPR:9,4,24(S)-hydroxycholesterol is actively eliminated from neuronal cells by ABCA1.
Dose-dependent inhibition of platelet << cyclooxygenase-1 >> and monocyte cyclooxygenase-2 by [[ meloxicam ]] in healthy subjects.,Dose-dependent inhibition of platelet [ENTITY_A] and monocyte cyclooxygenase-2 by [ENTITY_B] in healthy subjects.,INHIBITOR,CPR:4,1,Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
"4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. << d-Amino acid oxidase >> (DAAO) catalyzes the oxidation of d-amino acids including [[ d-serine ]], a coagonist of the N-methyl-d-aspartate receptor.","4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. [ENTITY_A] (DAAO) catalyzes the oxidation of d-amino acids including [ENTITY_B], a coagonist of the N-methyl-d-aspartate receptor.",SUBSTRATE,CPR:9,4,"4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor."
"Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of << HO-1 >>/[[ CO ]].","Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of [ENTITY_A]/[ENTITY_B].",PRODUCT-OF,CPR:9,4,"Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/CO."
"Moreover, treatment of U937 cells with << 2-hydroxy-3-methylanthraquinone >> resulted in activation of [[ caspase-3 ]].","Moreover, treatment of U937 cells with [ENTITY_A] resulted in activation of [ENTITY_B].",ACTIVATOR,CPR:3,0,"Moreover, treatment of U937 cells with 2-hydroxy-3-methylanthraquinone resulted in activation of caspase-3."
"<< GW9662 >>, a PPARgamma antagonist, prevented (P < 0.01) the lutein-induced [[ iNOS ]] mRNA downregulation in HD11 cells.","[ENTITY_A], a PPARgamma antagonist, prevented (P < 0.01) the lutein-induced [ENTITY_B] mRNA downregulation in HD11 cells.",INDIRECT-UPREGULATOR,CPR:3,0,"GW9662, a PPARgamma antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells."
"Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in << gemfibrozil >>-mediated inhibition of [[ iNOS ]].","Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in [ENTITY_A]-mediated inhibition of [ENTITY_B].",INHIBITOR,CPR:4,1,"Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS."
"Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated << anion channel >> and blocked by the transporter antagonist [[ D,L-threo-beta-benzyloxyaspartate ]].","Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated [ENTITY_A] and blocked by the transporter antagonist [ENTITY_B].",ANTAGONIST,CPR:6,3,"Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated anion channel and blocked by the transporter antagonist D,L-threo-beta-benzyloxyaspartate."
Nitric oxide (<< NO >>) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by [[ endothelial nitric oxide synthase ]] (eNOS).,Nitric oxide ([ENTITY_A]) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by [ENTITY_B] (eNOS).,PRODUCT-OF,CPR:9,4,Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (eNOS).
"A significant decrease in << HLA-DR >> expression was observed in the AP and fractionated [[ procyanidin ]]-treated cells in the presence of ovalbumin (OVA), but no effect on CD86 expression was observed.","A significant decrease in [ENTITY_A] expression was observed in the AP and fractionated [ENTITY_B]-treated cells in the presence of ovalbumin (OVA), but no effect on CD86 expression was observed.",INDIRECT-DOWNREGULATOR,CPR:4,1,"A significant decrease in HLA-DR expression was observed in the AP and fractionated procyanidin-treated cells in the presence of ovalbumin (OVA), but no effect on CD86 expression was observed."
"[H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and << ABCA1 >>-dependent [[ cholesterol ]] efflux and serum lipid and lipoprotein levels were assessed.","[H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and [ENTITY_A]-dependent [ENTITY_B] efflux and serum lipid and lipoprotein levels were assessed.",SUBSTRATE,CPR:9,4,"[H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and ABCA1-dependent cholesterol efflux and serum lipid and lipoprotein levels were assessed."
"Consistent with these locations, << N-ethylmaleimide >>, an inhibitor of [[ ACS4 ]], inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum.","Consistent with these locations, [ENTITY_A], an inhibitor of [ENTITY_B], inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum.",INHIBITOR,CPR:4,1,"Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum."
"The exception was << bupropion >>, a dual [[ norepinephrine transporter ]]/dopamine transporter blocker, which tended to increase spontaneous locomotor activity.","The exception was [ENTITY_A], a dual [ENTITY_B]/dopamine transporter blocker, which tended to increase spontaneous locomotor activity.",INHIBITOR,CPR:4,1,"The exception was bupropion, a dual norepinephrine transporter/dopamine transporter blocker, which tended to increase spontaneous locomotor activity."
"Treatment with << EVn-50 >> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of [[ Cdc25c ]].","Treatment with [ENTITY_A] or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c."
"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, << ACY-1 >>) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of [[ N-acylated L-amino acids ]] except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.","A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, [ENTITY_A]) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of [ENTITY_B] except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",SUBSTRATE,CPR:9,4,"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced."
<< Phenformin >> causes lactic acidosis in clinical situations due to inhibition of [[ mitochondrial respiratory chain complex I ]].,[ENTITY_A] causes lactic acidosis in clinical situations due to inhibition of [ENTITY_B].,INHIBITOR,CPR:4,1,Phenformin causes lactic acidosis in clinical situations due to inhibition of mitochondrial respiratory chain complex I.
"Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum << PTH >> effectively in the 5/6 NX rats, but [[ paricalcitol ]] was less potent in raising serum Ca than doxercalciferol.","Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum [ENTITY_A] effectively in the 5/6 NX rats, but [ENTITY_B] was less potent in raising serum Ca than doxercalciferol.",DOWNREGULATOR,CPR:4,1,"Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum PTH effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than doxercalciferol."
"The beneficial role of << 17beta-estradiol >> on blood pressure, cardiac hypertrophy, vascular [[ osteopontin ]] expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate.","The beneficial role of [ENTITY_A] on blood pressure, cardiac hypertrophy, vascular [ENTITY_B] expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate.",INDIRECT-UPREGULATOR,CPR:3,0,"The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular osteopontin expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate."
"The << 5-HT(2B/2C)-receptor >> antagonist [[ SB 206553 ]] facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect.","The [ENTITY_A] antagonist [ENTITY_B] facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect.",ANTAGONIST,CPR:6,3,"The 5-HT(2B/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect."
"Furthermore, << thrombin >> diminished cAMP production in ECs, which were prevented by treatment with [[ genistein ]].","Furthermore, [ENTITY_A] diminished cAMP production in ECs, which were prevented by treatment with [ENTITY_B].",INHIBITOR,CPR:4,1,"Furthermore, thrombin diminished cAMP production in ECs, which were prevented by treatment with genistein."
Further investigation demonstrated that 8k reduced << H2O2 >>-induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of [[ Bcl-2 ]].,Further investigation demonstrated that 8k reduced [ENTITY_A]-induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of [ENTITY_B].,INDIRECT-DOWNREGULATOR,CPR:4,1,Further investigation demonstrated that 8k reduced H2O2-induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of Bcl-2.
"With this background, the present study was designed to explore the possible effect of << nimesulide >> (a preferential [[ COX-2 ]] inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice.","With this background, the present study was designed to explore the possible effect of [ENTITY_A] (a preferential [ENTITY_B] inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice.",INHIBITOR,CPR:4,1,"With this background, the present study was designed to explore the possible effect of nimesulide (a preferential COX-2 inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice."
"Our data also prove that indomethacin is not only an activator of << CA >> but also antagonizes the effect of [[ acetazolamide ]], a specific inhibitor of this enzyme.","Our data also prove that indomethacin is not only an activator of [ENTITY_A] but also antagonizes the effect of [ENTITY_B], a specific inhibitor of this enzyme.",INHIBITOR,CPR:4,1,"Our data also prove that indomethacin is not only an activator of CA but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme."
"This effect was reverted in the presence of << atropine >> (ATR; 0.1 microM), which blocks the pre-synaptic [[ muscarinic M2 receptor ]].","This effect was reverted in the presence of [ENTITY_A] (ATR; 0.1 microM), which blocks the pre-synaptic [ENTITY_B].",INHIBITOR,CPR:4,1,"This effect was reverted in the presence of atropine (ATR; 0.1 microM), which blocks the pre-synaptic muscarinic M2 receptor."
"<< DBDCT >> up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of [[ Bax ]]/Bcl-2.","[ENTITY_A] up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of [ENTITY_B]/Bcl-2.",INDIRECT-UPREGULATOR,CPR:3,0,"DBDCT up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax/Bcl-2."
"In hippocampal dentate gyrus, << MPH >>-receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of [[ neural cell adhesion molecule ]]).","In hippocampal dentate gyrus, [ENTITY_A]-receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of [ENTITY_B]).",INDIRECT-UPREGULATOR,CPR:3,0,"In hippocampal dentate gyrus, MPH-receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule)."
"Chronic consumption of << alcohol >> also stimulated abrupt increases in pro-inflammatory cytokines such as [[ nuclear factor (NF)-κB ]], tumor necrosis factor (TNF)-α and interleukin (IL)-1β in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently.","Chronic consumption of [ENTITY_A] also stimulated abrupt increases in pro-inflammatory cytokines such as [ENTITY_B], tumor necrosis factor (TNF)-α and interleukin (IL)-1β in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently.",ACTIVATOR,CPR:3,0,"Chronic consumption of alcohol also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-κB, tumor necrosis factor (TNF)-α and interleukin (IL)-1β in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently."
"Of these, the << thrombin >> inhibitor [[ dabigatran ]] and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.","Of these, the [ENTITY_A] inhibitor [ENTITY_B] and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.",INHIBITOR,CPR:4,1,"Of these, the thrombin inhibitor dabigatran and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe."
"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized << NET >> by a range of doses of [[ duloxetine ]] [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.","BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized [ENTITY_A] by a range of doses of [ENTITY_B] [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.",ANTAGONIST,CPR:6,3,"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process."
"Both << 5 alpha-NET >> and 3 beta,5 alpha-NET blocked the [[ PR ]] down-regulation induced by P4 as assessed by Western and Northern blot methods.","Both [ENTITY_A] and 3 beta,5 alpha-NET blocked the [ENTITY_B] down-regulation induced by P4 as assessed by Western and Northern blot methods.",INDIRECT-UPREGULATOR,CPR:3,0,"Both 5 alpha-NET and 3 beta,5 alpha-NET blocked the PR down-regulation induced by P4 as assessed by Western and Northern blot methods."
"At clinically relevant concentrations, << candesartan >> is an insurmountable and long-lasting antagonist of the vascular contractile responses to [[ Ang II ]].","At clinically relevant concentrations, [ENTITY_A] is an insurmountable and long-lasting antagonist of the vascular contractile responses to [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"At clinically relevant concentrations, candesartan is an insurmountable and long-lasting antagonist of the vascular contractile responses to Ang II."
"Thus, << hydralazine >> activates the [[ HIF ]] pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype.","Thus, [ENTITY_A] activates the [ENTITY_B] pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype.",ACTIVATOR,CPR:3,0,"Thus, hydralazine activates the HIF pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype."
"For determination of [<< PA >>+Pli]-activity, [[ arginine ]] was added after this incubation.","For determination of [[ENTITY_A]+Pli]-activity, [ENTITY_B] was added after this incubation.",SUBSTRATE,CPR:9,4,"For determination of [PA+Pli]-activity, arginine was added after this incubation."
Effect of << fenoterol >>-induced constitutive [[ beta(2)-adrenoceptor ]] activity on contractile receptor function in airway smooth muscle.,Effect of [ENTITY_A]-induced constitutive [ENTITY_B] activity on contractile receptor function in airway smooth muscle.,ACTIVATOR,CPR:3,0,Effect of fenoterol-induced constitutive beta(2)-adrenoceptor activity on contractile receptor function in airway smooth muscle.
"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while << osteocalcin >> (OCN) was augmented in CCL3(-/-) and [[ Met ]]-RANTES-treated mice.","The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while [ENTITY_A] (OCN) was augmented in CCL3(-/-) and [ENTITY_B]-RANTES-treated mice.",INDIRECT-UPREGULATOR,CPR:3,0,"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and Met-RANTES-treated mice."
"<< Carvedilol >> produced significant inhibition of the [[ alpha 1 adrenoceptor ]] mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.","[ENTITY_A] produced significant inhibition of the [ENTITY_B] mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.",INHIBITOR,CPR:4,1,"Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses."
Apocynin and << raisanberine >> alleviate intermittent hypoxia induced abnormal StAR and [[ 3β-HSD ]] and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.,Apocynin and [ENTITY_A] alleviate intermittent hypoxia induced abnormal StAR and [ENTITY_B] and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.,SUBSTRATE,CPR:9,4,Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.
"Again, inhibition of the actin-activated << myosin >> Mg2+-ATPase and myosin filament assembly by [[ felodipine ]] and the p-chloro analogue could be reversed by raising the calmodulin concentration.","Again, inhibition of the actin-activated [ENTITY_A] Mg2+-ATPase and myosin filament assembly by [ENTITY_B] and the p-chloro analogue could be reversed by raising the calmodulin concentration.",INHIBITOR,CPR:4,1,"Again, inhibition of the actin-activated myosin Mg2+-ATPase and myosin filament assembly by felodipine and the p-chloro analogue could be reversed by raising the calmodulin concentration."
"<< Ergot alkaloids >> were also effective in inhibiting [[ VIP ]]-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.","[ENTITY_A] were also effective in inhibiting [ENTITY_B]-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.",INHIBITOR,CPR:4,1,"Ergot alkaloids were also effective in inhibiting VIP-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively."
"Concanavalin A (Con A)-induced << IFN-gamma >>, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist [[ isoproterenol ]] and by the selective beta2AR agonist fenoterol.","Concanavalin A (Con A)-induced [ENTITY_A], GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist [ENTITY_B] and by the selective beta2AR agonist fenoterol.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol."
"<< Nitrooxy >> derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective [[ COX-2 ]] inhibitors in in vitro experimental models.","[ENTITY_A] derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective [ENTITY_B] inhibitors in in vitro experimental models.",INHIBITOR,CPR:4,1,"Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models."
"<< Phosphate >>, a product of the reaction, was found to be a potent inhibitor of [[ MjAdSS ]] showing biphasic inhibition of enzyme activity.","[ENTITY_A], a product of the reaction, was found to be a potent inhibitor of [ENTITY_B] showing biphasic inhibition of enzyme activity.",INHIBITOR,CPR:4,1,"Phosphate, a product of the reaction, was found to be a potent inhibitor of MjAdSS showing biphasic inhibition of enzyme activity."
"<< Tolbutamide >> and gliclazide block the K(ATP) channel K(ir)6.2/Sur1, causing membrane depolarization and stimulating [[ insulin ]] secretion in pancreatic beta cells.","[ENTITY_A] and gliclazide block the K(ATP) channel K(ir)6.2/Sur1, causing membrane depolarization and stimulating [ENTITY_B] secretion in pancreatic beta cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Tolbutamide and gliclazide block the K(ATP) channel K(ir)6.2/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells."
"To test the role of << nicotinic receptors >> in the drugs' effects on [3H]-ACh release, [[ mecamylamine ]] (MEC) 100 microM was used to block such receptors.","To test the role of [ENTITY_A] in the drugs' effects on [3H]-ACh release, [ENTITY_B] (MEC) 100 microM was used to block such receptors.",INHIBITOR,CPR:4,1,"To test the role of nicotinic receptors in the drugs' effects on [3H]-ACh release, mecamylamine (MEC) 100 microM was used to block such receptors."
"In addition, activation of protein kinase C and increases in intracellular << cAMP >> also enhance cholinergic activity in T cells, and [[ lymphocyte function associated antigen-1 ]] (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation.","In addition, activation of protein kinase C and increases in intracellular [ENTITY_A] also enhance cholinergic activity in T cells, and [ENTITY_B] (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation.",INDIRECT-UPREGULATOR,CPR:3,0,"In addition, activation of protein kinase C and increases in intracellular cAMP also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation."
RESULTS: << DZN >> induced histophatological damages and elevated the level of cardiac marker [[ CK-MB ]].,RESULTS: [ENTITY_A] induced histophatological damages and elevated the level of cardiac marker [ENTITY_B].,INDIRECT-UPREGULATOR,CPR:3,0,RESULTS: DZN induced histophatological damages and elevated the level of cardiac marker CK-MB.
"As the << Mg(2+) >> ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the [[ ALDH1 ]]-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).","As the [ENTITY_A] ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the [ENTITY_B]-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).",DOWNREGULATOR,CPR:4,1,"As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)."
"<< TZDs >> also inhibited [[ alkaline phosphatase ]] activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031).","[ENTITY_A] also inhibited [ENTITY_B] activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031).",INHIBITOR,CPR:4,1,"TZDs also inhibited alkaline phosphatase activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031)."
"Here we demonstrate that PPARgamma, turns on << retinoic acid >> synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as [[ retinol dehydrogenase 10 ]] and retinaldehyde dehydrogenase type 2 (RALDH2).","Here we demonstrate that PPARgamma, turns on [ENTITY_A] synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as [ENTITY_B] and retinaldehyde dehydrogenase type 2 (RALDH2).",PRODUCT-OF,CPR:9,4,"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2)."
"Luciferase reporter assays showed that transcription of << FDX1 >> was synergistically activated by the NR5A family and [[ 8Br-cAMP ]] treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN.","Luciferase reporter assays showed that transcription of [ENTITY_A] was synergistically activated by the NR5A family and [ENTITY_B] treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN.",INDIRECT-UPREGULATOR,CPR:3,0,"Luciferase reporter assays showed that transcription of FDX1 was synergistically activated by the NR5A family and 8Br-cAMP treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN."
"Kinetics of inhibition of << human and rat dihydroorotate dehydrogenase >> by atovaquone, lawsone derivatives, [[ brequinar sodium ]] and polyporic acid.","Kinetics of inhibition of [ENTITY_A] by atovaquone, lawsone derivatives, [ENTITY_B] and polyporic acid.",INHIBITOR,CPR:4,1,"Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid."
"The EC50 for inhibition of the << leukotriene C synthetase >> of RBL cells was directly proportional to the [[ LTA4 ]] concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4.","The EC50 for inhibition of the [ENTITY_A] of RBL cells was directly proportional to the [ENTITY_B] concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4.",SUBSTRATE,CPR:9,4,"The EC50 for inhibition of the leukotriene C synthetase of RBL cells was directly proportional to the LTA4 concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4."
"Furthermore, << BRN-250 >> inhibited the [[ VEGF ]]-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway.","Furthermore, [ENTITY_A] inhibited the [ENTITY_B]-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway.",INHIBITOR,CPR:4,1,"Furthermore, BRN-250 inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway."
"Specifically, << hGSTA4 >> cells had significantly higher GSH concentrations when exposed to 5-15 microM [[ 4-HNE ]], but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of 4-HNE.","Specifically, [ENTITY_A] cells had significantly higher GSH concentrations when exposed to 5-15 microM [ENTITY_B], but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of 4-HNE.",SUBSTRATE,CPR:9,4,"Specifically, hGSTA4 cells had significantly higher GSH concentrations when exposed to 5-15 microM 4-HNE, but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of 4-HNE."
"In a cell-based model, << bleomycin >> suppressed Nrf2 activation via [[ extracellular signal-related kinase ]] phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.","In a cell-based model, [ENTITY_A] suppressed Nrf2 activation via [ENTITY_B] phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.",ACTIVATOR,CPR:3,0,"In a cell-based model, bleomycin suppressed Nrf2 activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion."
"In conclusion, only specific apical NHE3 inhibition increased DBS, whereas prostaglandin synthesis, Na+-HCO3- cotransporter activation, or intracellular << HCO3 >>- formation by [[ carbonic anhydrase ]] was not involved.","In conclusion, only specific apical NHE3 inhibition increased DBS, whereas prostaglandin synthesis, Na+-HCO3- cotransporter activation, or intracellular [ENTITY_A]- formation by [ENTITY_B] was not involved.",PRODUCT-OF,CPR:9,4,"In conclusion, only specific apical NHE3 inhibition increased DBS, whereas prostaglandin synthesis, Na+-HCO3- cotransporter activation, or intracellular HCO3- formation by carbonic anhydrase was not involved."
"<< Tolbutamide >> and gliclazide block the [[ K(ATP) channel ]] K(ir)6.2/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells.","[ENTITY_A] and gliclazide block the [ENTITY_B] K(ir)6.2/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells.",INHIBITOR,CPR:4,1,"Tolbutamide and gliclazide block the K(ATP) channel K(ir)6.2/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells."
Histological studies demonstrated that << curcumin >> substantially inhibited [[ OVA ]]-induced eosinophilia in lung tissue.,Histological studies demonstrated that [ENTITY_A] substantially inhibited [ENTITY_B]-induced eosinophilia in lung tissue.,INHIBITOR,CPR:4,1,Histological studies demonstrated that curcumin substantially inhibited OVA-induced eosinophilia in lung tissue.
"These findings demonstrate that cinnamon << polyphenols >> can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of [[ iNOS ]], NF-κB activation.","These findings demonstrate that cinnamon [ENTITY_A] can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of [ENTITY_B], NF-κB activation.",INHIBITOR,CPR:4,1,"These findings demonstrate that cinnamon polyphenols can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of iNOS, NF-κB activation."
Global target profile of the << kinase >> inhibitor [[ bosutinib ]] in primary chronic myeloid leukemia cells.,Global target profile of the [ENTITY_A] inhibitor [ENTITY_B] in primary chronic myeloid leukemia cells.,INHIBITOR,CPR:4,1,Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
These results show that << olanzapine >> eliminates [[ D2 receptor ]] priming and cognitive impairment and also alleviates decreases in neurotrophins and acetylcholinergic markers produced by D2 priming in the hippocampus.,These results show that [ENTITY_A] eliminates [ENTITY_B] priming and cognitive impairment and also alleviates decreases in neurotrophins and acetylcholinergic markers produced by D2 priming in the hippocampus.,INDIRECT-DOWNREGULATOR,CPR:4,1,These results show that olanzapine eliminates D2 receptor priming and cognitive impairment and also alleviates decreases in neurotrophins and acetylcholinergic markers produced by D2 priming in the hippocampus.
<< LTD4 >> also induced expression of [[ cysteinyl leukotriene receptor 1 ]] (CysLT(1)R) and NF-κB p65 in the hippocampus and cortex.,[ENTITY_A] also induced expression of [ENTITY_B] (CysLT(1)R) and NF-κB p65 in the hippocampus and cortex.,INDIRECT-UPREGULATOR,CPR:3,0,LTD4 also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-κB p65 in the hippocampus and cortex.
Development and validation of a non-radioactive << DNA polymerase >> assay for studying cytomegalovirus resistance to [[ foscarnet ]].,Development and validation of a non-radioactive [ENTITY_A] assay for studying cytomegalovirus resistance to [ENTITY_B].,INHIBITOR,CPR:4,1,Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet.
These G-proteins are likely to be involved in the adrenaline-induced inhibition of dihydropyridine-sensitive Ca2+ currents and in other signal transduction pathways contributing to the << adrenaline >>-induced inhibition of [[ insulin ]] secretion.,These G-proteins are likely to be involved in the adrenaline-induced inhibition of dihydropyridine-sensitive Ca2+ currents and in other signal transduction pathways contributing to the [ENTITY_A]-induced inhibition of [ENTITY_B] secretion.,INDIRECT-DOWNREGULATOR,CPR:4,1,These G-proteins are likely to be involved in the adrenaline-induced inhibition of dihydropyridine-sensitive Ca2+ currents and in other signal transduction pathways contributing to the adrenaline-induced inhibition of insulin secretion.
"Following << CdCl₂ >> treatment, [[ ICAM2 ]] was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h.","Following [ENTITY_A] treatment, [ENTITY_B] was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h.",UPREGULATOR,CPR:3,0,"Following CdCl₂ treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h."
The fact that << acetaminophen >> acts functionally as a selective [[ COX-2 ]] inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.,The fact that [ENTITY_A] acts functionally as a selective [ENTITY_B] inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.,INHIBITOR,CPR:4,1,The fact that acetaminophen acts functionally as a selective COX-2 inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.
We found that << Ag >> NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing [[ albumin ]] release.,We found that [ENTITY_A] NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing [ENTITY_B] release.,INDIRECT-DOWNREGULATOR,CPR:4,1,We found that Ag NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing albumin release.
"CK significantly inhibited << DMN >>-induced increases in serum [[ alanine aminotransferase ]] (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.","CK significantly inhibited [ENTITY_A]-induced increases in serum [ENTITY_B] (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.",ACTIVATOR,CPR:3,0,"CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content."
"The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not ATP, whereas mammalian << serine racemase >> activity is increased by [[ ATP ]].","The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not ATP, whereas mammalian [ENTITY_A] activity is increased by [ENTITY_B].",ACTIVATOR,CPR:3,0,"The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not ATP, whereas mammalian serine racemase activity is increased by ATP."
"Increased immunohistochemical labeling of << HIF-1alpha >>, VEGF, and BNP in the ventricular myocardium was observed in the banding group and [[ carvedilol ]] again normalized the labeling.","Increased immunohistochemical labeling of [ENTITY_A], VEGF, and BNP in the ventricular myocardium was observed in the banding group and [ENTITY_B] again normalized the labeling.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Increased immunohistochemical labeling of HIF-1alpha, VEGF, and BNP in the ventricular myocardium was observed in the banding group and carvedilol again normalized the labeling."
The results suggested that << fisetin >> treatment inhibits [[ mTORC1 ]] activity in an Akt-dependent manner.,The results suggested that [ENTITY_A] treatment inhibits [ENTITY_B] activity in an Akt-dependent manner.,INHIBITOR,CPR:4,1,The results suggested that fisetin treatment inhibits mTORC1 activity in an Akt-dependent manner.
"We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that << human type 12 RDH >> reduces dihydrotestosterone to [[ androstanediol ]], and is thus also involved in steroid metabolism.","We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that [ENTITY_A] reduces dihydrotestosterone to [ENTITY_B], and is thus also involved in steroid metabolism.",PRODUCT-OF,CPR:9,4,"We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that human type 12 RDH reduces dihydrotestosterone to androstanediol, and is thus also involved in steroid metabolism."
"<< Cocaine >> block of [[ hH1 channels ]] was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.","[ENTITY_A] block of [ENTITY_B] was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.",INHIBITOR,CPR:4,1,"Cocaine block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block."
"In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150μgL(-1) << oxyfluorfen >> showed a higher [[ CAT ]] activity than controls.","In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150μgL(-1) [ENTITY_A] showed a higher [ENTITY_B] activity than controls.",ACTIVATOR,CPR:3,0,"In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150μgL(-1) oxyfluorfen showed a higher CAT activity than controls."
<< I3A >> induced a higher level of secretion of the inflammatory cytokine [[ interleukin 6 ]] compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.,[ENTITY_A] induced a higher level of secretion of the inflammatory cytokine [ENTITY_B] compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.,INDIRECT-UPREGULATOR,CPR:3,0,I3A induced a higher level of secretion of the inflammatory cytokine interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.
<< Long-chain alkanols >> are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral [[ nicotinic acetylcholine receptor ]] (AChR) by binding to one or more specific sites on the AChR.,[ENTITY_A] are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral [ENTITY_B] (AChR) by binding to one or more specific sites on the AChR.,INHIBITOR,CPR:4,1,Long-chain alkanols are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic acetylcholine receptor (AChR) by binding to one or more specific sites on the AChR.
"In conclusion, immortalized SHR and WKY PTE cells take up << l-alanine >> mainly through a high-affinity [[ Na(+)-dependent amino acid transporter ]], with functional features of ASCT2 transport.","In conclusion, immortalized SHR and WKY PTE cells take up [ENTITY_A] mainly through a high-affinity [ENTITY_B], with functional features of ASCT2 transport.",SUBSTRATE,CPR:9,4,"In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity Na(+)-dependent amino acid transporter, with functional features of ASCT2 transport."
These data suggested that << ambenonium >> had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of [[ muscarinic receptors ]].,These data suggested that [ENTITY_A] had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of [ENTITY_B].,ANTAGONIST,CPR:6,3,These data suggested that ambenonium had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of muscarinic receptors.
"Our results showed that low dose BPA and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only << BPA >> could downregulate the expression of [[ E-cadherin ]] protein.","Our results showed that low dose BPA and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only [ENTITY_A] could downregulate the expression of [ENTITY_B] protein.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Our results showed that low dose BPA and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only BPA could downregulate the expression of E-cadherin protein."
"Interference with << lipoxygenase >> enzymes, rather than a steroid-like inhibition of [[ arachidonic acid ]] release from intracellular phospholipids, seems to be the mode of action.","Interference with [ENTITY_A] enzymes, rather than a steroid-like inhibition of [ENTITY_B] release from intracellular phospholipids, seems to be the mode of action.",SUBSTRATE,CPR:9,4,"Interference with lipoxygenase enzymes, rather than a steroid-like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action."
"Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced << NPC1L1 >> expression only in [[ 7-ketocholesterol ]]-incubated cells.","Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced [ENTITY_A] expression only in [ENTITY_B]-incubated cells.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells."
"Effect of << lintitript >>, a new [[ CCK-A receptor ]] antagonist, on gastric emptying of a solid-liquid meal in humans.","Effect of [ENTITY_A], a new [ENTITY_B] antagonist, on gastric emptying of a solid-liquid meal in humans.",ANTAGONIST,CPR:6,3,"Effect of lintitript, a new CCK-A receptor antagonist, on gastric emptying of a solid-liquid meal in humans."
"<< ACTH >>-stimulated peak [[ cortisol ]], delta cortisol, and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover.","[ENTITY_A]-stimulated peak [ENTITY_B], delta cortisol, and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover.",PRODUCT-OF,CPR:9,4,"ACTH-stimulated peak cortisol, delta cortisol, and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover."
Inhibitor of << cGMP-specific PDE5 >> ([[ zaprinast ]]; 0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis.,Inhibitor of [ENTITY_A] ([ENTITY_B]; 0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis.,INHIBITOR,CPR:4,1,Inhibitor of cGMP-specific PDE5 (zaprinast; 0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis.
The << mu-opioid receptor >>-selective agonist [[ lofentanil ]] potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM).,The [ENTITY_A]-selective agonist [ENTITY_B] potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM).,AGONIST,CPR:5,2,The mu-opioid receptor-selective agonist lofentanil potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM).
"Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to << zileuton >>, suggesting that troglitazone inhibits LT production by direct inhibition of [[ 5-LOX ]] activity.","Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to [ENTITY_A], suggesting that troglitazone inhibits LT production by direct inhibition of [ENTITY_B] activity.",INHIBITOR,CPR:4,1,"Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to zileuton, suggesting that troglitazone inhibits LT production by direct inhibition of 5-LOX activity."
We found that << simvastatin >> abolishes anti-[[ CD11a ]] mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.,We found that [ENTITY_A] abolishes anti-[ENTITY_B] mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.,DOWNREGULATOR,CPR:4,1,We found that simvastatin abolishes anti-CD11a mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.
<< Endothelial NO synthase >> expression was increased by [[ cilazapril ]] but not by losartan.,[ENTITY_A] expression was increased by [ENTITY_B] but not by losartan.,INDIRECT-UPREGULATOR,CPR:3,0,Endothelial NO synthase expression was increased by cilazapril but not by losartan.
"<< Am80 >> slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by [[ VEGF ]].","[ENTITY_A] slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by [ENTITY_B].",INHIBITOR,CPR:4,1,"Am80 slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by VEGF."
"Activation of << STAT3 >>, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and [[ TCDD ]].","Activation of [ENTITY_A], which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and [ENTITY_B].",ACTIVATOR,CPR:3,0,"Activation of STAT3, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and TCDD."
The << Bcl2 >>/Bax ratio increased and Mfn2 expression decreased in MIN6 cells after [[ glucose ]] stimulation.,The [ENTITY_A]/Bax ratio increased and Mfn2 expression decreased in MIN6 cells after [ENTITY_B] stimulation.,INDIRECT-UPREGULATOR,CPR:3,0,The Bcl2/Bax ratio increased and Mfn2 expression decreased in MIN6 cells after glucose stimulation.
"Long-term selection for << lenalidomide >> resistance in H929 myeloma cell lines was accompanied by a reduction in [[ CRBN ]], while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable.","Long-term selection for [ENTITY_A] resistance in H929 myeloma cell lines was accompanied by a reduction in [ENTITY_B], while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Long-term selection for lenalidomide resistance in H929 myeloma cell lines was accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable."
"Abrupt removal of << amrinone >> or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented [[ TNF ]] production.","Abrupt removal of [ENTITY_A] or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented [ENTITY_B] production.",INDIRECT-UPREGULATOR,CPR:3,0,"Abrupt removal of amrinone or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented TNF production."
"While imatinib was unable to block << cisplatin >>-induced DNA damage and damage response, such as the upregulation of [[ p53 ]], imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.","While imatinib was unable to block [ENTITY_A]-induced DNA damage and damage response, such as the upregulation of [ENTITY_B], imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.",INDIRECT-UPREGULATOR,CPR:3,0,"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death."
In all patients << loperamide >> induced a significant fall in plasma [[ ACTH ]] levels.,In all patients [ENTITY_A] induced a significant fall in plasma [ENTITY_B] levels.,INDIRECT-DOWNREGULATOR,CPR:4,1,In all patients loperamide induced a significant fall in plasma ACTH levels.
"Both << risperidone >> and 9-hydroxyrisperidone are substrates of [[ P-glycoprotein ]] (P-gp), a transport protein involved in drug absorption, distribution, and elimination.","Both [ENTITY_A] and 9-hydroxyrisperidone are substrates of [ENTITY_B] (P-gp), a transport protein involved in drug absorption, distribution, and elimination.",SUBSTRATE,CPR:9,4,"Both risperidone and 9-hydroxyrisperidone are substrates of P-glycoprotein (P-gp), a transport protein involved in drug absorption, distribution, and elimination."
"Whereas the addition of << apomorphine >> in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed [[ TRPA1 ]] channels, resulting from a reduction of single-channel open times.","Whereas the addition of [ENTITY_A] in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed [ENTITY_B] channels, resulting from a reduction of single-channel open times.",INHIBITOR,CPR:4,1,"Whereas the addition of apomorphine in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed TRPA1 channels, resulting from a reduction of single-channel open times."
"<< Dicumarol >>, a potent inhibitor of [[ quinone oxidoreductase ]], at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin.","[ENTITY_A], a potent inhibitor of [ENTITY_B], at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin.",INHIBITOR,CPR:4,1,"Dicumarol, a potent inhibitor of quinone oxidoreductase, at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin."
"Synthesis and cancer stem cell-based activity of substituted << 5-morpholino-7H-thieno[3,2-b]pyran-7-ones >> designed as next generation [[ PI3K ]] inhibitors.",Synthesis and cancer stem cell-based activity of substituted [ENTITY_A] designed as next generation [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,"Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors."
<< (R)-Ketoprofen >> (1) was previously reported to be a potent and specific noncompetitive inhibitor of [[ CXCL8 ]]-induced human PMNs chemotaxis.,[ENTITY_A] (1) was previously reported to be a potent and specific noncompetitive inhibitor of [ENTITY_B]-induced human PMNs chemotaxis.,INHIBITOR,CPR:4,1,(R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCL8-induced human PMNs chemotaxis.
Pregnane X Receptor Mediates Dyslipidemia Induced by the << HIV Protease >> Inhibitor [[ Amprenavir ]] in Mice.,Pregnane X Receptor Mediates Dyslipidemia Induced by the [ENTITY_A] Inhibitor [ENTITY_B] in Mice.,INHIBITOR,CPR:4,1,Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice.
"Interestingly, the << CP[c]Ph >> dependent up-regulation of [[ CYP1A ]] mRNA is positively correlated with the incidences of clastogenic changes in rainbow trout erythrocytes.","Interestingly, the [ENTITY_A] dependent up-regulation of [ENTITY_B] mRNA is positively correlated with the incidences of clastogenic changes in rainbow trout erythrocytes.",INDIRECT-UPREGULATOR,CPR:3,0,"Interestingly, the CP[c]Ph dependent up-regulation of CYP1A mRNA is positively correlated with the incidences of clastogenic changes in rainbow trout erythrocytes."
"Antiarrhythmic effects of << (-)-epicatechin-3-gallate >>, a novel [[ sodium channel ]] agonist in cultured neonatal rat ventricular myocytes.","Antiarrhythmic effects of [ENTITY_A], a novel [ENTITY_B] agonist in cultured neonatal rat ventricular myocytes.",AGONIST,CPR:5,2,"Antiarrhythmic effects of (-)-epicatechin-3-gallate, a novel sodium channel agonist in cultured neonatal rat ventricular myocytes."
"The mechanism of interaction between JBP485 and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of << 1,25(OH)(2)D(3) >> on expression of [[ Oats ]] in rat kidney.","The mechanism of interaction between JBP485 and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of [ENTITY_A] on expression of [ENTITY_B] in rat kidney.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The mechanism of interaction between JBP485 and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of 1,25(OH)(2)D(3) on expression of Oats in rat kidney."
CONCLUSION: << GW572016 >> potently inhibits receptor phosphorylation in either [[ EGFR ]]- or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects.,CONCLUSION: [ENTITY_A] potently inhibits receptor phosphorylation in either [ENTITY_B]- or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects.,INHIBITOR,CPR:4,1,CONCLUSION: GW572016 potently inhibits receptor phosphorylation in either EGFR- or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects.
"The acute toxicity of << organophosphorus >> (OP) compounds in mammals is due to their irreversible inhibition of [[ acetylcholinesterase ]] (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels.","The acute toxicity of [ENTITY_A] (OP) compounds in mammals is due to their irreversible inhibition of [ENTITY_B] (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels.",INHIBITOR,CPR:4,1,"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels."
"Additionally, these effects of << ATO >> on γ-H2AX, Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an [[ ATM ]] inhibitor.","Additionally, these effects of [ENTITY_A] on γ-H2AX, Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an [ENTITY_B] inhibitor.",ACTIVATOR,CPR:3,0,"Additionally, these effects of ATO on γ-H2AX, Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an ATM inhibitor."
"This study examined the inward transport of << l-[(14)C]alanine >>, an [[ ASCT2 ]] preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats.","This study examined the inward transport of [ENTITY_A], an [ENTITY_B] preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats.",SUBSTRATE,CPR:9,4,"This study examined the inward transport of l-[(14)C]alanine, an ASCT2 preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats."
"<< TCPOBOP >>, a CAR ligand, modestly induced [[ mdr1a ]].fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation.","[ENTITY_A], a CAR ligand, modestly induced [ENTITY_B].fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation.",INDIRECT-UPREGULATOR,CPR:3,0,"TCPOBOP, a CAR ligand, modestly induced mdr1a.fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation."
Effects of << felodipine >> (a dihydropyridine [[ calcium channel ]] blocker) and analogues on calmodulin-dependent enzymes.,Effects of [ENTITY_A] (a dihydropyridine [ENTITY_B] blocker) and analogues on calmodulin-dependent enzymes.,INHIBITOR,CPR:4,1,Effects of felodipine (a dihydropyridine calcium channel blocker) and analogues on calmodulin-dependent enzymes.
"Under isotonic conditions, << N-ethylmaleimide >> (NEM) produced [[ KCC ]] activation and transient cell shrinkage.","Under isotonic conditions, [ENTITY_A] (NEM) produced [ENTITY_B] activation and transient cell shrinkage.",ACTIVATOR,CPR:3,0,"Under isotonic conditions, N-ethylmaleimide (NEM) produced KCC activation and transient cell shrinkage."
"RESULTS: << NF-kappaB >>/Rel activity induced by tumor necrosis factor alpha, [[ 12-O-tetradecanoylphorbol-13-acetate ]], or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.","RESULTS: [ENTITY_A]/Rel activity induced by tumor necrosis factor alpha, [ENTITY_B], or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.",ACTIVATOR,CPR:3,0,"RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine."
"Inhibition of << mTOR >> by small dose of [[ rapamycin ]] reduces podocyte apoptosis, attenuates glomerular injury and albuminuria.","Inhibition of [ENTITY_A] by small dose of [ENTITY_B] reduces podocyte apoptosis, attenuates glomerular injury and albuminuria.",INHIBITOR,CPR:4,1,"Inhibition of mTOR by small dose of rapamycin reduces podocyte apoptosis, attenuates glomerular injury and albuminuria."
"Binding of << hydroxyflutamide >> to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of [[ PSA ]] expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR.","Binding of [ENTITY_A] to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of [ENTITY_B] expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR.",INDIRECT-UPREGULATOR,CPR:3,0,"Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR."
A << TXA2 synthetase >> inhibitor ([[ OKY-046 ]]) attenuated the contraction to a small extent only at high concentrations.,A [ENTITY_A] inhibitor ([ENTITY_B]) attenuated the contraction to a small extent only at high concentrations.,INHIBITOR,CPR:4,1,A TXA2 synthetase inhibitor (OKY-046) attenuated the contraction to a small extent only at high concentrations.
"The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for << 4-chloropropofol >> in [[ Na(V)1.2 ]].","The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for [ENTITY_A] in [ENTITY_B].",INHIBITOR,CPR:4,1,"The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for 4-chloropropofol in Na(V)1.2."
"In conclusion, fenoterol-induced constitutive << beta(2)-adrenoceptor >> activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist [[ timolol ]].","In conclusion, fenoterol-induced constitutive [ENTITY_A] activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist [ENTITY_B].",AGONIST-INHIBITOR,CPR:5,2,"In conclusion, fenoterol-induced constitutive beta(2)-adrenoceptor activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist timolol."
"Because of their low asparagine synthetase (<< ASNS >>) expression and [[ asparagine ]] biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.","Because of their low asparagine synthetase ([ENTITY_A]) expression and [ENTITY_B] biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.",PRODUCT-OF,CPR:9,4,"Because of their low asparagine synthetase (ASNS) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion."
"<< Bile acids >> are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, [[ constitutive androstane receptor ]], and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.","[ENTITY_A] are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, [ENTITY_B], and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.",ACTIVATOR,CPR:3,0,"Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism."
<< Phenothiazines >> inhibit [[ S100A4 ]] function by inducing protein oligomerization.,[ENTITY_A] inhibit [ENTITY_B] function by inducing protein oligomerization.,INHIBITOR,CPR:4,1,Phenothiazines inhibit S100A4 function by inducing protein oligomerization.
"Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of << cucurbitacin I >> on [[ Rac1 ]] activation by heregulin.","Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of [ENTITY_A] on [ENTITY_B] activation by heregulin.",INHIBITOR,CPR:4,1,"Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin."
<< Alendronate >> inhibition of [[ protein-tyrosine-phosphatase-meg1 ]].,[ENTITY_A] inhibition of [ENTITY_B].,INHIBITOR,CPR:4,1,Alendronate inhibition of protein-tyrosine-phosphatase-meg1.
Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of alpha(2)-adrenoceptor agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the << alpha(2)-adrenoceptor >>-mediated inhibition induced by [[ moxonidine ]].,Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of alpha(2)-adrenoceptor agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the [ENTITY_A]-mediated inhibition induced by [ENTITY_B].,INHIBITOR,CPR:4,1,Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of alpha(2)-adrenoceptor agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the alpha(2)-adrenoceptor-mediated inhibition induced by moxonidine.
<< Phenols >> like the ones investigated here possess a [[ CA ]] inhibition mechanism distinct of that of the sulfonamides/sulfamates used clinically or the coumarins.,[ENTITY_A] like the ones investigated here possess a [ENTITY_B] inhibition mechanism distinct of that of the sulfonamides/sulfamates used clinically or the coumarins.,INHIBITOR,CPR:4,1,Phenols like the ones investigated here possess a CA inhibition mechanism distinct of that of the sulfonamides/sulfamates used clinically or the coumarins.
"Moreover, << Acrolein >> resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of [[ ADAM-10 ]] in hippocampus and cortex.","Moreover, [ENTITY_A] resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of [ENTITY_B] in hippocampus and cortex.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, Acrolein resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of ADAM-10 in hippocampus and cortex."
"The tacrine pressor response was inhibited in a dose-dependent manner by the i.c.v. administration of the non-selective << muscarinic receptor >> antagonist [[ atropine ]] (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).","The tacrine pressor response was inhibited in a dose-dependent manner by the i.c.v. administration of the non-selective [ENTITY_A] antagonist [ENTITY_B] (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).",ANTAGONIST,CPR:6,3,"The tacrine pressor response was inhibited in a dose-dependent manner by the i.c.v. administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)."
These results suggest that PDE4B mediates the antipsychotic effects of rolipram in CAR and that the << PDE4B >>-regulated [[ cyclic adenosine monophosphate ]] signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.,These results suggest that PDE4B mediates the antipsychotic effects of rolipram in CAR and that the [ENTITY_A]-regulated [ENTITY_B] signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.,SUBSTRATE,CPR:9,4,These results suggest that PDE4B mediates the antipsychotic effects of rolipram in CAR and that the PDE4B-regulated cyclic adenosine monophosphate signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.
"Furthermore, tPA induced rapid << tyrosine >> phosphorylation on the beta subunit of LRP-1, which was followed by the activation of [[ Mek1 ]] and its downstream Erk-1 and -2.","Furthermore, tPA induced rapid [ENTITY_A] phosphorylation on the beta subunit of LRP-1, which was followed by the activation of [ENTITY_B] and its downstream Erk-1 and -2.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2."
We have examined the effect of dihydropyridine << Ca2+-channel >> blockers [[ felodipine ]] and nicardipine on CaMPDE.,We have examined the effect of dihydropyridine [ENTITY_A] blockers [ENTITY_B] and nicardipine on CaMPDE.,INHIBITOR,CPR:4,1,We have examined the effect of dihydropyridine Ca2+-channel blockers felodipine and nicardipine on CaMPDE.
"Our data showed that chronic << ethanol >> over-activated CYP2E1 but suppressed [[ HO-1 ]] with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.).","Our data showed that chronic [ENTITY_A] over-activated CYP2E1 but suppressed [ENTITY_B] with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.).",DOWNREGULATOR,CPR:4,1,"Our data showed that chronic ethanol over-activated CYP2E1 but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.)."
"The mRNA levels of << SOD1 >>, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+[[ NaAsO2 ]] treatment group.","The mRNA levels of [ENTITY_A], CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+[ENTITY_B] treatment group.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The mRNA levels of SOD1, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+NaAsO2 treatment group."
"<< Cat-1 >>, the transporter for the essential [[ amino acids ]], arginine and lysine, is one of the up-regulated genes.","[ENTITY_A], the transporter for the essential [ENTITY_B], arginine and lysine, is one of the up-regulated genes.",SUBSTRATE,CPR:9,4,"Cat-1, the transporter for the essential amino acids, arginine and lysine, is one of the up-regulated genes."
The concentration of << estramustine phosphate >> required to inhibit the assembly or to induce the disassembly of [[ chick brain MAP2 ]]:tubulin microtubules is markedly dependent upon the microtubule protein concentration.,The concentration of [ENTITY_A] required to inhibit the assembly or to induce the disassembly of [ENTITY_B]:tubulin microtubules is markedly dependent upon the microtubule protein concentration.,ACTIVATOR,CPR:3,0,The concentration of estramustine phosphate required to inhibit the assembly or to induce the disassembly of chick brain MAP2:tubulin microtubules is markedly dependent upon the microtubule protein concentration.
Wattakaka volubilis << steroidal glycoside >> mixture (WVSM) and PPG (1-50μM) significantly inhibited the [[ COX-2 ]] and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.,Wattakaka volubilis [ENTITY_A] mixture (WVSM) and PPG (1-50μM) significantly inhibited the [ENTITY_B] and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.,INHIBITOR,CPR:4,1,Wattakaka volubilis steroidal glycoside mixture (WVSM) and PPG (1-50μM) significantly inhibited the COX-2 and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.
"The nonselective opioid receptor partial agonist buprenorphine and the nonselective << opioid receptor >> antagonist [[ (-)-quadazocine ]] exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.","The nonselective opioid receptor partial agonist buprenorphine and the nonselective [ENTITY_A] antagonist [ENTITY_B] exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.",ANTAGONIST,CPR:6,3,"The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors."
<< Vitamin C >> forestalls cigarette smoke induced [[ NF-κB ]] activation in alveolar epithelial cells.,[ENTITY_A] forestalls cigarette smoke induced [ENTITY_B] activation in alveolar epithelial cells.,INHIBITOR,CPR:4,1,Vitamin C forestalls cigarette smoke induced NF-κB activation in alveolar epithelial cells.
"<< Sulfasalazine >>, a potent suppressor of lymphoma growth by inhibition of the [[ x(c)- cystine transporter ]]: a new action for an old drug.","[ENTITY_A], a potent suppressor of lymphoma growth by inhibition of the [ENTITY_B]: a new action for an old drug.",INHIBITOR,CPR:4,1,"Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug."
"On the other hand, high doses of << okadaic acid >> (10 ng/mouse, i.c.v.) and cantharidin (1 microg/mouse, i.c.v.), which also block [[ PP1 ]], and calyculin-A (0.1 fg/mouse-1 ng/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception.","On the other hand, high doses of [ENTITY_A] (10 ng/mouse, i.c.v.) and cantharidin (1 microg/mouse, i.c.v.), which also block [ENTITY_B], and calyculin-A (0.1 fg/mouse-1 ng/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception.",INHIBITOR,CPR:4,1,"On the other hand, high doses of okadaic acid (10 ng/mouse, i.c.v.) and cantharidin (1 microg/mouse, i.c.v.), which also block PP1, and calyculin-A (0.1 fg/mouse-1 ng/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception."
A << KCC >> inhibitor-[[ [(dihydroindenyl)oxy] alkanoic acid ]] (DIOA)-blocked RVD more in HCEC than RCEC.,A [ENTITY_A] inhibitor-[ENTITY_B] (DIOA)-blocked RVD more in HCEC than RCEC.,INHIBITOR,CPR:4,1,A KCC inhibitor-[(dihydroindenyl)oxy] alkanoic acid (DIOA)-blocked RVD more in HCEC than RCEC.
"<< Felbamate >> produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the [[ rat NR1a ]] subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV).","[ENTITY_A] produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the [ENTITY_B] subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV).",INHIBITOR,CPR:4,1,"Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)."
The monoacylglycerol lipase (<< MAGL >>) inhibitor [[ JZL184 ]] produces antinociceptive and anti-inflammatory effects.,The monoacylglycerol lipase ([ENTITY_A]) inhibitor [ENTITY_B] produces antinociceptive and anti-inflammatory effects.,INHIBITOR,CPR:4,1,The monoacylglycerol lipase (MAGL) inhibitor JZL184 produces antinociceptive and anti-inflammatory effects.
This suppression was well correlated with the inhibitory effect of << auranofin >> on the homodimerization of [[ TLR4 ]] induced by an agonist.,This suppression was well correlated with the inhibitory effect of [ENTITY_A] on the homodimerization of [ENTITY_B] induced by an agonist.,INHIBITOR,CPR:4,1,This suppression was well correlated with the inhibitory effect of auranofin on the homodimerization of TLR4 induced by an agonist.
"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and << IMG >> or hyperoside inhibited production of thrombin and [[ FXa ]] in HUVECs.","Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and [ENTITY_A] or hyperoside inhibited production of thrombin and [ENTITY_B] in HUVECs.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs."
Postoperative concentrations of << plasminogen >> were decreased significantly in the [[ tranexamic acid ]] group (P < 0.001).,Postoperative concentrations of [ENTITY_A] were decreased significantly in the [ENTITY_B] group (P < 0.001).,INDIRECT-DOWNREGULATOR,CPR:4,1,Postoperative concentrations of plasminogen were decreased significantly in the tranexamic acid group (P < 0.001).
"Little is known in terms of multi-matrix << cytochrome P450 >> activity induction under repeated oral exposure to planar [[ halogenated and polycyclic aromatic hydrocarbons ]] (PHH, PAH).","Little is known in terms of multi-matrix [ENTITY_A] activity induction under repeated oral exposure to planar [ENTITY_B] (PHH, PAH).",ACTIVATOR,CPR:3,0,"Little is known in terms of multi-matrix cytochrome P450 activity induction under repeated oral exposure to planar halogenated and polycyclic aromatic hydrocarbons (PHH, PAH)."
<< Amiloride >> is a specific inhibitor of [[ uPA ]] but does not inhibit tPA.,[ENTITY_A] is a specific inhibitor of [ENTITY_B] but does not inhibit tPA.,INHIBITOR,CPR:4,1,Amiloride is a specific inhibitor of uPA but does not inhibit tPA.
"Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of << AA >> metabolites in [[ PPAR ]] activation.","Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of [ENTITY_A] metabolites in [ENTITY_B] activation.",ACTIVATOR,CPR:3,0,"Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation."
"In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that << TCDD >> up-regulated the expression and secretion of [[ tumor necrosis factor-alpha ]] (TNF-α) in a time-dependent manner in cultured HAPI microglial cells.","In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that [ENTITY_A] up-regulated the expression and secretion of [ENTITY_B] (TNF-α) in a time-dependent manner in cultured HAPI microglial cells.",INDIRECT-UPREGULATOR,CPR:3,0,"In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that TCDD up-regulated the expression and secretion of tumor necrosis factor-alpha (TNF-α) in a time-dependent manner in cultured HAPI microglial cells."
"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, << sodium hydrosulphide >> (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in [[ SP ]] concentration and expression of PPT-A and NK1-R in acinar cells.","To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, [ENTITY_A] (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in [ENTITY_B] concentration and expression of PPT-A and NK1-R in acinar cells.",INDIRECT-UPREGULATOR,CPR:3,0,"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and NK1-R in acinar cells."
These findings demonstrate that << PEPT2 >> is the primary transporter responsible for [[ cefadroxil ]] uptake in the choroid plexus.,These findings demonstrate that [ENTITY_A] is the primary transporter responsible for [ENTITY_B] uptake in the choroid plexus.,SUBSTRATE,CPR:9,4,These findings demonstrate that PEPT2 is the primary transporter responsible for cefadroxil uptake in the choroid plexus.
"Design and synthesis of novel << 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one >> derivatives as [[ telomerase ]] inhibitors.",Design and synthesis of novel [ENTITY_A] derivatives as [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,"Design and synthesis of novel 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one derivatives as telomerase inhibitors."
"The concomitant application of subconvulsive dose of pentetrazole (55.0 mg/kg) with low dose of << flumazenil >> (5.0 mg/kg) - a [[ BDZ receptor ]] antagonist, immediately induced BDZ withdrawal signs in these animals.","The concomitant application of subconvulsive dose of pentetrazole (55.0 mg/kg) with low dose of [ENTITY_A] (5.0 mg/kg) - a [ENTITY_B] antagonist, immediately induced BDZ withdrawal signs in these animals.",ANTAGONIST,CPR:6,3,"The concomitant application of subconvulsive dose of pentetrazole (55.0 mg/kg) with low dose of flumazenil (5.0 mg/kg) - a BDZ receptor antagonist, immediately induced BDZ withdrawal signs in these animals."
"This methodology was subsequently used to assess the relative contribution of << OATP1B1 >> uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), [[ pitavastatin ]] (84%-98%) and lopinavir (64%-89%).","This methodology was subsequently used to assess the relative contribution of [ENTITY_A] uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), [ENTITY_B] (84%-98%) and lopinavir (64%-89%).",SUBSTRATE,CPR:9,4,"This methodology was subsequently used to assess the relative contribution of OATP1B1 uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)."
"Characterization of binding sites of a new << neurotensin receptor >> antagonist, [[ [3H]SR 142948A ]], in the rat brain.","Characterization of binding sites of a new [ENTITY_A] antagonist, [ENTITY_B], in the rat brain.",ANTAGONIST,CPR:6,3,"Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain."
In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or << ADP >>-stimulated [[ CD62P ]] expression.,In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or [ENTITY_A]-stimulated [ENTITY_B] expression.,INDIRECT-UPREGULATOR,CPR:3,0,In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or ADP-stimulated CD62P expression.
"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 << sodium channels >>[[ sodium ]] channels expressed in Chinese Hamster Ovary (CHO-K1) cells.","In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 [ENTITY_A][ENTITY_B] channels expressed in Chinese Hamster Ovary (CHO-K1) cells.",SUBSTRATE,CPR:9,4,"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 sodium channelssodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells."
This information may be useful in the development of more potent << sodium channel >>[[ sodium ]] channel blockers.,This information may be useful in the development of more potent [ENTITY_A][ENTITY_B] channel blockers.,SUBSTRATE,CPR:9,4,This information may be useful in the development of more potent sodium channelsodium channel blockers.
"<< Cyproterone acetate >>, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit [[ 3 beta-HSD ]] activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.","[ENTITY_A], a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit [ENTITY_B] activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.",INHIBITOR,CPR:4,1,"Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit 3 beta-HSD activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively."
"Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in << interleukin >> synthesis induced by dietary [[ oxysterols ]].","Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in [ENTITY_A] synthesis induced by dietary [ENTITY_B].",INDIRECT-UPREGULATOR,CPR:3,0,"Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in interleukin synthesis induced by dietary oxysterols."
The activation of << Rac1 >> was induced by [[ silica ]] nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation.,The activation of [ENTITY_A] was induced by [ENTITY_B] nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation.,ACTIVATOR,CPR:3,0,The activation of Rac1 was induced by silica nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation.
"Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as << dabigatran >> are novel synthetic [[ thrombin ]] antagonists.","Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as [ENTITY_A] are novel synthetic [ENTITY_B] antagonists.",ANTAGONIST,CPR:6,3,"Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists."
Synthesis of derivatives of << methyl rosmarinate >> and their inhibitory activities against matrix metalloproteinase-1 ([[ MMP-1 ]]).,Synthesis of derivatives of [ENTITY_A] and their inhibitory activities against matrix metalloproteinase-1 ([ENTITY_B]).,INHIBITOR,CPR:4,1,Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).
"It was found that a single intragastric gavage by << L-methionine >> resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of [[ PON1 ]] and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.","It was found that a single intragastric gavage by [ENTITY_A] resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of [ENTITY_B] and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.",INHIBITOR,CPR:4,1,"It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group."
"In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential << 5-HT2A >> receptor agonist [[ DOI ]] (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action.","In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential [ENTITY_A] receptor agonist [ENTITY_B] (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action.",AGONIST,CPR:5,2,"In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential 5-HT2A receptor agonist DOI (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action."
CONCLUSIONS: Inhibition of << PDE4 >> by [[ rolipram ]] unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP/B.,CONCLUSIONS: Inhibition of [ENTITY_A] by [ENTITY_B] unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP/B.,INHIBITOR,CPR:4,1,CONCLUSIONS: Inhibition of PDE4 by rolipram unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP/B.
Design and synthesis of << bicyclic pyrazinone and pyrimidinone amides >> as potent [[ TF ]]-FVIIa inhibitors.,Design and synthesis of [ENTITY_A] as potent [ENTITY_B]-FVIIa inhibitors.,INHIBITOR,CPR:4,1,Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitors.
"We report the discovery of novel series of highly potent << TLR7 >> agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various [[ tertiary amines ]] onto the N(9)-position of the adenine moiety.","We report the discovery of novel series of highly potent [ENTITY_A] agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various [ENTITY_B] onto the N(9)-position of the adenine moiety.",AGONIST,CPR:5,2,"We report the discovery of novel series of highly potent TLR7 agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety."
"While the substituted << benzamide >> prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative [[ 5-HT4 ]] receptor.","While the substituted [ENTITY_A] prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative [ENTITY_B] receptor.",AGONIST,CPR:5,2,"While the substituted benzamide prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor."
"Since the original discovery of << azoles >> analogs as [[ PXR ]] antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists.","Since the original discovery of [ENTITY_A] analogs as [ENTITY_B] antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists.",ANTAGONIST,CPR:6,3,"Since the original discovery of azoles analogs as PXR antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists."
The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of << IKKs >> and can be antagonized by excess [[ adenosine triphosphate ]].,The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of [ENTITY_A] and can be antagonized by excess [ENTITY_B].,INHIBITOR,CPR:4,1,The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of IKKs and can be antagonized by excess adenosine triphosphate.
These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the << ABCA1 >> transporter during the [[ cholesterol ]] efflux process.,These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the [ENTITY_A] transporter during the [ENTITY_B] efflux process.,SUBSTRATE,CPR:9,4,These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the ABCA1 transporter during the cholesterol efflux process.
"As a consequence, << phenserine >> reduces [[ beta-amyloid ]] peptide (Abeta) formation in vitro and in vivo.","As a consequence, [ENTITY_A] reduces [ENTITY_B] peptide (Abeta) formation in vitro and in vivo.",INDIRECT-DOWNREGULATOR,CPR:4,1,"As a consequence, phenserine reduces beta-amyloid peptide (Abeta) formation in vitro and in vivo."
"<< Sorafenib >> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 ([[ VEGFR-2 ]], VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.","[ENTITY_A] and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 ([ENTITY_B], VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.",INHIBITOR,CPR:4,1,"Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor."
"By contrast, << telmisartan >> attenuated [[ 11beta-hydroxysteroid dehydrogenase type 1 ]] mRNA level in differentiated adipocytes.","By contrast, [ENTITY_A] attenuated [ENTITY_B] mRNA level in differentiated adipocytes.",INDIRECT-UPREGULATOR,CPR:3,0,"By contrast, telmisartan attenuated 11beta-hydroxysteroid dehydrogenase type 1 mRNA level in differentiated adipocytes."
<< Amino acid >> derived quinazolines as [[ Rock ]]/PKA inhibitors.,[ENTITY_A] derived quinazolines as [ENTITY_B]/PKA inhibitors.,INHIBITOR,CPR:4,1,Amino acid derived quinazolines as Rock/PKA inhibitors.
Synthesis and in Vitro Characterisation of << Ifenprodil >>-Based Fluorescein Conjugates as [[ GluN1 ]]/GluN2B N-Methyl-D-aspartate Receptor Antagonists.,Synthesis and in Vitro Characterisation of [ENTITY_A]-Based Fluorescein Conjugates as [ENTITY_B]/GluN2B N-Methyl-D-aspartate Receptor Antagonists.,ANTAGONIST,CPR:6,3,Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B N-Methyl-D-aspartate Receptor Antagonists.
"Our data also prove that << indomethacin >> is not only an activator of [[ CA ]] but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme.","Our data also prove that [ENTITY_A] is not only an activator of [ENTITY_B] but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme.",ACTIVATOR,CPR:3,0,"Our data also prove that indomethacin is not only an activator of CA but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme."
Cardiac effects of the << beta 3-adrenoceptor >> agonist [[ BRL35135 ]] in man.,Cardiac effects of the [ENTITY_A] agonist [ENTITY_B] in man.,AGONIST,CPR:5,2,Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man.
Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the << NADPH oxidase >> inhibitor [[ apocynin ]] or superoxide dismutase.,Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the [ENTITY_A] inhibitor [ENTITY_B] or superoxide dismutase.,INHIBITOR,CPR:4,1,Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the NADPH oxidase inhibitor apocynin or superoxide dismutase.
"Active compounds, such as the << nitrobenzyl >> analogue 6c, were found to exhibit sub-micromolar IC50 values in [[ Bcl-2 ]] expressing human cancer cell lines.","Active compounds, such as the [ENTITY_A] analogue 6c, were found to exhibit sub-micromolar IC50 values in [ENTITY_B] expressing human cancer cell lines.",INHIBITOR,CPR:4,1,"Active compounds, such as the nitrobenzyl analogue 6c, were found to exhibit sub-micromolar IC50 values in Bcl-2 expressing human cancer cell lines."
"The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective << sigma1 receptor >> antagonist [[ BD 1047 ]], suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.","The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective [ENTITY_A] antagonist [ENTITY_B], suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.",ANTAGONIST,CPR:6,3,"The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors."
"PURPOSE: XL184 (<< cabozantinib >>) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 ([[ VEGFR2 ]]), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.","PURPOSE: XL184 ([ENTITY_A]) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 ([ENTITY_B]), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.",INHIBITOR,CPR:4,1,"PURPOSE: XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models."
"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased << isoprenaline >>-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the [[ beta(2)-adrenoceptor ]].","Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased [ENTITY_A]-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the [ENTITY_B].",AGONIST,CPR:5,2,"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the beta(2)-adrenoceptor."
"These results provide an example that attachment of a bulky side chain to the C-7α position of E2 can produce ER antagonists with << ER >> affinity comparable to that of [[ ICI-182,780 ]].",These results provide an example that attachment of a bulky side chain to the C-7α position of E2 can produce ER antagonists with [ENTITY_A] affinity comparable to that of [ENTITY_B].,ANTAGONIST,CPR:6,3,"These results provide an example that attachment of a bulky side chain to the C-7α position of E2 can produce ER antagonists with ER affinity comparable to that of ICI-182,780."
"By ""working upwards"" from mTOR, we observed that << TCDD >> inhibited endogenous and IGF-I-induced [[ AKT ]] and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.","By ""working upwards"" from mTOR, we observed that [ENTITY_A] inhibited endogenous and IGF-I-induced [ENTITY_B] and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.",INDIRECT-DOWNREGULATOR,CPR:4,1,"By ""working upwards"" from mTOR, we observed that TCDD inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1."
"These events are stimulated by NE and by guanethidine, an << hNET >> substrate, and they are blocked by [[ cocaine ]] and the antidepressant desipramine.","These events are stimulated by NE and by guanethidine, an [ENTITY_A] substrate, and they are blocked by [ENTITY_B] and the antidepressant desipramine.",INHIBITOR,CPR:4,1,"These events are stimulated by NE and by guanethidine, an hNET substrate, and they are blocked by cocaine and the antidepressant desipramine."
"RESULTS: << Imatinib >>, despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or [[ VEGFR ]] inhibition.","RESULTS: [ENTITY_A], despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or [ENTITY_B] inhibition.",INHIBITOR,CPR:4,1,"RESULTS: Imatinib, despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or VEGFR inhibition."
"In eukaryotes, the most prominent Mo-enzymes are (1) << sulfite oxidase >>, which catalyzes the final step in the degradation of [[ sulfur ]]-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.","In eukaryotes, the most prominent Mo-enzymes are (1) [ENTITY_A], which catalyzes the final step in the degradation of [ENTITY_B]-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.",SUBSTRATE,CPR:9,4,"In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation."
"<< Palonosetron >> is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation [[ 5-HT3 receptor ]] antagonists.","[ENTITY_A] is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation [ENTITY_B] antagonists.",ANTAGONIST,CPR:6,3,"Palonosetron is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists."
"<< Imatinib >>-induced changes were blocked with the EGFR antagonist cetuximab, which suggested direct involvement of [[ EGFR ]] in this process.","[ENTITY_A]-induced changes were blocked with the EGFR antagonist cetuximab, which suggested direct involvement of [ENTITY_B] in this process.",ACTIVATOR,CPR:3,0,"Imatinib-induced changes were blocked with the EGFR antagonist cetuximab, which suggested direct involvement of EGFR in this process."
"In Alexander cells, only when they were transfected with FXR+RXR, << GW4064 >> caused up-regulation of SHP and OSTβ, and a down-regulation of [[ CYP27A1 ]].","In Alexander cells, only when they were transfected with FXR+RXR, [ENTITY_A] caused up-regulation of SHP and OSTβ, and a down-regulation of [ENTITY_B].",INDIRECT-DOWNREGULATOR,CPR:4,1,"In Alexander cells, only when they were transfected with FXR+RXR, GW4064 caused up-regulation of SHP and OSTβ, and a down-regulation of CYP27A1."
Pharmacophore identification of << c-Myc >> inhibitor [[ 10074-G5 ]].,Pharmacophore identification of [ENTITY_A] inhibitor [ENTITY_B].,INHIBITOR,CPR:4,1,Pharmacophore identification of c-Myc inhibitor 10074-G5.
"In a human whole blood assay, IC(50) values for << lumiracoxib >> were 0.13 microM for [[ COX-2 ]] and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).","In a human whole blood assay, IC(50) values for [ENTITY_A] were 0.13 microM for [ENTITY_B] and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).",INHIBITOR,CPR:4,1,"In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515)."
"Sitagliptin. << Sitagliptin >>, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting [[ DPP-4 ]] inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.","Sitagliptin. [ENTITY_A], an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting [ENTITY_B] inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.",INHIBITOR,CPR:4,1,"Sitagliptin. Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide."
"The putative << alpha 1L-adrenoceptor >> antagonist [[ JTH-601 ]], but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA.","The putative [ENTITY_A] antagonist [ENTITY_B], but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA.",ANTAGONIST,CPR:6,3,"The putative alpha 1L-adrenoceptor antagonist JTH-601, but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA."
"Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the << dopamine D1 receptor >> antagonist [[ SCH 39166 ]] ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).","Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the [ENTITY_A] antagonist [ENTITY_B] ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).",ANTAGONIST,CPR:6,3,"Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg)."
"In hippocampal dentate gyrus, << MPH >>-receiving rats showed a 51% decrease in [[ NET ]]-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule).","In hippocampal dentate gyrus, [ENTITY_A]-receiving rats showed a 51% decrease in [ENTITY_B]-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule).",INDIRECT-DOWNREGULATOR,CPR:4,1,"In hippocampal dentate gyrus, MPH-receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule)."
"Additionally, there was a significant difference in plasma concentrations of << (R)-5-hydroxyomeprazole >> among [[ CYP2C19 ]] genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole.","Additionally, there was a significant difference in plasma concentrations of [ENTITY_A] among [ENTITY_B] genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole.",SUBSTRATE,CPR:9,4,"Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among CYP2C19 genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole."
"<< BCRP >> appeared to play a more important role for absorption and intestinal and renal elimination of [[ apixaban ]] than P-gp in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species.","[ENTITY_A] appeared to play a more important role for absorption and intestinal and renal elimination of [ENTITY_B] than P-gp in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species.",SUBSTRATE,CPR:9,4,"BCRP appeared to play a more important role for absorption and intestinal and renal elimination of apixaban than P-gp in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species."
"In DU-PM cells with acquired resistance to << elisidepsin >>, ErbB3 expression was decreased, while [[ Bcl2 ]] was increased.","In DU-PM cells with acquired resistance to [ENTITY_A], ErbB3 expression was decreased, while [ENTITY_B] was increased.",INDIRECT-UPREGULATOR,CPR:3,0,"In DU-PM cells with acquired resistance to elisidepsin, ErbB3 expression was decreased, while Bcl2 was increased."
"<< Orlistat >>, a new [[ lipase ]] inhibitor for the management of obesity.","[ENTITY_A], a new [ENTITY_B] inhibitor for the management of obesity.",INHIBITOR,CPR:4,1,"Orlistat, a new lipase inhibitor for the management of obesity."
"These compounds are competitive and, in a few cases, non-competitive inhibitors for << AChE >>, the most potent being compound (14), though three-fold less active than [[ tacrine ]].","These compounds are competitive and, in a few cases, non-competitive inhibitors for [ENTITY_A], the most potent being compound (14), though three-fold less active than [ENTITY_B].",INHIBITOR,CPR:4,1,"These compounds are competitive and, in a few cases, non-competitive inhibitors for AChE, the most potent being compound (14), though three-fold less active than tacrine."
"The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of << orexin-A >> was reversed by the administration of [[ SB334867 ]] as well as by hypothalamic BDNF knockdown.","The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of [ENTITY_A] was reversed by the administration of [ENTITY_B] as well as by hypothalamic BDNF knockdown.",DOWNREGULATOR,CPR:4,1,"The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of SB334867 as well as by hypothalamic BDNF knockdown."
Isometric contraction induced by a submaximal concentration of << Ang II >> (10(-7) mol/L) was reduced in a dose-dependent way by [[ torasemide ]] (IC(50)=0.5+/-0.04 micromol/L).,Isometric contraction induced by a submaximal concentration of [ENTITY_A] (10(-7) mol/L) was reduced in a dose-dependent way by [ENTITY_B] (IC(50)=0.5+/-0.04 micromol/L).,INHIBITOR,CPR:4,1,Isometric contraction induced by a submaximal concentration of Ang II (10(-7) mol/L) was reduced in a dose-dependent way by torasemide (IC(50)=0.5+/-0.04 micromol/L).
"In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the hERG activity, conformational modifications of the core structure resulted in the identification of fused << oxadiazepines >> such as 7i which had an improved [[ hERG ]] inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.","In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the hERG activity, conformational modifications of the core structure resulted in the identification of fused [ENTITY_A] such as 7i which had an improved [ENTITY_B] inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.",INHIBITOR,CPR:4,1,"In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the hERG activity, conformational modifications of the core structure resulted in the identification of fused oxadiazepines such as 7i which had an improved hERG inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats."
"We found that << wogonin >> can suppress the H2O2-stimulated [[ actin ]] remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.","We found that [ENTITY_A] can suppress the H2O2-stimulated [ENTITY_B] remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.",INDIRECT-DOWNREGULATOR,CPR:4,1,"We found that wogonin can suppress the H2O2-stimulated actin remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231."
"RESULTS: << Indomethacin >>, in vitro and in vivo. induces an increase in erythorcyte [[ CA I ]] and CA II activity.","RESULTS: [ENTITY_A], in vitro and in vivo. induces an increase in erythorcyte [ENTITY_B] and CA II activity.",ACTIVATOR,CPR:3,0,"RESULTS: Indomethacin, in vitro and in vivo. induces an increase in erythorcyte CA I and CA II activity."
"<< Jaceosidin >>, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via [[ ATM ]]-Chk1/2 activation.","[ENTITY_A], isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via [ENTITY_B]-Chk1/2 activation.",ACTIVATOR,CPR:3,0,"Jaceosidin, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via ATM-Chk1/2 activation."
"In the rabbit pulmonary artery, << rilmenidine >> and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the [[ alpha(2)-autoreceptors ]], sharing this property with rauwolscine, phentolamine, and idazoxan.","In the rabbit pulmonary artery, [ENTITY_A] and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the [ENTITY_B], sharing this property with rauwolscine, phentolamine, and idazoxan.",ANTAGONIST,CPR:6,3,"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the alpha(2)-autoreceptors, sharing this property with rauwolscine, phentolamine, and idazoxan."
"BACKGROUND: << Lapatinib >>, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 ([[ HER2 ]]) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.","BACKGROUND: [ENTITY_A], the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 ([ENTITY_B]) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.",INHIBITOR,CPR:4,1,"BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007."
The present study demonstrated that << human multidrug resistance-associated protein 3 >> vesicles accepted conjugated [[ 3β-hydroxy-Δ(5)-bile acids ]] along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.,The present study demonstrated that [ENTITY_A] vesicles accepted conjugated [ENTITY_B] along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.,SUBSTRATE,CPR:9,4,The present study demonstrated that human multidrug resistance-associated protein 3 vesicles accepted conjugated 3β-hydroxy-Δ(5)-bile acids along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.
"Similarly, << felodipine >> and the p-chloro analogue blocked [[ myosin ]] filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not.","Similarly, [ENTITY_A] and the p-chloro analogue blocked [ENTITY_B] filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not.",INHIBITOR,CPR:4,1,"Similarly, felodipine and the p-chloro analogue blocked myosin filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not."
"Furthermore, these << phosphorylated flavonoids >> demonstrated good to high selectivity for [[ CEase ]] over AChE, which only showed micromolar potency inhibition of AChE.","Furthermore, these [ENTITY_A] demonstrated good to high selectivity for [ENTITY_B] over AChE, which only showed micromolar potency inhibition of AChE.",INHIBITOR,CPR:4,1,"Furthermore, these phosphorylated flavonoids demonstrated good to high selectivity for CEase over AChE, which only showed micromolar potency inhibition of AChE."
Inhibition of << AChE >> in the CSF after [[ rivastigmine ]] administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours.,Inhibition of [ENTITY_A] in the CSF after [ENTITY_B] administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours.,INHIBITOR,CPR:4,1,Inhibition of AChE in the CSF after rivastigmine administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours.
"Presently, a combination of an antimuscarinic agent, e.g. atropine, << AChE >> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of [[ OP ]] poisoning in humans.","Presently, a combination of an antimuscarinic agent, e.g. atropine, [ENTITY_A] reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of [ENTITY_B] poisoning in humans.",INHIBITOR,CPR:4,1,"Presently, a combination of an antimuscarinic agent, e.g. atropine, AChE reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans."
"<< Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase >> (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding [[ 3-keto-4-ene-steroids ]] and is thus involved in the biosynthesis of all classes of hormonal steroids.","[ENTITY_A] (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding [ENTITY_B] and is thus involved in the biosynthesis of all classes of hormonal steroids.",PRODUCT-OF,CPR:9,4,"Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids."
"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, << glycine >> and GABA, share the same [[ vesicular inhibitory amino acid transporter ]] (VIAAT) and are both present in neurons during postnatal development.","The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, [ENTITY_A] and GABA, share the same [ENTITY_B] (VIAAT) and are both present in neurons during postnatal development.",SUBSTRATE,CPR:9,4,"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and GABA, share the same vesicular inhibitory amino acid transporter (VIAAT) and are both present in neurons during postnatal development."
<< Fisetin >> treatment of preadipocytes reduced the phosphorylation of [[ S6K1 ]] and mTORC1 in a time- and concentration-dependent manner.,[ENTITY_A] treatment of preadipocytes reduced the phosphorylation of [ENTITY_B] and mTORC1 in a time- and concentration-dependent manner.,INHIBITOR,CPR:4,1,Fisetin treatment of preadipocytes reduced the phosphorylation of S6K1 and mTORC1 in a time- and concentration-dependent manner.
"Investigating the enteroenteric recirculation of << apixaban >>, a [[ factor Xa ]] inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.","Investigating the enteroenteric recirculation of [ENTITY_A], a [ENTITY_B] inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.",INHIBITOR,CPR:4,1,"Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats."
"<< Jaceosidin >>, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating [[ cdc25C ]]-cdc2 via ATM-Chk1/2 activation.","[ENTITY_A], isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating [ENTITY_B]-cdc2 via ATM-Chk1/2 activation.",INHIBITOR,CPR:4,1,"Jaceosidin, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via ATM-Chk1/2 activation."
Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the << dipeptidyl peptidase-4 >> inhibitor [[ vildagliptin ]] in an advanced-aged diet-induced obesity mouse model.,Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the [ENTITY_A] inhibitor [ENTITY_B] in an advanced-aged diet-induced obesity mouse model.,INHIBITOR,CPR:4,1,Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model.
<< Cadmium >> activates [[ NADPH oxidase ]].,[ENTITY_A] activates [ENTITY_B].,ACTIVATOR,CPR:3,0,Cadmium activates NADPH oxidase.
The anticonvulsant << felbamate >> blocks [[ N-methyl-D-asparate (NMDA) receptors ]] but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists.,The anticonvulsant [ENTITY_A] blocks [ENTITY_B] but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists.,INHIBITOR,CPR:4,1,The anticonvulsant felbamate blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists.
"<< PEA >> was a potent and full agonist at each species of [[ TAAR1 ]], whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1.","[ENTITY_A] was a potent and full agonist at each species of [ENTITY_B], whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1.",AGONIST-ACTIVATOR,CPR:5,2,"PEA was a potent and full agonist at each species of TAAR1, whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1."
"<< Miglustat >>, an imino sugar that reversibly inhibits [[ glucosylceramide synthase ]] and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option.","[ENTITY_A], an imino sugar that reversibly inhibits [ENTITY_B] and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option.",INHIBITOR,CPR:4,1,"Miglustat, an imino sugar that reversibly inhibits glucosylceramide synthase and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option."
"Low levels of << serotonin >> may reduce the density of the [[ serotonin transporter ]] (SERT) by either increasing trafficking or reducing synthesis; a ""neuroadaptive response"".","Low levels of [ENTITY_A] may reduce the density of the [ENTITY_B] (SERT) by either increasing trafficking or reducing synthesis; a ""neuroadaptive response"".",DOWNREGULATOR,CPR:4,1,"Low levels of serotonin may reduce the density of the serotonin transporter (SERT) by either increasing trafficking or reducing synthesis; a ""neuroadaptive response""."
Radioligand binding studies with the nonselective << alpha 1-adrenoceptor >> antagonist radioligand [[ 125I-BE2254 ]] showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).,Radioligand binding studies with the nonselective [ENTITY_A] antagonist radioligand [ENTITY_B] showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).,ANTAGONIST,CPR:6,3,Radioligand binding studies with the nonselective alpha 1-adrenoceptor antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).
<< L-BMAA >> induced ER stress and enhanced [[ caspase 12 ]] cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations.,[ENTITY_A] induced ER stress and enhanced [ENTITY_B] cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations.,INDIRECT-UPREGULATOR,CPR:3,0,L-BMAA induced ER stress and enhanced caspase 12 cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations.
"Saturation and competition studies in the presence or absence of the << histamine H1 receptor >> antagonist, [[ levocabastine ]], revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).","Saturation and competition studies in the presence or absence of the [ENTITY_A] antagonist, [ENTITY_B], revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).",ANTAGONIST,CPR:6,3,"Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)."
DNPKA markedly reduced these << GnRH >>-stimulated [[ FSHβ ]] responses at both low and high pulse frequencies.,DNPKA markedly reduced these [ENTITY_A]-stimulated [ENTITY_B] responses at both low and high pulse frequencies.,INDIRECT-UPREGULATOR,CPR:3,0,DNPKA markedly reduced these GnRH-stimulated FSHβ responses at both low and high pulse frequencies.
"When the << PTB-binding site >> in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from [[ GalN ]]-treated rats compared to the level in control rats.","When the [ENTITY_A] in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from [ENTITY_B]-treated rats compared to the level in control rats.",INDIRECT-UPREGULATOR,CPR:3,0,"When the PTB-binding site in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from GalN-treated rats compared to the level in control rats."
<< Resiquimod >>-stimulated pDC also produce a number of other [[ cytokines ]] including TNF-alpha and IP-10.,[ENTITY_A]-stimulated pDC also produce a number of other [ENTITY_B] including TNF-alpha and IP-10.,INDIRECT-UPREGULATOR,CPR:3,0,Resiquimod-stimulated pDC also produce a number of other cytokines including TNF-alpha and IP-10.
Block of << erg3 >> by [[ sertindole ]] also displayed a positive voltage-dependence.,Block of [ENTITY_A] by [ENTITY_B] also displayed a positive voltage-dependence.,INHIBITOR,CPR:4,1,Block of erg3 by sertindole also displayed a positive voltage-dependence.
"We report the discovery of a novel series of ATP-competitive << Janus kinase 3 >> (JAK3) inhibitors based on the [[ 5H-pyrrolo[2,3-b]pyrazine ]] scaffold.",We report the discovery of a novel series of ATP-competitive [ENTITY_A] (JAK3) inhibitors based on the [ENTITY_B] scaffold.,INHIBITOR,CPR:4,1,"We report the discovery of a novel series of ATP-competitive Janus kinase 3 (JAK3) inhibitors based on the 5H-pyrrolo[2,3-b]pyrazine scaffold."
"To mechanistically evaluate this regional selectivity, we assessed << cyclo-oxygenase-2 >> (COX-2) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and [[ AOM ]]-treated rats.","To mechanistically evaluate this regional selectivity, we assessed [ENTITY_A] (COX-2) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and [ENTITY_B]-treated rats.",INDIRECT-UPREGULATOR,CPR:3,0,"To mechanistically evaluate this regional selectivity, we assessed cyclo-oxygenase-2 (COX-2) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and AOM-treated rats."
"Moreover, they established that the inhibitory effect of << cucurbitacin I >> on [[ Rac1 ]] activity involves the alteration of the balance between Rho and Rac.","Moreover, they established that the inhibitory effect of [ENTITY_A] on [ENTITY_B] activity involves the alteration of the balance between Rho and Rac.",INHIBITOR,CPR:4,1,"Moreover, they established that the inhibitory effect of cucurbitacin I on Rac1 activity involves the alteration of the balance between Rho and Rac."
<< Catalpol >> inhibits LPS plus [[ IFN-γ ]]-induced inflammatory response in astrocytes primary cultures.,[ENTITY_A] inhibits LPS plus [ENTITY_B]-induced inflammatory response in astrocytes primary cultures.,INHIBITOR,CPR:4,1,Catalpol inhibits LPS plus IFN-γ-induced inflammatory response in astrocytes primary cultures.
"Furthermore, << substance P >> (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue [[ caerulein ]]-treated acinar cells.","Furthermore, [ENTITY_A] (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue [ENTITY_B]-treated acinar cells.",INDIRECT-UPREGULATOR,CPR:3,0,"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein-treated acinar cells."
"Mutants << Y751A >>, D950A, and F1004A had reduced sensitivity to [[ milrinone ]] (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).","Mutants [ENTITY_A], D950A, and F1004A had reduced sensitivity to [ENTITY_B] (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).",INHIBITOR,CPR:4,1,"Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)."
Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting << cholesterol >> efflux by the [[ ABCA1 ]] transporter.,Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting [ENTITY_A] efflux by the [ENTITY_B] transporter.,SUBSTRATE,CPR:9,4,Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter.
"In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the << alpha 1 adrenoceptor >> antagonist, [[ prazosin ]] (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.","In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the [ENTITY_A] antagonist, [ENTITY_B] (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.",ANTAGONIST,CPR:6,3,"In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors."
"Furthermore, inhibition of << HO-1 >> with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of [[ Paeoniflorin ]] against radiation-induced damage in EA.hy926 cells.","Furthermore, inhibition of [ENTITY_A] with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of [ENTITY_B] against radiation-induced damage in EA.hy926 cells.",ACTIVATOR,CPR:3,0,"Furthermore, inhibition of HO-1 with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells."
<< MT1R >> was increased in ovaries and uteri of [[ melatonin ]]-treated rats.,[ENTITY_A] was increased in ovaries and uteri of [ENTITY_B]-treated rats.,INDIRECT-UPREGULATOR,CPR:3,0,MT1R was increased in ovaries and uteri of melatonin-treated rats.
"The expression of the osteoblast markers runt-related transcription factor 2 (<< RUNX2 >>) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and [[ Met ]]-RANTES-treated mice.","The expression of the osteoblast markers runt-related transcription factor 2 ([ENTITY_A]) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and [ENTITY_B]-RANTES-treated mice.",INDIRECT-DOWNREGULATOR,CPR:4,1,"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and Met-RANTES-treated mice."
<< Ruxolitinib >> is a small-molecule inhibitor of [[ JAK1 ]] and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.,[ENTITY_A] is a small-molecule inhibitor of [ENTITY_B] and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.,INHIBITOR,CPR:4,1,Ruxolitinib is a small-molecule inhibitor of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.
Sodium-dependent norepinephrine-induced currents in << norepinephrine-transporter >>-transfected HEK-293 cells blocked by [[ cocaine ]] and antidepressants.,Sodium-dependent norepinephrine-induced currents in [ENTITY_A]-transfected HEK-293 cells blocked by [ENTITY_B] and antidepressants.,INHIBITOR,CPR:4,1,Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants.
"This led to the discovery of << aliskiren >>, a highly potent and selective inhibitor of [[ human renin ]] in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients.","This led to the discovery of [ENTITY_A], a highly potent and selective inhibitor of [ENTITY_B] in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients.",INHIBITOR,CPR:4,1,"This led to the discovery of aliskiren, a highly potent and selective inhibitor of human renin in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients."
"The << tyrosine hydroxylase >> inhibitor [[ α-methyltyrosine ]] (300µM, 24h) completely abolished MeHg-induced DA release.","The [ENTITY_A] inhibitor [ENTITY_B] (300µM, 24h) completely abolished MeHg-induced DA release.",INHIBITOR,CPR:4,1,"The tyrosine hydroxylase inhibitor α-methyltyrosine (300µM, 24h) completely abolished MeHg-induced DA release."
We conclude that << felbamate >> exhibits modest selectivity for [[ NMDA receptors ]] composed of NR1a/NR2B subunits.,We conclude that [ENTITY_A] exhibits modest selectivity for [ENTITY_B] composed of NR1a/NR2B subunits.,INHIBITOR,CPR:4,1,We conclude that felbamate exhibits modest selectivity for NMDA receptors composed of NR1a/NR2B subunits.
"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of << TCDD >> on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of [[ Lgr5 ]], a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of [ENTITY_A] on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of [ENTITY_B], a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.",INDIRECT-DOWNREGULATOR,CPR:4,1,"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD."
"We report here the pharmacological properties of a third selective << COX-2 >> inhibitor, [[ valdecoxib ]], which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied.","We report here the pharmacological properties of a third selective [ENTITY_A] inhibitor, [ENTITY_B], which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied.",INHIBITOR,CPR:4,1,"We report here the pharmacological properties of a third selective COX-2 inhibitor, valdecoxib, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied."
<< Bicyclic pyrazinone and pyrimidinone amides >> were designed and synthesized as potent TF-[[ FVIIa ]] inhibitors.,[ENTITY_A] were designed and synthesized as potent TF-[ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Bicyclic pyrazinone and pyrimidinone amides were designed and synthesized as potent TF-FVIIa inhibitors.
"<< Rg1 >> attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting [[ HIF-1α ]] expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.","[ENTITY_A] attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting [ENTITY_B] expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Rg1 attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination."
"Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) << Promethazine >>, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several [[ calmodulin ]] functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.","Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) [ENTITY_A], a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several [ENTITY_B] functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.",INHIBITOR,CPR:4,1,"Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin."
<< Orlistat >> is an inhibitor of [[ pancreatic lipase ]] which is able to block the absorption of 30% of ingested fat.,[ENTITY_A] is an inhibitor of [ENTITY_B] which is able to block the absorption of 30% of ingested fat.,INHIBITOR,CPR:4,1,Orlistat is an inhibitor of pancreatic lipase which is able to block the absorption of 30% of ingested fat.
"Saturated << palmitic and stearic acids >> increased ceramides, up-regulated PTP1B, and had AKt and [[ PTP1B ]] phosphorylation at Ser 50 impaired.","Saturated [ENTITY_A] increased ceramides, up-regulated PTP1B, and had AKt and [ENTITY_B] phosphorylation at Ser 50 impaired.",ACTIVATOR,CPR:3,0,"Saturated palmitic and stearic acids increased ceramides, up-regulated PTP1B, and had AKt and PTP1B phosphorylation at Ser 50 impaired."
"Combination treatment with the selective << 5-HT1A >> antagonist [[ WAY100635 ]] produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone.","Combination treatment with the selective [ENTITY_A] antagonist [ENTITY_B] produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone.",ANTAGONIST,CPR:6,3,"Combination treatment with the selective 5-HT1A antagonist WAY100635 produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone."
"In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full << kappa-opioid >> agonists [[ (-)-U50,488 ]] and dynorphin A.","In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full [ENTITY_A] agonists [ENTITY_B] and dynorphin A.",AGONIST,CPR:5,2,"In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and dynorphin A."
"<< Lapatinib >> is metabolized primarily by the [[ cytochrome P450 3A4 ]] isozyme, with 1 metabolite remaining active against EGFR but not HER2.","[ENTITY_A] is metabolized primarily by the [ENTITY_B] isozyme, with 1 metabolite remaining active against EGFR but not HER2.",SUBSTRATE,CPR:9,4,"Lapatinib is metabolized primarily by the cytochrome P450 3A4 isozyme, with 1 metabolite remaining active against EGFR but not HER2."
"Thus, the << NF-κB >> signaling pathway can be activated after [[ TCDD ]] treatment.","Thus, the [ENTITY_A] signaling pathway can be activated after [ENTITY_B] treatment.",ACTIVATOR,CPR:3,0,"Thus, the NF-κB signaling pathway can be activated after TCDD treatment."
"Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on << P-gp >> as the main mechanism for the increased transport of [[ darunavir ]] across the small intestine.","Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on [ENTITY_A] as the main mechanism for the increased transport of [ENTITY_B] across the small intestine.",SUBSTRATE,CPR:9,4,"Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on P-gp as the main mechanism for the increased transport of darunavir across the small intestine."
"CONCLUSION/INTERPRETATION: This study provides evidence that << troglitazone >> reduces [[ PAI-1 ]] production in human adipocytes, probably at the transcriptional level.","CONCLUSION/INTERPRETATION: This study provides evidence that [ENTITY_A] reduces [ENTITY_B] production in human adipocytes, probably at the transcriptional level.",INDIRECT-DOWNREGULATOR,CPR:4,1,"CONCLUSION/INTERPRETATION: This study provides evidence that troglitazone reduces PAI-1 production in human adipocytes, probably at the transcriptional level."
<< Topotecan >> is a [[ topoisomerase I ]] inhibitor which is currently evaluated as an adjuvant agent for malignant glioma.,[ENTITY_A] is a [ENTITY_B] inhibitor which is currently evaluated as an adjuvant agent for malignant glioma.,INHIBITOR,CPR:4,1,Topotecan is a topoisomerase I inhibitor which is currently evaluated as an adjuvant agent for malignant glioma.
<< Toosendanin >> induces apoptosis through suppression of [[ JNK ]] signaling pathway in HL-60 cells.,[ENTITY_A] induces apoptosis through suppression of [ENTITY_B] signaling pathway in HL-60 cells.,INDIRECT-DOWNREGULATOR,CPR:4,1,Toosendanin induces apoptosis through suppression of JNK signaling pathway in HL-60 cells.
A << naloxone-steroid hybrid azine >> with selective and long-acting opioid antagonism at [[ delta receptors ]] in vitro.,A [ENTITY_A] with selective and long-acting opioid antagonism at [ENTITY_B] in vitro.,ANTAGONIST,CPR:6,3,A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro.
PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to << 5-fluorouracil >> (5-FU) by thymidine phosphorylase ([[ TP ]]) inside target tissues.,PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to [ENTITY_A] (5-FU) by thymidine phosphorylase ([ENTITY_B]) inside target tissues.,PRODUCT-OF,CPR:9,4,PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues.
<< Carvedilol >> reduced mortality and heart failure in patients with higher pre-treatment plasma [[ N-BNP ]] and adrenomedullin.,[ENTITY_A] reduced mortality and heart failure in patients with higher pre-treatment plasma [ENTITY_B] and adrenomedullin.,INDIRECT-DOWNREGULATOR,CPR:4,1,Carvedilol reduced mortality and heart failure in patients with higher pre-treatment plasma N-BNP and adrenomedullin.
<< Dimethylfumarate >> attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/[[ Smad ]] signaling.,[ENTITY_A] attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/[ENTITY_B] signaling.,INDIRECT-DOWNREGULATOR,CPR:4,1,Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/Smad signaling.
"However, whether increasing << EETs >> production by [[ CYP2J2 ]] overexpression in vivo could prevent abdominal aortic aneurysm (AAA) remains unknown.","However, whether increasing [ENTITY_A] production by [ENTITY_B] overexpression in vivo could prevent abdominal aortic aneurysm (AAA) remains unknown.",PRODUCT-OF,CPR:9,4,"However, whether increasing EETs production by CYP2J2 overexpression in vivo could prevent abdominal aortic aneurysm (AAA) remains unknown."
"As free << sildenafil >> plasma concentrations approach concentrations sufficient to inhibit retinal [[ PDE6 ]], usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently.","As free [ENTITY_A] plasma concentrations approach concentrations sufficient to inhibit retinal [ENTITY_B], usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently.",INHIBITOR,CPR:4,1,"As free sildenafil plasma concentrations approach concentrations sufficient to inhibit retinal PDE6, usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently."
Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to << DON >> lead to similar intestinal lesions and activation of [[ MAPK ]].,Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to [ENTITY_A] lead to similar intestinal lesions and activation of [ENTITY_B].,ACTIVATOR,CPR:3,0,Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to DON lead to similar intestinal lesions and activation of MAPK.
Puerarin promotes proliferation by altering cell cycle distribution whereas << puerarin >>-mediated survival may be associated with up-regulation of [[ Bcl-xL ]] expression.,Puerarin promotes proliferation by altering cell cycle distribution whereas [ENTITY_A]-mediated survival may be associated with up-regulation of [ENTITY_B] expression.,INDIRECT-UPREGULATOR,CPR:3,0,Puerarin promotes proliferation by altering cell cycle distribution whereas puerarin-mediated survival may be associated with up-regulation of Bcl-xL expression.
"<< Sorafenib >> has the added advantage of inhibiting multiple different [[ Raf ]] isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.","[ENTITY_A] has the added advantage of inhibiting multiple different [ENTITY_B] isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.",INHIBITOR,CPR:4,1,"Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta."
The results also confirmed previous reports that << amezinium >> is highly selective for [[ MAO-A ]].,The results also confirmed previous reports that [ENTITY_A] is highly selective for [ENTITY_B].,INHIBITOR,CPR:4,1,The results also confirmed previous reports that amezinium is highly selective for MAO-A.
"<< BuChE >> activity in CSF was significantly lower after [[ rivastigmine ]] than after placebo for up to 3.6 hours after dosing, but this difference was not sustained.","[ENTITY_A] activity in CSF was significantly lower after [ENTITY_B] than after placebo for up to 3.6 hours after dosing, but this difference was not sustained.",INHIBITOR,CPR:4,1,"BuChE activity in CSF was significantly lower after rivastigmine than after placebo for up to 3.6 hours after dosing, but this difference was not sustained."
"<< Homocysteine >>, the atherogenic product of the [[ NNMT ]]-catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures.","[ENTITY_A], the atherogenic product of the [ENTITY_B]-catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures.",PRODUCT-OF,CPR:9,4,"Homocysteine, the atherogenic product of the NNMT-catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures."
The << Paeoniflorin >>-induced [[ HO-1 ]] expression was abrogated by Nrf2 siRNA.,The [ENTITY_A]-induced [ENTITY_B] expression was abrogated by Nrf2 siRNA.,INDIRECT-UPREGULATOR,CPR:3,0,The Paeoniflorin-induced HO-1 expression was abrogated by Nrf2 siRNA.
"<< Docetaxel >> is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of [[ bcl-2 ]] inactivation, which induce apoptosis.","[ENTITY_A] is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of [ENTITY_B] inactivation, which induce apoptosis.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Docetaxel is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of bcl-2 inactivation, which induce apoptosis."
"Platelet-induced << COX-2 >>-dependent [[ PGE2 ]] synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2.","Platelet-induced [ENTITY_A]-dependent [ENTITY_B] synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2.",PRODUCT-OF,CPR:9,4,"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2."
"In the current study, we show that systematic modification of an << aminoalkylindole >> scaffold identifies two new compounds with dual [[ CB1R ]] antagonist/CB2R agonist activity.","In the current study, we show that systematic modification of an [ENTITY_A] scaffold identifies two new compounds with dual [ENTITY_B] antagonist/CB2R agonist activity.",ANTAGONIST,CPR:6,3,"In the current study, we show that systematic modification of an aminoalkylindole scaffold identifies two new compounds with dual CB1R antagonist/CB2R agonist activity."
"Our findings indicate that << imatinib >> protects oocytes from cisplatin-induced cell death by inhibiting [[ c-Abl ]] kinase, which would otherwise activate TAp73-BAX-mediated apoptosis.","Our findings indicate that [ENTITY_A] protects oocytes from cisplatin-induced cell death by inhibiting [ENTITY_B] kinase, which would otherwise activate TAp73-BAX-mediated apoptosis.",INHIBITOR,CPR:4,1,"Our findings indicate that imatinib protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-BAX-mediated apoptosis."
"Purified << PAOh1 >>/SMO oxidizes both [[ spermine ]] (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.","Purified [ENTITY_A]/SMO oxidizes both [ENTITY_B] (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.",SUBSTRATE,CPR:9,4,"Purified PAOh1/SMO oxidizes both spermine (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine."
<< Amantadine >> induces [[ c-fos ]] in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists.,[ENTITY_A] induces [ENTITY_B] in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists.,INDIRECT-UPREGULATOR,CPR:3,0,Amantadine induces c-fos in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists.
"At -20 mV, 10 nM << cisapride >> reduced [[ HERG ]] tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells).","At -20 mV, 10 nM [ENTITY_A] reduced [ENTITY_B] tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells).",INDIRECT-DOWNREGULATOR,CPR:4,1,"At -20 mV, 10 nM cisapride reduced HERG tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells)."
Our data demonstrate differences in the mechanism of stimulation of << phenylalanine hydroxylase >> and nitric oxide synthase by [[ H(4)biopterin ]].,Our data demonstrate differences in the mechanism of stimulation of [ENTITY_A] and nitric oxide synthase by [ENTITY_B].,INHIBITOR,CPR:4,1,Our data demonstrate differences in the mechanism of stimulation of phenylalanine hydroxylase and nitric oxide synthase by H(4)biopterin.
A << nicotinic receptor >> antagonist ([[ hexamethonium ]]) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction.,A [ENTITY_A] antagonist ([ENTITY_B]) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction.,ANTAGONIST,CPR:6,3,A nicotinic receptor antagonist (hexamethonium) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction.
"However, << 5-HT(1A) >> agonism may be important only for [[ quetiapine ]]-induced ACh release.","However, [ENTITY_A] agonism may be important only for [ENTITY_B]-induced ACh release.",AGONIST,CPR:5,2,"However, 5-HT(1A) agonism may be important only for quetiapine-induced ACh release."
"In the lateral geniculate nucleus, << brexpiprazole >> displayed [[ alpha1B-adrenoceptor ]] antagonistic action.","In the lateral geniculate nucleus, [ENTITY_A] displayed [ENTITY_B] antagonistic action.",ANTAGONIST,CPR:6,3,"In the lateral geniculate nucleus, brexpiprazole displayed alpha1B-adrenoceptor antagonistic action."
<< Metformin >> increases [[ AMP-activated protein kinase ]] activity in skeletal muscle of subjects with type 2 diabetes.,[ENTITY_A] increases [ENTITY_B] activity in skeletal muscle of subjects with type 2 diabetes.,ACTIVATOR,CPR:3,0,Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes.
Inhibition of << monoamine oxidase >> by [[ phthalide ]] analogues.,Inhibition of [ENTITY_A] by [ENTITY_B] analogues.,INHIBITOR,CPR:4,1,Inhibition of monoamine oxidase by phthalide analogues.
"CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as << lenalidomide >>- and pomalidomide-induced [[ cytokine ]] production in T cells.","CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as [ENTITY_A]- and pomalidomide-induced [ENTITY_B] production in T cells.",INDIRECT-UPREGULATOR,CPR:3,0,"CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide-induced cytokine production in T cells."
"Therefore, comparative histochemical and biochemical studies of << u-PA >> and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate [[ Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin ]].","Therefore, comparative histochemical and biochemical studies of [ENTITY_A] and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate [ENTITY_B].",SUBSTRATE,CPR:9,4,"Therefore, comparative histochemical and biochemical studies of u-PA and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin."
<< Cilostazol >> undergoes intensive and finally complete hepatic metabolism via the [[ cytochrome P450 ]] systems.,[ENTITY_A] undergoes intensive and finally complete hepatic metabolism via the [ENTITY_B] systems.,SUBSTRATE,CPR:9,4,Cilostazol undergoes intensive and finally complete hepatic metabolism via the cytochrome P450 systems.
<< Lofentanil >> exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant [[ ORL1 ]] receptors (EC(50) 50 nM).,[ENTITY_A] exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant [ENTITY_B] receptors (EC(50) 50 nM).,AGONIST-ACTIVATOR,CPR:5,2,Lofentanil exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant ORL1 receptors (EC(50) 50 nM).
"In the current study, we reveal the inhibitory effects of << baicalin >> on the metabolism of dextromethorphan (DXM), a dual probe substrate of [[ CYP2D ]] and CYP3A, in rats.","In the current study, we reveal the inhibitory effects of [ENTITY_A] on the metabolism of dextromethorphan (DXM), a dual probe substrate of [ENTITY_B] and CYP3A, in rats.",INHIBITOR,CPR:4,1,"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats."
"In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves << spermine >> in the absence of prior acetylation by [[ SSAT ]].","In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves [ENTITY_A] in the absence of prior acetylation by [ENTITY_B].",SUBSTRATE,CPR:9,4,"In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves spermine in the absence of prior acetylation by SSAT."
"Although << ICA >> greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of [[ EAG ]] inactivation without altering its voltage dependence.","Although [ENTITY_A] greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of [ENTITY_B] inactivation without altering its voltage dependence.",INHIBITOR,CPR:4,1,"Although ICA greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence."
"Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the << cholesterol >> side-chain cleavage enzyme, [[ P450scc ]], and its two electron-transfer partners, ferredoxin reductase and ferredoxin.","Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the [ENTITY_A] side-chain cleavage enzyme, [ENTITY_B], and its two electron-transfer partners, ferredoxin reductase and ferredoxin.",SUBSTRATE,CPR:9,4,"Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the cholesterol side-chain cleavage enzyme, P450scc, and its two electron-transfer partners, ferredoxin reductase and ferredoxin."
"Our results first demonstrate that << auranofin >> suppresses the multiple steps in [[ TLR4 ]] signaling, especially the homodimerization of TLR4.","Our results first demonstrate that [ENTITY_A] suppresses the multiple steps in [ENTITY_B] signaling, especially the homodimerization of TLR4.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4."
"The treatment with << arsenic >> exhibited a significant increase in some serum hepatic and renal biochemical parameters ([[ alanine aminotransferase ]], aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine).","The treatment with [ENTITY_A] exhibited a significant increase in some serum hepatic and renal biochemical parameters ([ENTITY_B], aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine).",INDIRECT-UPREGULATOR,CPR:3,0,"The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)."
"<< COX-1 >> inhibition was measured as percentage inhibition of serum [[ TXB2 ]] generation in clotting whole blood, and as closure time with use of the platelet function analyser PFA-100.","[ENTITY_A] inhibition was measured as percentage inhibition of serum [ENTITY_B] generation in clotting whole blood, and as closure time with use of the platelet function analyser PFA-100.",PRODUCT-OF,CPR:9,4,"COX-1 inhibition was measured as percentage inhibition of serum TXB2 generation in clotting whole blood, and as closure time with use of the platelet function analyser PFA-100."
"Synthesis and biological evaluation of << 1,3,4-thiadiazole >> analogues as novel [[ AChE ]] and BuChE inhibitors.",Synthesis and biological evaluation of [ENTITY_A] analogues as novel [ENTITY_B] and BuChE inhibitors.,INHIBITOR,CPR:4,1,"Synthesis and biological evaluation of 1,3,4-thiadiazole analogues as novel AChE and BuChE inhibitors."
"TRPM8 (<< CMR1 >>) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, [[ eucalyptol ]] and icilin.","TRPM8 ([ENTITY_A]) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, [ENTITY_B] and icilin.",ACTIVATOR,CPR:3,0,"TRPM8 (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin."
"In summary, << ketoconazole >> had no clinically significant effect on the pharmacokinetics or safety profile of ambrisentan; therefore, no changes in ambrisentan dose should be necessary when the drug is administered concomitantly with known [[ CYP3A4 ]] inhibitors.","In summary, [ENTITY_A] had no clinically significant effect on the pharmacokinetics or safety profile of ambrisentan; therefore, no changes in ambrisentan dose should be necessary when the drug is administered concomitantly with known [ENTITY_B] inhibitors.",INHIBITOR,CPR:4,1,"In summary, ketoconazole had no clinically significant effect on the pharmacokinetics or safety profile of ambrisentan; therefore, no changes in ambrisentan dose should be necessary when the drug is administered concomitantly with known CYP3A4 inhibitors."
"The levels of << PSA >> mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of [[ estramustine ]], respectively (IC50 = 10.97 +/- 1.68 microM).","The levels of [ENTITY_A] mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of [ENTITY_B], respectively (IC50 = 10.97 +/- 1.68 microM).",INDIRECT-DOWNREGULATOR,CPR:4,1,"The levels of PSA mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of estramustine, respectively (IC50 = 10.97 +/- 1.68 microM)."
"Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to << MP470 >>, a novel [[ c-Kit ]]/AXL kinase inhibitor.","Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to [ENTITY_A], a novel [ENTITY_B]/AXL kinase inhibitor.",INHIBITOR,CPR:4,1,"Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to MP470, a novel c-Kit/AXL kinase inhibitor."
"To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of << SIRT1 >> ([[ nicotinamide ]], sirtinol, EX527) in aorta segments isolated from young Wistar rats.","To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of [ENTITY_A] ([ENTITY_B], sirtinol, EX527) in aorta segments isolated from young Wistar rats.",INHIBITOR,CPR:4,1,"To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats."
"The choroid plexus uptake of << [(3)H]cefadroxil >> was studied in [[ peptide transporter 2 ]] (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability.","The choroid plexus uptake of [ENTITY_A] was studied in [ENTITY_B] (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability.",SUBSTRATE,CPR:9,4,"The choroid plexus uptake of [(3)H]cefadroxil was studied in peptide transporter 2 (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability."
Enhancement of << GLUT4 >> expression by [[ fisetin ]] was further confirmed in differentiated 3T3-L1 adipocytes.,Enhancement of [ENTITY_A] expression by [ENTITY_B] was further confirmed in differentiated 3T3-L1 adipocytes.,INDIRECT-UPREGULATOR,CPR:3,0,Enhancement of GLUT4 expression by fisetin was further confirmed in differentiated 3T3-L1 adipocytes.
Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of << dihydropteridinone >> based [[ Plk-2 ]] inhibitors.,Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of [ENTITY_A] based [ENTITY_B] inhibitors.,INHIBITOR,CPR:4,1,Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of dihydropteridinone based Plk-2 inhibitors.
The progress of the enzymatic reaction of the hydrolysis of << acetylthiocholine >> at pH 8 in the presence of [[ AChE ]] and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh).,The progress of the enzymatic reaction of the hydrolysis of [ENTITY_A] at pH 8 in the presence of [ENTITY_B] and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh).,SUBSTRATE,CPR:9,4,The progress of the enzymatic reaction of the hydrolysis of acetylthiocholine at pH 8 in the presence of AChE and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh).
Reactivation potentials of << BuChE >> (the difference between [[ oxime ]]-reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion.,Reactivation potentials of [ENTITY_A] (the difference between [ENTITY_B]-reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion.,ACTIVATOR,CPR:3,0,Reactivation potentials of BuChE (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion.
"Like conventional << ACE >> inhibitors, [[ omapatrilat ]] causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin.","Like conventional [ENTITY_A] inhibitors, [ENTITY_B] causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin.",INHIBITOR,CPR:4,1,"Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin."
"Inhibition of mTOR by low dose << rapamycin >> decreases HG-induced [[ Nox4 ]] and Nox1, NADPH oxidase activity and podocyte apoptosis.","Inhibition of mTOR by low dose [ENTITY_A] decreases HG-induced [ENTITY_B] and Nox1, NADPH oxidase activity and podocyte apoptosis.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Inhibition of mTOR by low dose rapamycin decreases HG-induced Nox4 and Nox1, NADPH oxidase activity and podocyte apoptosis."
"This activity, like << NQO1 >>, was inhibited by [[ dicoumarol ]] and immunologically related to NQO1.","This activity, like [ENTITY_A], was inhibited by [ENTITY_B] and immunologically related to NQO1.",INHIBITOR,CPR:4,1,"This activity, like NQO1, was inhibited by dicoumarol and immunologically related to NQO1."
"The results reinforce previous assumptions that << dopamine >> may interact with eicosanoid metabolism by means of [[ D(2) receptor ]] activation, and implicate an involvement of cPLA(2) and COX-2 in this effect.","The results reinforce previous assumptions that [ENTITY_A] may interact with eicosanoid metabolism by means of [ENTITY_B] activation, and implicate an involvement of cPLA(2) and COX-2 in this effect.",ACTIVATOR,CPR:3,0,"The results reinforce previous assumptions that dopamine may interact with eicosanoid metabolism by means of D(2) receptor activation, and implicate an involvement of cPLA(2) and COX-2 in this effect."
"In addition, the number and area of << glutathione S-transferase placental form >> (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg [[ MEG ]] compared with the control animals.","In addition, the number and area of [ENTITY_A] (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg [ENTITY_B] compared with the control animals.",INDIRECT-UPREGULATOR,CPR:3,0,"In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg MEG compared with the control animals."
"Whether << metformin >> or the satiety factor leptin, which also stimulates [[ AMPK ]] in muscle, regulates this enzyme in pancreatic islets is unknown.","Whether [ENTITY_A] or the satiety factor leptin, which also stimulates [ENTITY_B] in muscle, regulates this enzyme in pancreatic islets is unknown.",ACTIVATOR,CPR:3,0,"Whether metformin or the satiety factor leptin, which also stimulates AMPK in muscle, regulates this enzyme in pancreatic islets is unknown."
"Stereochemical studies established that << PAM >> inactivation by [[ 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid ]] is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous results with substrates and reversible inhibitors.","Stereochemical studies established that [ENTITY_A] inactivation by [ENTITY_B] is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous results with substrates and reversible inhibitors.",INHIBITOR,CPR:4,1,"Stereochemical studies established that PAM inactivation by 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous results with substrates and reversible inhibitors."
"Importantly, the carboxylic acid of << JY-3-094 >> improves the physicochemical properties of the lead compound, which will facilitate the incorporation of additional hydrophobicity that might enhance [[ Myc ]] inhibitory activity further still.","Importantly, the carboxylic acid of [ENTITY_A] improves the physicochemical properties of the lead compound, which will facilitate the incorporation of additional hydrophobicity that might enhance [ENTITY_B] inhibitory activity further still.",INHIBITOR,CPR:4,1,"Importantly, the carboxylic acid of JY-3-094 improves the physicochemical properties of the lead compound, which will facilitate the incorporation of additional hydrophobicity that might enhance Myc inhibitory activity further still."
"Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced << U50,488H >>-induced down-regulation of the [[ hkor ]].",Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced [ENTITY_A]-induced down-regulation of the [ENTITY_B].,DOWNREGULATOR,CPR:4,1,"Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced U50,488H-induced down-regulation of the hkor."
Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to << glutamine >> through the enzyme [[ glutamine synthetase ]] (GS).,Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to [ENTITY_A] through the enzyme [ENTITY_B] (GS).,PRODUCT-OF,CPR:9,4,Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to glutamine through the enzyme glutamine synthetase (GS).
"Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of << eicosapentaenoic acid >> (EPA) blocked [[ Delta-5-desaturase ]] activity, the terminal enzymatic step in AA synthesis.","Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of [ENTITY_A] (EPA) blocked [ENTITY_B] activity, the terminal enzymatic step in AA synthesis.",INHIBITOR,CPR:4,1,"Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid (EPA) blocked Delta-5-desaturase activity, the terminal enzymatic step in AA synthesis."
Identification and synthesis of << N-(thiophen-2-yl) benzamide >> derivatives as [[ BRAF ]](V600E) inhibitors.,Identification and synthesis of [ENTITY_A] derivatives as [ENTITY_B](V600E) inhibitors.,INHIBITOR,CPR:4,1,Identification and synthesis of N-(thiophen-2-yl) benzamide derivatives as BRAF(V600E) inhibitors.
"However, enzymes contributing to oxidative metabolism of << anandamide >>, namely [[ cyclooxygenase-1 ]] and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.","However, enzymes contributing to oxidative metabolism of [ENTITY_A], namely [ENTITY_B] and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.",SUBSTRATE,CPR:9,4,"However, enzymes contributing to oxidative metabolism of anandamide, namely cyclooxygenase-1 and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide."
"Drug-drug interactions are dependent on statins' pharmacokinetic profile: << simvastatin >>, lovastatin and atorvastatin are metabolized through [[ cytochrome P450 (CYP) 3A ]], while the metabolism of the other statins is independent of this CYP.","Drug-drug interactions are dependent on statins' pharmacokinetic profile: [ENTITY_A], lovastatin and atorvastatin are metabolized through [ENTITY_B], while the metabolism of the other statins is independent of this CYP.",SUBSTRATE,CPR:9,4,"Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and atorvastatin are metabolized through cytochrome P450 (CYP) 3A, while the metabolism of the other statins is independent of this CYP."
"MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (Acsl), we show in vitro that << valproic acid >> is a non-competitive inhibitor of [[ Acsl ]], as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.","MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (Acsl), we show in vitro that [ENTITY_A] is a non-competitive inhibitor of [ENTITY_B], as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.",INHIBITOR,CPR:4,1,"MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (Acsl), we show in vitro that valproic acid is a non-competitive inhibitor of Acsl, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme."
"<< Crocin >> (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of [[ cytochrome c ]] to the cytosol induced by DZN.","[ENTITY_A] (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of [ENTITY_B] to the cytosol induced by DZN.",DOWNREGULATOR,CPR:4,1,"Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN."
"Direct-acting << CB1 >> agonists, including [[ Δ(9)-tetrahydrocannabinol ]], WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.","Direct-acting [ENTITY_A] agonists, including [ENTITY_B], WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",AGONIST,CPR:5,2,"Direct-acting CB1 agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia."
"The synthetic stereoisomer, << [+]-Hup A >>, is less toxic due to poor [[ AChE ]] inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity.","The synthetic stereoisomer, [ENTITY_A], is less toxic due to poor [ENTITY_B] inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity.",INHIBITOR,CPR:4,1,"The synthetic stereoisomer, [+]-Hup A, is less toxic due to poor AChE inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity."
Pretreatment with << H(2)S >> or NaHS significantly inhibited LPS-induced [[ iNOS ]] expression and NO production.,Pretreatment with [ENTITY_A] or NaHS significantly inhibited LPS-induced [ENTITY_B] expression and NO production.,INDIRECT-DOWNREGULATOR,CPR:4,1,Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced iNOS expression and NO production.
Suppression of << Src >>/ERK and GSK-3/β-catenin signaling by [[ pinosylvin ]] inhibits the growth of human colorectal cancer cells.,Suppression of [ENTITY_A]/ERK and GSK-3/β-catenin signaling by [ENTITY_B] inhibits the growth of human colorectal cancer cells.,DOWNREGULATOR,CPR:4,1,Suppression of Src/ERK and GSK-3/β-catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells.
Role of organic cation/carnitine transporter 1 in uptake of << phenformin >> and inhibitory effect on [[ complex I ]] respiration in mitochondria.,Role of organic cation/carnitine transporter 1 in uptake of [ENTITY_A] and inhibitory effect on [ENTITY_B] respiration in mitochondria.,INHIBITOR,CPR:4,1,Role of organic cation/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria.
"Thus, the increase in mPFC << DAT >> function was an SHR-specific long term consequence of [[ methylphenidate ]] treatment during adolescence, which may be responsible for the treatment-induced alterations in behavior including the observed increases in cocaine self-administration.","Thus, the increase in mPFC [ENTITY_A] function was an SHR-specific long term consequence of [ENTITY_B] treatment during adolescence, which may be responsible for the treatment-induced alterations in behavior including the observed increases in cocaine self-administration.",UPREGULATOR,CPR:3,0,"Thus, the increase in mPFC DAT function was an SHR-specific long term consequence of methylphenidate treatment during adolescence, which may be responsible for the treatment-induced alterations in behavior including the observed increases in cocaine self-administration."
Our results suggest that << glutamate >> induces [[ GRIP1 ]] degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.,Our results suggest that [ENTITY_A] induces [ENTITY_B] degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.,DOWNREGULATOR,CPR:4,1,Our results suggest that glutamate induces GRIP1 degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.
"In contrast, there was little change in mRNA levels for << GTP cyclohydrolase I >> (GTPCH), the rate limiting enzyme in synthesis of the [[ tetrahydrobiopterin ]] (BH4), the obligate cofactor for TPH.","In contrast, there was little change in mRNA levels for [ENTITY_A] (GTPCH), the rate limiting enzyme in synthesis of the [ENTITY_B] (BH4), the obligate cofactor for TPH.",PRODUCT-OF,CPR:9,4,"In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (GTPCH), the rate limiting enzyme in synthesis of the tetrahydrobiopterin (BH4), the obligate cofactor for TPH."
"<< Tacrine >>, the first of the [[ cholinesterase ]] inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity.","[ENTITY_A], the first of the [ENTITY_B] inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity.",INHIBITOR,CPR:4,1,"Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity."
These results indicate that << carbetocin >> is a partial agonist/antagonist to the [[ oxytocin receptor ]] while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.,These results indicate that [ENTITY_A] is a partial agonist/antagonist to the [ENTITY_B] while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.,ANTAGONIST,CPR:6,3,These results indicate that carbetocin is a partial agonist/antagonist to the oxytocin receptor while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.
The mechanism revealed that << wogonin >> inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of [[ VE-cadherin ]] and β-catenin.,The mechanism revealed that [ENTITY_A] inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of [ENTITY_B] and β-catenin.,INDIRECT-DOWNREGULATOR,CPR:4,1,The mechanism revealed that wogonin inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and β-catenin.
"We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent << CCK-A receptor >> antagonist [[ lintitript ]].","We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent [ENTITY_A] antagonist [ENTITY_B].",ANTAGONIST,CPR:6,3,"We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent CCK-A receptor antagonist lintitript."
"Furthermore, treatment with << spironoclactone >> not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of [[ calpain ]] and AIF levels.","Furthermore, treatment with [ENTITY_A] not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of [ENTITY_B] and AIF levels.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of calpain and AIF levels."
"<< System y+ >> cationic [[ amino acid ]] transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3.","[ENTITY_A] cationic [ENTITY_B] transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3.",SUBSTRATE,CPR:9,4,"System y+ cationic amino acid transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3."
"However, consistent with its low << COX-1 >> inhibitory activity, [[ lumiracoxib ]] at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05).","However, consistent with its low [ENTITY_A] inhibitory activity, [ENTITY_B] at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05).",INHIBITOR,CPR:4,1,"However, consistent with its low COX-1 inhibitory activity, lumiracoxib at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05)."
"While << sophocarpine >> treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of [[ leptin ]] expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold).","While [ENTITY_A] treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of [ENTITY_B] expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold).",INDIRECT-DOWNREGULATOR,CPR:4,1,"While sophocarpine treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold)."
"Modulation of the function of CD36 (CD36-/- mice), << p38 >>(MAPK) ([[ SB203580 ]]), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.","Modulation of the function of CD36 (CD36-/- mice), [ENTITY_A](MAPK) ([ENTITY_B]), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.",INHIBITOR,CPR:4,1,"Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition."
"<< 17-Allylamino-17-demethoxygeldanamycin >> (17-AAG), an [[ Hsp90 ]] inhibitor, is currently under evaluation for its anticancer activity in clinical trials.","[ENTITY_A] (17-AAG), an [ENTITY_B] inhibitor, is currently under evaluation for its anticancer activity in clinical trials.",INHIBITOR,CPR:4,1,"17-Allylamino-17-demethoxygeldanamycin (17-AAG), an Hsp90 inhibitor, is currently under evaluation for its anticancer activity in clinical trials."
"Our results showed that << 2-hydroxy-3-methylanthraquinone >> decreased phosphorylation-ERK1/2 (p-ERK1/2), and increased [[ p-p38MAPK ]], but did not affect expressions of p-JNK1/2 in U937 cells.","Our results showed that [ENTITY_A] decreased phosphorylation-ERK1/2 (p-ERK1/2), and increased [ENTITY_B], but did not affect expressions of p-JNK1/2 in U937 cells.",ACTIVATOR,CPR:3,0,"Our results showed that 2-hydroxy-3-methylanthraquinone decreased phosphorylation-ERK1/2 (p-ERK1/2), and increased p-p38MAPK, but did not affect expressions of p-JNK1/2 in U937 cells."
"Third, << ABCA1 >>-RNAi suppressed hepatic [[ alpha-tocopherol ]] secretion.","Third, [ENTITY_A]-RNAi suppressed hepatic [ENTITY_B] secretion.",PRODUCT-OF,CPR:9,4,"Third, ABCA1-RNAi suppressed hepatic alpha-tocopherol secretion."
The binding of FHA-HIS was inhibited on 35-79% of the platelets by the << histamine H1 receptor >> antagonists [[ diphenhydramine ]] and clemastine.,The binding of FHA-HIS was inhibited on 35-79% of the platelets by the [ENTITY_A] antagonists [ENTITY_B] and clemastine.,ANTAGONIST,CPR:6,3,The binding of FHA-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and clemastine.
"Moreover, << minocycline >> efficiently suppressed the release of [[ cytochrome c ]] from mitochondria of the liver tissues from Jo2-challenged mice.","Moreover, [ENTITY_A] efficiently suppressed the release of [ENTITY_B] from mitochondria of the liver tissues from Jo2-challenged mice.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Moreover, minocycline efficiently suppressed the release of cytochrome c from mitochondria of the liver tissues from Jo2-challenged mice."
"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and << matrine >> carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and [[ hERG ]] blocking activity.","The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and [ENTITY_A] carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and [ENTITY_B] blocking activity.",INHIBITOR,CPR:4,1,"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and hERG blocking activity."
"<< Aldo-keto reductases >> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive [[ oxygen ]] species (ROS), which are capable of initiating and promoting carcinogenesis.","[ENTITY_A] (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive [ENTITY_B] species (ROS), which are capable of initiating and promoting carcinogenesis.",PRODUCT-OF,CPR:9,4,"Aldo-keto reductases (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis."
"Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of << HIV capsid >> assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-[[ phenyl ]] moiety.","Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of [ENTITY_A] assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-[ENTITY_B] moiety.",INHIBITOR,CPR:4,1,"Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-phenyl moiety."
"Injections of << m-CPBG >>, a selective [[ 5-HT3 ]] receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states.","Injections of [ENTITY_A], a selective [ENTITY_B] receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states.",AGONIST,CPR:5,2,"Injections of m-CPBG, a selective 5-HT3 receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states."
"<< Glucosamine >> at 50 mM was demonstrated to elevate both the mRNA and protein expression of [[ p53 ]] and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.","[ENTITY_A] at 50 mM was demonstrated to elevate both the mRNA and protein expression of [ENTITY_B] and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.",INDIRECT-UPREGULATOR,CPR:3,0,"Glucosamine at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression."
"<< Sorafenib >>, which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of [[ Raf-1 ]] and its favorable kinase selectivity profile.","[ENTITY_A], which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of [ENTITY_B] and its favorable kinase selectivity profile.",INHIBITOR,CPR:4,1,"Sorafenib, which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable kinase selectivity profile."
"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, << HDC >> activity and HDC mRNA induced by [[ TDI ]] in TDI-sensitized rats.","Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, [ENTITY_A] activity and HDC mRNA induced by [ENTITY_B] in TDI-sensitized rats.",ACTIVATOR,CPR:3,0,"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and HDC mRNA induced by TDI in TDI-sensitized rats."
"CONCLUSIONS: In the maximum registered dosage, << nabumetone >> inhibits thromboxane production much more than meloxicam, signifying less [[ COX-2 ]] selectivity of the former.","CONCLUSIONS: In the maximum registered dosage, [ENTITY_A] inhibits thromboxane production much more than meloxicam, signifying less [ENTITY_B] selectivity of the former.",DOWNREGULATOR,CPR:4,1,"CONCLUSIONS: In the maximum registered dosage, nabumetone inhibits thromboxane production much more than meloxicam, signifying less COX-2 selectivity of the former."
Assays examining the ability of << TFP >> to block [[ S100A4 ]]-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization.,Assays examining the ability of [ENTITY_A] to block [ENTITY_B]-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization.,INHIBITOR,CPR:4,1,Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization.
"<< Tomudex >> treatment resulted in the decrease in [[ p27(kip1) ]] expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure.","[ENTITY_A] treatment resulted in the decrease in [ENTITY_B] expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure.",INDIRECT-DOWNREGULATOR,CPR:4,1,"Tomudex treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure."
The specific binding is displaced by the selective << 5-HT1D >> agonist [[ sumatriptan ]] but not by the mixed 5-HT1A/1D agonist 5-carboxyamidotryptamine.,The specific binding is displaced by the selective [ENTITY_A] agonist [ENTITY_B] but not by the mixed 5-HT1A/1D agonist 5-carboxyamidotryptamine.,AGONIST,CPR:5,2,The specific binding is displaced by the selective 5-HT1D agonist sumatriptan but not by the mixed 5-HT1A/1D agonist 5-carboxyamidotryptamine.
